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Abstract 
 
Malignant melanoma is a form of skin cancer which, even though it represents its least prevalent 
form, is accountable for 90% of skin cancer related deaths. While treatment of malignant 
melanoma up until Stage III promises great success, the same so far does not apply to Stage IV 
melanoma patients. In recent years, the introduction of novel treatment regiments has raised 
patients hopes for survival, but limited treatment success requires further development and 
combination of current and novel strategies. 
Modifications in metabolic pathways such as the accumulation of the intracellular second 
messenger cyclic adenosine monophosphate (cAMP) have been recognized as a hallmark of 
cancer. In melanoma, elevated intracellular cAMP levels correlate with a greater metastatic 
potential and are believed to be the cause of regulatory T cell (Treg)-mediated 
immunosuppression in the tumour. In the present study, it was investigated how a micellar 
formulation of the adenylyl cylase inhibitor MDL-12, 330A hydrochloride made from the 
amphiphilic polypeptoid-block-polypeptide copolymer polysacrcosine-block-polyglutamatic 
acid benzylester (PSar-b-PGlu(OBn)) can be used to intervene in the formation of cAMP. 
The in vivo testing of cAMP reduction using the adenylyl cyclase inhibitor MDL-12, 330A 
hydrochloride showcased its potential as a therapeutic agent by significantly reducing the 
tumour burden in the context of the murine B16F10-OVA melanoma model. A detailed 
examination of the tumour immune cell infiltrate following cAMP reduction revealed drastic 
quantitative and functional changes. Based on these results, a treatment strategy for complete 
tumour rejection was successfully established, combining cAMP reduction with punctual Treg 
removal.  
In addition, the potential of azide functionalized polysarcosine brushes with polylysine 
backbone and polysarcosine side chains labelled with the fluorescent dye Alexa Fluor 647 and 
coupled with antigen and adjuvant could be demonstrated as a protective and therapeutic cancer 
vaccine. In order to completely eliminate tumour growth in a therapeutic approach, it would be 
interesting to try to combine it with cAMP reduction.  
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Zusammenfassung 
 
Das maligne Melanom ist eine Form von Hautkrebs, die, obwohl sie die am wenigsten 
verbreitete Form ausmacht, für 90% der durch Hautkrebs verursachten Todesfälle ursächlich 
ist. Während die Behandlung des malignen Melanoms bis zum Stadium III große Erfolge 
verspricht, gilt dies bisher nicht für Pateinten im Stadium IV. In den letzten Jahren hat die 
Einführung neuer Behandlungsansätze die Hoffnung vieler Patienten auf ein Überleben 
geweckt. Begrenzte Behandlungserfolge machen eine Weiterentwicklung und Kombination 
von aktuell verwendeten und neuen Strategien notwendig. 
Veränderungen in Stoffwechselwegen wie zum Beispiel die Anreicherung des intrazellulären 
Signalbotenstoffes zyklisches Adenosinmonophosphat (cAMP) sind unter anderem ein 
Kennzeichen von Krebs. In Melanomen korrelieren erhöhte intrazelluläre cAMP Spiegel mit 
einem größeren metastatischen Potential und sind vermutlich für die durch regulatorische T 
Zellen (Treg)-vermittelte Immunsuppression im Tumor mit verantwortlich. In der vorliegenden 
Arbeit wurde untersucht, wie unter Verwendung mizellarer Formulierungen des 
Adenylylzyklaseinhibitors MDL-12, 330A Hydrochloride bestehend aus dem amphiphilen 
polypeptoid-block-polypeptide Copolymer Polysacrcosine-Block-Polyglutaminsäure- 
benzylester (PSar-b-PGlu(OBn)) in die cAMP-Bildung in Melanomen eingegriffen werden 
kann. 
Die in vivo Erprobung der cAMP-Absenkung durch die Verwendung des cAMP Inhibitors 
MDL-12, 330A Hydrochloride zeigte sein Potenzial als Therapeutikum, indem es im Kontext 
des murinen B16F10-OVA Melanommodells die Tumorlast signifikant reduzieren konnte. Eine 
detaillierte Untersuchung des Tumorimmunzellinfiltrates nach cAMP Absenkung zeigte 
drastische quantitative und funktionelle Veränderungen. Basieren auf diesen Ergebnissen 
wurde erfolgreich eine Behandlungsstrategie zur kompletten Abstoßung des Tumors etabliert, 
welche die cAMP Absenkung mit einer punktuellen Entfernung der Tregs verband. 
Darüber hinaus konnte das Potential von azid-funktionalisierten Polysarkosinbürsten mit 
Polylysinrückrat und Polysarkosinseitenketten, die mit dem Fluoreszenzfarbstoff Alexa Fluor 
647 markiert und mit Antigen und Adjuvans gekoppelt wurden, als protektiver und 
therapeutischer Krebsimpfstoff aufgezeigt werden. Um das Tumorwachstum in einem 
therapeutischen Ansatz vollständig zu eliminieren, wäre es interessant zu versuchen, diesen mit 
der cAMP-Absenkung zu kombinieren. 
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1. Introduction  
 
 
1.1 Melanoma 
 
Malignant melanoma is a form of cutaneous skin cancer which mainly affects Non-Hispanic 
Caucasians. Even though melanoma represents its least prevalent form, it is accountable for 
90% of skin cancer related deaths (Garbe, C. et al., 2016). It develops from melanocytes, 
pigment producing cells derived from the neural crest, which are located at the bottom of the 
epidermis and hair follicles (Chichorek, M. et al., 2013). Apart from genetic predispositions the 
greatest exogenous risk factor is an early and frequent exposure to ultraviolet (UV) radiation 
(Garbe, C. et al., 2016). 
 
 
1.1.1 Historical Background 
 
Melanoma were first mentioned in the 5th century by Hippocrates of Cos and later by Rufus of 
Ephesesus. The first physical evidence originates from metastases in about 2400 year old Pre-
Columbian mummies found in Peru (Urteaga, O. & Pack, G.T., 1966; Rebecca, V.W. et al., 
2012). From the mid-late 17th century on “fatal black tumours with metastases and black fluid 
in the body” would frequently get mentioned and referenced in the European medical literature 
(Rebecca, V.W. et al., 2012). It was, however, not until 1806 that Rene Laennec would coin 
the term melanose after realizing that melanoma was a distinct disease (Laennec, R.T.H., 1812; 
Rebecca, V.W. et al., 2012). In 1820 and 1857 Dr. William Norris published his detailed 
observations on melanosis. He reported that most of his patients were fair skinned, suggested a 
link between melanoma and environmental factors, described the heritable nature of some 
melanomas and noted their widespread metastatic potential. He also concluded that any medical 
intervention would become obsolete the further the disease had progressed (Norris, W., 1820; 
Norris, W., 1857; Rebecca, V.W. et al., 2012). The pathologist Sir Robert Carswell would later 
be credited to have identified the disease as melanoma (Carswell, R., 1838; Rebecca, V.W., et 
al., 2012).  
 
 
1.1.2 Diagnosis and Staging  
 
The initial diagnosis of melanoma is still today mainly based on a combination of a 
dermatologists trained eye and dermoscopy (Garbe C. et al., 2016). It has, however, been 
greatly guided by two independently proposed melanoma classification systems suggested by 
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Wallace Clark in 1969 (Clark Jr, W.H., 1969) and Alexander Breslow in 1970 (Breslow, A., 
1970). The recommendations regarding melanoma staging are continuously updated by the 
American Joint Commission on Cancer (AJCC) and nowadays also do incorporate genetic data. 
At present the depth of the tumour (Breslow’s depth), a guideline for the recommended excision 
margin of a tumour, the level of ulceration, the tumour division rate as well as the presence of 
microsatellites are essentially contributing towards tumour staging (Garbe, C et al., 2016). 
Clark’s level, the level of anatomical invasion, has become less significant and is currently only 
applied to melanoma with a Breslow depth smaller than 1 mm or an undetermined mitotic rate 
(Balch, C.M. et al., 2009). 
 
The discovery of a potential lesion immediately leads to its removal and staging. Detection of 
certain characteristic proteins such as the S-100 protein, HMB45 or Melan-A strongly add 
towards the diagnosis of melanoma (Garbe, C. et al., 2016). The presence of metastases is 
evaluated by assessing the levels of lactate dehydrogenase (LDH) (Balch, C.M. et al., 2009), 
lymph node and sentinel lymph node biopsies and by the different available imaging techniques. 
The rate of survival for patients with a melanoma up until Stage III are relatively high and is 
significantly increased by adjuvant Interferon-alpha (IFN-α) therapy. Stage IV melanoma with 
solitary metastases are often still treated using a curative approach which includes radiation 
therapy. A palliative approach, systemic therapy, is however chosen as soon as multiple 
metastases have been detected (Figure 1.1) (Keilholz, U. et al., 2014). 
 
 
 
 
 
 
  Introduction 
  
3 
Figure 1.1 Guidelines for the primary therapy of malignant melanoma. 
The discovery of a potential lesion during an examination of a dermatologist leads to its immediate 
removal and staging based on national recommendations, for example by the American Joint 
Commission on Cancer (AJCC). Based on the staging, guidelines for the treatment of a patient have 
been suggested. A curative approach is followed up until Stage IIIB which includes operation, lymph 
node biopsy, adjuvant Interferon-alpha (IFN-α) therapy and observation. Stage IV melanoma patients 
with solitary metastases are often still treated using a curative approach which includes radiation. A 
palliative approach, systemic therapy, is chosen as soon as Stage IV melanoma with multiple metastases 
have been detected. Redrawn from Keilholz, U. et al., 2014. 
 
 
 
1.1.3 Systemic Therapy of Stage IV Melanoma Patients  
 
Mandatory molecular analysis must be performed on metastases or if not otherwise feasible the 
primary tumour of Stage IV melanoma patients considered for systemic therapy. Testing is done 
regarding the most common mutations in cutaneous melanoma: BRAF V600E or V600K, 
NRAS, CKIT and NF1. Based on the results of the molecular analysis a seemingly appropriate 
treatment regimen can be selected (Figure 1.2) (Keilholz, U. et al., 2014). Between 2011 and 
2013, the approval and introduction of in total four novel drugs into the clinic, Ipilimumab, 
Vemurafenib, Dabrafenib and Trametinib, greatly varied the therapeutic options and made it 
easier to opt for an alternative treatment scheme in case of excessive side effects or resistance. 
Ipilimumab, a human Immunoglobulin G subclass 1 (IgG1) monoclonal antibody and at present 
most commonly used medication blocks the cytotoxic lymphocyte associated antigen 4 (CTLA-
4). Vemurafenib and Dabrafenib however act against BRAF while Trametinib inhibits 
MEK1/2. In case of CKIT mutations, tyrosine-kinase inhibitors such as Imatinib are used. 
NRAS specific inhibitors are currently under development. The first Programmed Death 
Receptor-1 (PD-1) and Programmed Death Receptor-1 Ligand (PD-1L) antibodies were 
approved in 2014 and are expected to significantly alter the currently recommended treatment 
strategies. Nivolumab and Pembrolizumab act by blocking the interaction of PD-1 on immune 
cells and PD-L1, a ligand commonly expressed on tumours, resulting in increased immune 
activation including elevated tumour cell killing by cytotoxic T lymphocytes (CTLs) (Stadler, 
S. et al., 2015). Recently the combination of both Ipilimumab and Nivolumab has been 
advocated due to reports of favourable response rates regardless of a patient’s mutational status 
(Wolchok, J.D., et al., 2013; Sznol, M. et al., 2014; Stadler, S. et al., 2015).  
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Figure 1.2 Guidelines for the treatment of patients with Stage IV melanoma.  
The discovery of a potential lesion during an examination of a dermatologist lead to its immediate 
removal and staging based on national recommendations, for example by the American Joint 
Commission on Cancer (AJCC). At present the depth of the tumour (Breslow`s depth), the tumour 
division rate, the level of ulceration, the presence of microsatellites but also genetic data are considered 
during staging. A palliative approach, systemic therapy, is chosen as soon as Stage IV melanoma with 
multiple metastases have been detected. Treatment guidelines have been suggested based on the 
mutational status and the response to therapy by Stage IV melanoma patient’s. Redrawn from Keilholz, 
U. et al., 2014. 
 
 
 
1.1.4 The Future of Systemic Therapy of Stage IV Melanoma Patients 
 
The combination of the currently available therapeutics has been strongly advocated and a great 
number of trials are ongoing. Novel strategies currently investigated include Indoleamine 2,3-
dioxygenase-1 (IDO1) inhibitors as well as Lymphocyte-activation gene-3 (LAG-3) inhibitors. 
IDO1 is an enzyme responsible for the degradation of tryptophane, an amino acid overexpressed 
by a great number of tumours, partially responsible for a mindered T cell response. LAG-3 is 
up-regulated on activated T cells, regulates T cell activation and homeostasis, engages Dendritic 
Cells (DCs) and influences the secretion of the immunosuppressive cytokines Interleukin 10 
(Il-10) and Transforming growth factor beta (TGF-β). Inhibition of any two of these molecules 
have been suggested to ultimately help to revoke immune suppression. Current and novel 
strategies must be carefully investigated, and their interactions need to be closely monitored to 
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ultimately come up with a regimen that promises a long-term response in case of Stage IV 
melanoma (Koller, K.M. et al., 2016). 
 
 
1.2 Cyclic Adenosine Monophosphate (cAMP) and Melanoma 
 
1.2.1 cAMP 
 
Cylic adenosine monophosphate (cAMP) is an intracellular second messenger which was first 
discovered in 1957 by Earl Sutherland and colleagues (Berthet, J. et al., 1957). It is ubiquitously 
expressed in a wide range of organisms and affects a variety of functions through its five target 
proteins: protein kinase A (PKA), exchange proteins directly activated by cAMP (EPACs), 
Popeye domain-containing proteins (POPDCs), cyclic nucleotide receptors involved in sperm 
function (CRISs) or cyclic nucleotide-gated ion channels (CNGs) (Amunjela, J.N. & Tucker, 
S.J., 2016). Amongst others these processes include cellular growth, differentiation, 
proliferation, Ca2+-dependent signalling, reproduction, cardiac function, vision, inflammation, 
as well as tumour development (Azevedo, M.F. et al., 2014).  
 
The cAMP signalling cascade is initiated by extracellular cues such as hormones or 
neurotransmitters. It leads to the stimulation of the Gs protein-coupled receptor (GsPCR) at the 
plasma membrane or the endosomal compartment and the exchange of guanosine diphosphate 
(GDP) for guanosine-5’-triphosphate (GTP). Activated G proteins then in turn associate with 
adenylyl cyclases (ACs) which leads to the conversion of adenosine triphosphate (ATP) to 
cyclic adenosine monophosphate (cAMP). Upon contact with the appropriate target, cAMP gets 
degraded by phosphodiesterases (PDE) to 5’adenosine monophosphate-activated protein kinase 
(5’AMP) (Figure 1.3) (Lefkimmiatis, K. & Zaccolo, M., 2014). 
 
Not only the great number of cAMP targets but also the differential expression and diversity of 
effector proteins adds towards the complexity of the cAMP signalling cascade (Azevedo, M.F. 
et al., 2014; Sadana, R. & Dessauer, C.W., 2009). The conversion of ATP to cAMP is regulated 
by in total ten adenylyl cyclases, nine transmembrane adenylyl cyclases (tAC1-9) and one 
soluble adenylyl cyclase (sAC10) (Lefkimmiatis, K. & Zaccolo, M., 2014). Furthermore, eight 
out of a total of eleven phosphodiesterases (PDE), three cAMP selective (PDE4, PDE7 and 
PDE8) and five cAMP and cyclic guanosine monophosphate (cGMP) responsive (PDE1, PDE2, 
PDE3, PDE10 and PDE11) phosphodiesterases, are involved in cAMP degradation (Azevedo, 
M.F. et al., 2014) as well as the creation of signalling compartments as small as 300 nm (Surdo, 
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N.C., et al., 2017, Musheshe, N. et al., 2017). The contribution of each adenylyl cyclase and 
phosphodiesterase to individual processes has yet to be determined. So far however, their 
spatiotemporal distribution across signalling compartments represented by lipid rafts needs to 
be resolved (Cooper, D.M.F. et al., 2005; Seifert, R. et al., 2012).    
 
 
 
 
 
Figure 1.3 The cAMP signalling pathway. 
The cAMP signalling pathway is initiated by extracellular cues, for example hormones or 
neurotransmitters. It leads to the stimulation of the G protein-coupled receptor (GsPCR) at the plasma 
membrane or the endosomal compartment and the exchange of guanosine diphosphate (GDP) for 
guanosine-5’-triphosphate (GTP). Activated G proteins associate with transmembrane adenylyl cyclases 
(tACs) or soluble adenylyl cyclases (sACs) which leads to the conversion of adenosine triphosphate 
(ATP) to cyclic adenosine monophosphate (cAMP). Phosphodiesterases (PDEs) initiate the degradation 
of cAMP to 5´ adenosine monophosphate-activated protein kinase (5´AMP). cAMP acts upon five 
effector proteins: protein kinase A (PKA), exchange proteins directly activated by cAMP (EPACs), 
Popeye domain-containing proteins (POPDCs), cyclic nucleotide receptors involved in sperm function 
(CRISs) or cyclic nucleotide-gated ion channels (CNGs). Adapted from: Amujela, J.N. & Tucker, S.J., 
2016 and Musheshe, N. et al., 2017.  
 
 
 
1.2.2 cAMP and the Skin 
 
The skin is one of the largest mammalian organs which protects the remainder of the body from 
the environment while carrying out important immunological and metabolic functions (Di 
Meglio, P. et al., 2011). Protection against UV radiation, a major risk factor for melanoma, is 
modulated by pigmentation and represents one of the most important protective mechanisms 
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critically dependent on cAMP (Kondo, T. & Hearing, V.J., 2011). Keratinocytes and 
melanocytes, located at the bottom of the epidermis and hair follicles, together form the so 
called epidermal melanin unit. Melanocytes, originally derived as melanoblasts from the neural 
crest, harbour organelles called melanosomes where pigment, also referred to as melanin, is 
produced. Upon association with keratinocytes, the skins main barrier against environmental 
damage, differentially shaped melanosomes start to determine skin colour and play a critical 
role in photoprotection (Slominski, A. et al., 2004, Costin, G.E. & Hearing, V.J. et al., 2007). 
 
While skin colour is primarily determined by a person’s genetic traits, the mixture of two 
chemically distinct forms of melanin, namely the black-to-brown eumelanin and the yellow-to-
reddish pheomelanin, are responsible for differential pigmentation (Costin, G.E. & Hearing, 
V.J. et al., 2007). Melanin synthesis starts when L-Tyrosine is converted to levodopa (L-DOPA) 
and subsequently to L-Dopaquinone (DOPAquinone) by their oxidation through the tyrosinase 
enzyme (TYR). At that stage the pathway starts to diverge and tyrosine-realted-protein-1 
(TYRP1) as well as tyrosine-related-protein-2 (TYRP2) become the main drivers for the 
formation of highly polymerized black and brown eumelanin respectively. Glutathion or cystine 
however become important factors in the synthesis of the photolabile sulfur containing less 
polymerized yellow-to-reddish pheomelanin. While eumelanin is an effective UV blocker, 
pheomelanin renders a person susceptible to damage by UV radiation and reactive oxygen 
species (ROS) (Slominski, A. et al., 2004; Costin, G.E. & Hearing; V.J. et al., 2007; Konto; T. 
& Hearing, V.J. et al., 2011; Garcia-Borron, J.C. et al., 2014). 
 
Melanin synthesis itself, is mainly driven by the G protein-coupled melanocortin-1 receptor 
(MC1R), which is primarily expressed in melanocytes but also in keratinocytes, fibroblasts, and 
immune cells (Nasti, T.H. & Timares, L., 2015). It is stimulated by the α-Melanocyte-
stimulating hormone (α-MSH) as well as the adrenocorticotropic hormone (ACTH) which leads 
to the activation of adenylyl cyclases and the conversion of ATP to cAMP. PKA in turn initiates 
the binding of the cAMP response element binding protein (CREB) to the cAMP response 
element (CRE) situated in the microphthalmia-associated transcription factor (MITF) 
(Rodriguez, C.I. & Setaluri, V., 2014; Nasti, T.H. & Timares, L., 2015; Herraiz, C. et al., 2017). 
It’s up-regulation then leads to eumelanogenesis due to the increase of TYR, TYRP1 and 
TYRP2 (Garcia-Borron, J.C. et al., 2014). Pheomelanogenesis is a consequence of the 
inhibition of the MC1R by the agouti protein (Herraiz, C. et al., 2017). MITF is also closely 
associated to the Ras-Raf-MEK-ERK pathway, which regulates melanogenesis by the down 
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regulation of the activity of the transcription factor (Figure 1.4) (Chang, T.S., 2012, Nardin; 
C.A. et al., 2014; Wellbrock, C. & Arozarena, I., 2015).   
 
 
 
 
 
Figure 1.4 Signalling pathways involved in the regulation of melanogenesis. 
Melanocortin-1 receptor (MC1R) is a G protein-coupled receptor (GsPCR) which is stimulated by α-
Melanocyte-stimulating hormone (α-MSH). Its activation leads to the stimulation of adenylyl cyclases 
(ACs) and the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). 
The cAMP effector protein protein kinase A (PKA) initiates the binding of the cAMP response element 
binding site (CREB) to the cAMP response element (CRE) situated in the microphthalmia-associated 
transcription factor (MITF). Its upregulation exerts its effect on the tyrosine enzyme (TYR), the tyrosine-
related-protein-1 (TYRP1) and tyrosine-related-protein-2 (TYRP2) and the initiation of melanogenesis. 
MITF is also closely associated to the Ras-Raf-MEK-ERK pathway, which regulates 
melanogenesis by the down regulation of the activity of the transcription factor. BRAF: 
serine/threonine-protein kinase B-Raf; CKIT: mast/stem cell growth factor receptor; CBP: 
CREB-binding protein; CRAF: RAF proto-oncogene serine/threonine-protein kinase; DNA: 
deoxyribonucleic acid; ERK: extracellular signal-regulated kinase; hUBC9: ubiquitine-
conjugating enzyme UBC9; MEK: mitogen-activated protein kinase kinase; RAS: family of 
related proteins that belongs to the class of small GTPases, SCF: stem cell factor; U-U-MITF: 
ubiquinated MITF. Redrawn and adapted from: Chang, T.S., 2012 and Nardin, C.A. et al., 2014.  
 
 
 
1.2.3 cAMP and Melanoma 
 
cAMP is a highly complex signalling cascade which has a major significance in skin 
pigmentation and its protection against UV radiation (Costin, G.E. & Hearing, V.J., 2007). 
  Introduction 
  
9 
Disruption of this pathway due to aberrant signalling can easily result in the initiation of 
melanoma (Rodriguez, C.I. & Setaluri, V., 2014). A link between these two processes was 
established when it was noted that melanoma do indeed generate elevated intracellular cAMP 
levels which also correlates with an increased metastatic potential (Shepard, J.R. et al., 1984; 
Ito, A. et al., 2000; Raskovalova, T. et al., 2007; Villares, G.J. et al., 2009). Its repression with 
the help of the adenylyl cyclase inhibitor MDL-12, 330A hydrochloride has previously been 
confirmed in the human melanoma cell line MaMel91 (Birke, A. et al., 2014) and was reported 
to revoke regulatory T cell (Treg) induced immunosuppression (Klein, M. et al., 2012).  
 
The soluble AC10 has been closely linked to hyperproliferative skin disorders which includes 
skin cancer. It is upregulated in the nuclei of keratinocytes which has previously been linked to 
activated CREB (Zippin, J.H. et al., 2010, Schmid, A. et al., 2014). Furthermore, it has been 
noted that upon the acquisition of invasive properties, sAC10 is lost from the nucleus in the 
context of malignant melanoma (Zippin, J.H. et al., 2004, Schmid, A. et al., 2014). tAC1-9 are 
indirectly associated with malignant melanoma (Rodriguez, C.I. & Setaluri, V., 2014). While 
MC1R polymorphisms are essential for the variation of pigmentation (Garcia-Borron, J.C. et 
al., 2014), unfavourable mutations in MC1R (Scherer, D. & Kumar, R., 2010) or the Ras-Raf-
MEK-ERK pathway contribute towards the initiation of melanoma (Wang, A.X. & Qi, X.Y., 
2013).  
 
Out of the five cAMP target proteins, only three have been associated with various forms of 
cancer (Amunjela, J.N. & Tucker, S.J., 2016). While in melanoma cells EPACs have been 
reported to increase migration (Balijinnyam, E. et al., 2009), they have also been suggested to 
be involved in transcriptional repression (Lakhter, A.J. & Naidu, S.R., 2017). PKA is an 
essential element in the regulation of melanogenesis and its crosstalk with the Ras-Raf-MEK-
ERK pathway (Rodriguez, C.I. & Setaluri, V., 2014; Nasti, T.H. & Timares, L., 2015; Herraiz, 
C. et al., 2017; Chang, T.S., 2012, Nardin; C.A. et al., 2014; Wellbrock, C. & Arozarena, I., 
2015). Its expression in metastatic melanoma is significantly increased (Mantovani, et al., 2008; 
Amujela, J.N. & Tucker, S.J., 2016) as it targets the cellular transcription factor CREB 
(Delghandi, M.P. et al., 2005; Amujela, J.N. & Tucker, S.J., 2016). POPDCs, the most recently 
uncovered cAMP effector proteins, have been associated with several types of cancer. So far 
however no specific link to melanoma has been reported (Amujela, J.N. & Tucker, S.J., 2016).     
 
Certain PDEs have also been associated with melanoma development and progression. PDE2 
has been suggested to inhibit growth and invasion in melanoma (Hiramoto, K. et al., 2014). In 
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the human malignant melanoma pseudomyxoma peritonei cell line a point mutation was found 
in the PDE2A (Morita, H. et al., 2013, Azevedo, M.F. et al., 2014). PDE4 has been suggested 
to play a major role in melanocyte biology (Rodriguez, C.I. & Setaluri, V., 2014). Various kinds 
of cancer, which includes melanoma, have however also been found to have homozygous 
microdeletions associated with elevated PDE4 expression (Lin, D.C. et al., 2013; Azevedo, 
M.F. et al., 2014; Rodriguez, C.I. & Setaluri, V., 2014). Furthermore, both PDE2 and PDE4 
have been linked to immune cell functions. While PDE2 drives the conversion of monocytes to 
macrophages (Bender, A.T. et al., 2004; Azevedo, M.F. et al., 2014), PDE4 is crucial for the 
activation of T cells and other inflammatory cells (Abrahamsen, H. et al., 2004; Azevedo, M.F. 
et al., 2014).  
 
 
1.3 Nanoparticles in Tumour Therapy  
 
1.3.1 Nanoparticles 
 
Nanoparticles or ultrafine particles have been defined by the International Organization for 
Standardization (ISO) according to ISO/TS 80004-2:2015. They are identified as having a 
length range approximately from 1 to 100 nm as well as three external dimensions orthogonal 
to each other which do not significantly differ in size (ISO, 2015). 
 
Assessments of nanoparticles have furthermore been issued by the Australian National 
Industrial Chemical Notification and Assessment Scheme (NICAS) (NICAS, 2010), Health 
Canada (Health Canada, 2011), the United States Food and Drug Administration (US-FDA, 
2014) and the Scientific Committee on Emerging and Newly Identified Health Risks 
(SCENIHR) of the European Commission (SCENIHR, 2010).  
 
 
1.3.2 Historical Background 
 
Nanoparticles have been used as far back as the 4th century BC for the decoration of a Roman 
glass cage cup, the Lycurgus Cup, made of dichroic glass (Krukemeyer, M.G. et al., 2015) or 
as material for the legendary 17th century Damascus sword (Reibold, M et al., 2006; 
Krukemeyer, M.G. et al., 2015). Only in 1959, following the development of the 
Ultramicroscope in 1902 by Richard Zsigmond and Henry Siegendorf and the detection of nm 
sized structures, the invention of the Transmission Electron Microscope (TEM) in 1931 by Max 
Knoll and Ernst Ruska and the development of the Field-Emission Microscope (FEM) in 1936 
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by Erwin Müller, the physicist Richard Feynman initiated the though process on 
nanotechnology (Feynman, R.P., 1960; Krukemeyer, M.G., et al., 2015). Even before Norio 
Tanigushi had coined the term nanotechnology in 1974 (Tanigushi, N., 1974: Krukemeyer, 
M.G. et al., 2015), nanoparticles for targeted drug delivery had already been devised in the 
laboratory of Paul Speiser by the end of the 1960s (Kreuter, J., 2007; Krukemeyer, M.G. et al., 
2015). 
 
Direct visualization of nm sized structures became possible when in 1981 the Scanning 
Tunnelling Microscope (STM) was invented by both Gerd Binning and Heinrich Rohrer. Only 
a few years later Gerd Binning would in 1986 also devised the Atomic Force Microscope 
(AFM) (Krukemeyer, M.G. et al., 2015). In the same year, K. Eric Drexler, published the first 
textbook on nanotechnology (Drexler, K.E., 1986; Krukemeyer, M.G. et al., 2015). The first 
textbook on nanomedicine was released in 1999 by Robert A. Freitas (Freitas Jr., R.A., 1999; 
Krukemeyer, M.G. et al., 2015). Since then the continuous refinement of techniques and 
equipment pertaining to nanotechnology has significantly aided its advance. Nanotechnology 
does nowadays not only find applications in medicine but also in electronics, transportation, 
space exploration as well as energy and environmental technology (Nikalje, A.P., 2015).    
 
 
1.3.3 Nanoparticles and Cancer Therapy 
 
Cancer therapeutics such as for example chemotherapeutics, are extremely aggressive agents 
that are generally administered systemically in high doses by intravenous injection. Initially 
elevated drug plasma levels, however, get quickly cleared as a result of drug breakdown and 
excretion. Nonselective administration as well as high drug dosages cause serious side effects 
which one hopes to overcome by alternative drug formulations. Nanoparticles represent one 
strategy with which one aspires to achieve a prolonged and selective delivery of increased 
dosages of therapeutics. Furthermore, it represents a promising platform to make anticancer 
drugs with unfavorable physicochemical and biopharmaceutical properties available for therapy 
(Berciano-Guerrero, M.A. et al., 2014).  
 
Already in 1995, Doxil® (approved and marketed as Caelyx in Europe since 1997), a liposomal 
formulation of doxorubicine became one of the first nanoparticle-based therapeutics approved 
by the Food and Drug Administration (FDA) for the treatment of the human immunodeficiency 
virus (HIV) associated Kaposi’s sarcoma. Since then a vast number of different nanoparticle-
based formulations for cancer therapy have been approved or are being investigated in 
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numerous ongoing clinical trials (Ryan, S.M & Brayden, D.J., 2014). These include: liposomes, 
niosomes, dendrimers, polymeric micelles, polymeric nanoparticles, solid lipids, magnetic 
nanoparticles, inorganic nanoparticles, quantum dots, carbon nanotubes, human albumin as 
well as polymersomes (Berciano-Guerrero, M.A. et al., 2014). Next to drug delivery, 
nanoparticles-based approaches have been investigated as vaccines, adjuvants or for imaging 
purposes (Bae, K.H., et al., 2011; Zhu, M. et al., 2014; Fang, H.R. & Zhang, L., 2016). 
 
Selective targeting of systemically applied nanoparticles towards tumours is difficult to achieve 
since their journey through the body can easily be halted by for instance thrombocytes or 
macrophages and the reticuloendothelial system (RES) (Friberg, S. & Nyström, A.M., 2016). 
Introduction and retention of nanoparticles at the tumour site has however been suggested to be 
helped by the controversially discussed enhanced permeation and retention (EPR) effect, a 
passive enrichment mechanism that exploits the features of tumour tissue. These features 
include lack of lymph drainage, high vascular density as well as enhanced vascular 
permeability. Association of nanoparticles with the tumour site is furthermore helped by the 
functionalization of nanoparticles with site specific receptors (Matsumura, J. & Maeda, H., 
1986; Nichols, J.W. & Bae, Y.H., 2014; Danhier, F., 2016; Din, F., et al., 2017.; Tang, J.Q. et 
al., 2017).  
 
A major problems of cancer therapy is its recurrence and the emergence of drug resistance 
towards first line therapeutics. Therefore, it is important to tackle problems such as the 
incomplete elimination or a failed re-education of cancer stem cells (CSCs), which is however 
extremely difficult due to their flexible phenotype. Furthermore, multidrug resistance (MDR) 
mechanisms resulting from pathway adaptions such as altered expression of drug efflux pumps, 
alterations in the ATP-binding cassette transporter (ABC transporter) superfamily, apoptotic 
processes and events associated with the WNT, NOTCH, HEDGEHOG or NANOG signalling 
pathways, need to be taken into consideration (Friberg, S. & Nyström, A.M., 2016). 
Nanoparticles able to encapsulate drugs of diverse physicochemical properties, of differing 
ratios or with a temporally sequenced release profile have been established and will most likely 
become increasingly important (Hu, C.M. & Zhang, L., 2012). 
 
Nanoparticle formulations for melanoma therapy have previously and are currently devised, 
investigated, and tested in numerous pre-clinical and clinical studies. So far, however, no 
nanoparticle has been approved for the treatment of metastatic melanoma (Berciano-Guerrero, 
M.A. et al., 2014). Promising approaches include the use and the manipulation of the tumour 
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environment. Tumour necrosis factor alpha (TNF-α)-enhanced doxorubicin was devised for the 
enhancement of tumour perfusion leading to improved drug delivery (Curnis, F. et al., 2002; 
Mundra, V. et al., 2015). Increased expression of the secreted protein acidic and rich in cysteine 
(SPARC) in human melanoma was to be exploited to increase the accumulation of albumin-
bound paclitaxel (PTX) nanoparticles to melanoma (Hersh, E.M. et al., 2015; Mundra, V. et 
al., 2015). Furthermore, novel targets which convey resistance towards therapy have been 
uncovered. These include the overexpression of the anti-apoptotic class III ß-tubulin (TUBB3) 
(Akasaka, K. et al., 2009; Mundra, V. et al., 2015) and the increase of ABCB5+ cells upon 
therapy (Chartrain, M. et al., 2012; Mundra, V. et al., 2015). In addition, several molecules 
such as CD20, CD271, CD133 and ABCB5 have been reported as melanoma stem cell markers 
and may contribute towards specific targeting by nanoparticles (Lee, N., et al., 2016; Mundra, 
V. et al., 2015).   
 
 
1.4 Aims and Objectives 
 
cAMP is a ubiquitously expressed second messenger closely linked to molecular events in skin 
pigmentation. It has however also been associated with melanoma most notably with increased 
intracellular cAMP levels which correlate with its metastatic potential. Manipulation of the 
cAMP pathway with the intent of decreasing cAMP to physiological levels in the tumour 
environment was therefore studied in the context of the transplantable B16F10-OVA murine 
tumour model.  
 
Possible points of intervention for the manipulation of the cAMP pathway are adenylyl 
cyclases, phosphodiesterases, and the cAMP effector proteins. The adenylyl cyclase inhibitor 
MDL-12, 330A hydrochloride was chosen for the intervention with the cAMP pathway due to 
its ability to non-reversibly inhibit but not completely block all nine transmembrane and the 
sole soluble adenylyl cyclase.  
 
Since cAMP does not only play a role in skin pigmentation but also in processes such as cardiac 
function or inflammation it is important to assure a continuous local application of a cAMP 
pathway modulator. To achieve continuous site directed delivery of MDL-12, 330A 
hydrochloride but also to further the development and testing of novel nanoparticles, MDL-12, 
330A hydrochloride loaded micelles were generated and analysed for their ability to interfere 
with cAMP production at the tumour site. 
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The effect of cAMP intervention in the B16F10-OVA melanoma model was investigated. For 
this purpose, growing tumours were continuously treated with MDL-12, 330A hydrochloride 
loaded micelles and in addition to the effect on their growth, alterations in the composition and 
function of the immune cell infiltrate were investigated. Based on these results strategies to 
abolish tumour growth by combining both cAMP modulation, selective cell depletion as well 
as other nanoparticle-based systems were though of and tested.  
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2. Materials  
 
 
2.1 Laboratory Equipment and Technical Accessories 
 
Apperatus Designation and Manufacturer 
Autoclave Varioklav Steam Stererlizer                                                 
(HP Medizintechnik GmbH, Oberschließheim, 
Germany) 
Calipper DIGITALCALIPER, 0-150 mm                                                                     
(Toko International BV, Zoetermeer, Netherlands) 
Cell Harvester Semiautomatic Cell Harvester Type 11019                                                
(SKATRON Instruments AS, Lier, Norway) 
Centifuges Heraeus Multifuge 3L-R Centrifuge, Heraeus Biofuge 
Prima R                                                                                           
(both ThermoFisher Scientific, Waltham, MA, USA) 
Counter 1205 BETAPLATE® Liquid Scintillation Counter                    
(LKB Instruments, Mount Waverly, Victoria, Australia) 
Counting Chamber Neubauer Counting Chamber, improved, depth 0.100 
mm (0.0025 mm2)                                                                                                                  
(LO-Laboroptik, Lancing, GB) 
Dissection Kit Motorenfamilie Medical/Prestige Medical Deluxe 
Anatomy Dissections Kit                                                                         
(GB Intruments Limited, Kilwinning, Scotland, UK) 
Flow Cytometer BD™ LSR II                                                                                      
(BDBiosciences, Becton, Dickinson and Company, 
Franklin Lakes, NJ, USA) 
Freezer economic-froster (-20 °C freezer)                                                         
(Robert Bosch GmbH, Gerlingen-Schillerhöhe, 
Germany)                    
Hera freeze HFU B series, (-80 °C freezer)                              
(ThermoFisher Scientific Inc., Waltham, USA)                                       
Arperge 110, (-180 °C freezer)                                                                      
(Air liquide S.A., Paris, France)              
Fridge FKS 1800-20, profi line                                                                 
(Liebherr-International AG, Bulle, Switzerland)                         
Tefcold FSC 1450                                                                       
(NordCap GmbH & Co. KG, Bremen, Germany) 
Ice Machine Scotsman AF80 Ice Flaker                                                                         
(Hubbard Systems, Ipswich, GB) 
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Incubator Heracell 150i CO2 Incubator                                                
Heraeus BB16 Function Line CO2 Incubator                         
(ThermoFisher Scientific Inc., Waltham, MA, USA) 
Magnetic Stirrer IKAMAG® RCT                                                                      
(Labotec Labortechnik Wiesbaden GmbH, Wiesbaden, 
Germany) 
Magnetic Welding Machine polystar®601M Magnetic Welding Machine                            
(Allpax GmbH+Co. KG, Papenburg, Germany) 
Microplate Reader ELx808 Absorbance Microplate Reader                               
(BioTek, Winooski, VT, USA) 
Microscopes Laboratory Microscopes Nikon Eclipse TS100 and E100 
(both: Nikon, Chiyoda, Tokio, Japan) 
EVOSfl Fluorescence Microscope from AMG 
(ThermoFisher Scientific Inc., Waltham, MA, USA) 
pH Meter pH211 Microprocessor pH Meter                                                                
(Hanna Intruments Inc., Woonsocket, RI, USA) 
Pipetts 2, 10, 20, 100, 200 and 1000 µl PIPETMAN                             
(all Gilson Inc., Middleton, WI, USA) 
Pipettus pipetus® junior                                                         
(Hirschmann Laborgeräte GmbH & Co. KG, Eberstadt, 
Germany) 
Razor Tondeo Exo-XS, Black Velvet                                                                        
(TONDEO, Solingen, Germany) 
Thermomixer Thermomixer Compact Type 5350                                                            
(Eppendorf, Hamburg, Germany) 
Vortex Mixer Vortex Genie 2™                                                                        
(Bender & Hobein AG, Zürich, Switzerland) 
Water Bath Thermostat 27761                                                    
(Eppendorf AG, Hamburg, Germany) 
Weighing Scale MC1 Analytic AC 210 S, BA610 Top-loading Balance                                                             
(Sartorius, Data Weighing Systems, Elk Grove Village, 
USA) 
Work Bench HeraSafe KS, KS9 and KS18                                                              
(ThermoFisher Scientific Inc., Waltham, MA, USA) 
 
Table 2.1 Laboratory equipment and technical accessories. Model and company 
purchased from used equipment and technical accessories. 
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2.2 Consumables 
 
Material Designation and Manufacturer 
Biopsie Punches Stiefel Biopsy Punch 8 mm                                                      
(GalaxoSmithKline, Brentford, UK) 
Blood Lancet Solofix® Blood Lancets                                                                        
(B.Braun Melsungen AG, Melsungen, Germany) 
Cannulas BD Microlance™ 3 23G11/4" - Nr.14 0.6x30 mm                            
BD Microlance™ 3 26G1/2" 0.45x13 mm                                              
(all BDMedical, Becton Dickinson and Company, Franklin Lankes, 
NJ, USA) 
Cell Culture Flask Tissue Culture Flask 75 cm2, Filter Screw Cap                                                                                                                                           
(TPP AG, Trasadingen, Switzerland) 
Cell Culture Dish 6-well, 24-well, 96-well flat-bottom, 96-well round-bottom, 96-well 
pointed-bottom sterile tissue culture plates with lid                                                                                   
(all Corning, Corning, NY, USA)                                                      
96-well round-bottom plate, non-sterile, no lid                                        
(Greiner Bio-One GmbH, Frickenhausen, Germany) 
Cell Strainer 70 µm Nylon Cell Strainer BD Falcon                                                                       
(Corning, Corning, NY, USA) 
Cover Slips Cover Slips for the Haemocytometer                                                               
(Menzel Gläser, ThermoFisher Scientific Inc., Waltham, MA, USA) 
Cryo Tubes Nunc™ CryoTube™ Vials, 1.8 ml                                                            
(ThermoFisher Scientific Inc., Waltham, MA, USA) 
FACS-Tubes 5 ml Polystyrene Round-Bottom Tubes, 12 x75 mm style                                                                                 
(Corning, Corning, NY, USA) 
Falcons 15 ml and 50 ml Falcons                                                                                          
(both Greiner Bio-One GmbH, Frickenhausen, Germany) 
Gloves Disposable Gloves, Nitril                                                                      
(VWR International, Radnor, PA, USA) 
Petri Dish Petri Dish, 94x16 mm                                                                         
(Greiner Bio-One GmbH, Frickenhausen, Germany) 
Pipette Tips Pipette Tips 0.1-20 ul                                                                           
(Brand GmbH, Wertheim, Germany)                                                     
Pipette Tips Gilson®-Style 200 ul, Pipette Tips Gilson®-Style 1000 
ul  
(Greiner Bio-One GmbH, Frickenhausen, Germany) 
Recation Tubes 0.5 and 1.5 ml Safe Seal Reaction Tubes                                                                
(Sarsted, Nürnbrecht, Germany)                                                          
2 ml Safe Seal Reaction Tubes                                                        
(Eppendorf AG, Hamburg, Germany) 
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Sample Bags Sample Bag for Betaplate™, maximum membrane size 102x258 mm  
(PerkinElmer, Inc., Waltham, MA, USA) 
Scalpel Feather Disposable Scalpel                                                                    
(Feather Safety Razor Co., Ltd., Osaka, Japan) 
Sheets Printed Filtermat A, for use with 1205 Betaplate™, glass fibre filter, 
size 102x258 mm                                                                                   
(PerkinElmer, Inc., Waltham, MA, USA) 
Syringes Omnican 0.01-1 ml Syringes 0.3 mm x 12 mm, Injekt®-F Syringe 
0.01 ml - 1ml/Luer Solo                                                                                 
(both B.Braun Melsungen AG, Melsungen, Germany)                               
10 ml Syringe BD Discardit™ II, BD Micro-Fine™+Demi U-100 
Insulin Syringe 0.3 mm (30G) x 8 mm                                                                               
(both BDMedical, Becton, Dickinson and Company, Franklin Lakes, 
NJ, USA) 
 
Table 2.2 Consumables. Exact description and company purchased from consumables used.  
 
 
 
2.3 Chemicals, Reagents, and Ready-To-Use Reagents 
 
Reagents Manufacturer 
Albumin Fraction V, free from biotine 
(BSA) 
Roth GmbH & Co. KG, Karlsruhe, Germany 
Ammonium Chloride (NH4Cl) Merck KGaA, Darmstadt, Geramany 
Anti-Gr-1 Antibody (Clone: RB6-8C5) M. Radsak, Institute of Immunology, University 
Medical Center Mainz, Mainz, Germany 
Aqua dest. (ddH2O) B.Braun Melsungen AG, Melsungen, Germany 
BD FACS™ Lysing Solution BD Biosciences, Becton, Dickinson and Company, 
Franklin Lakes, USA 
BD FACS Flow™  BD Biosciences, Becton, Dickinson and Company, 
Franklin Lakes, USA 
CellTrace™ Carboxyfluorescein 
Succinimidyl Ester (CFSE) Cell 
Proliferation Kit 
Invitrogen™, ThermoFisher Scientific Inc., 
Waltham, MA, USA 
CellTrace™ Violet Proliferation Kit Invitrogen™, ThermoFisher Scientific Inc., 
Waltham, MA, USA 
Collagenase Type II Gibco®, ThermoFisher Scientific Inc., Waltham, 
MA, USA 
Collagenase Typ 4 Worthington Biochemical Cooperation, Lakewood, 
NJ, USA 
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Dimethyl Sulfoxide (DMSO) Hybri-
Max® 
Sigma-Aldrich, St. Louis, MO, USA 
Deoxyribonuclease I (DNase I) from 
bovine pancreas 
F. Hoffmann-La Roche AG, Basel, Switzerland 
Diphteriatoxin (DT) Merck KGaA, Darmstadt, Germany 
Direct cAMP Enzyme-linked 
Immunosorbent Assay (ELISA) kit 
Enzo Life Sciences, Farmingdale, USA 
Dispase II (neutral protease, grade II) 
from bacillus polymyxa 
F. Hoffmann-La Roche AG, Basel, Switzerland 
Ethanol 70% denatured Roth GmbH & Co. KG, Karlsruhe, Germany 
Ethylenediaminetetraacetic Acid 
(EDTA) Disodium Salt Dihydrate 
(C10H14N2O8Na2.2H2O) 
AppliChem GmbH, Darmstadt, Germany 
Fetal Claf Serum (FCS) Gibco®, ThermoFisher Scientific Inc., Waltham, 
MA, USA 
FORENE® 100% (V/V) (Isoflurane) Abbott Laboratories, Chicago, IL, USA 
G418-BC Sulfate Biochrom, Merck KGaA, Darmstadt, Germany 
Hank’s Balanced Salt Solution (1x) 
(HBSS) 
Gibco®, ThermoFisher Scientific Inc., Waltham, 
MA, USA 
Heparin-Natrium-25000-ratiopharm® Ratiopharm GmbH, Ulm, Germany 
Human Albumin 20%, salzarm (HSA) CSL Behring LLC, King of Prussia, PA, USA 
Hydrochloric Acid (HCL) Roth GmbH & Co. KG, Karlsruhe, Germany 
MDL-12,330A hydrochloroide Calbiochem, Merck KGaA, Darmstadt, Germany 
Ovalbumin (OVA), Alexa Fluor 647 
(AF647) Conjugate 
Invitrogen™, ThermoFisher Scientific Inc., 
Waltham, MA, 
Ovalbumin EndoFit™ InvivoGen, San Diego, CA, USA 
Penicillin-Streptomycin (10.000 Units 
Penicillin, 10 mg Streptomycin/ml in 
0,9% NaCl) 
Sigma-Aldrich, St. Louis, MO, USA 
Potassium Hydrogen Carbonate 
(KHCO3) 
Carl Roth, Karlsruhe, Germany 
Privigen Infusion Solution (normal 
Immunoglobulin for humans IVIg 100 
mg/ML) 
CSL Behring LLC, King of Prussia, PA, USA 
Rotizint®eco plus  Roth GmbH & Co. KG, Karlsruhe, Germany 
Sodium Chloride (NaCl) Roth GmbH & Co. KG, Karlsruhe, Germany 
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Sodium Phosphate Monobasic 
Dihydrate 
(NaH2PO4·2H2O) 
Merck KGaA, Darmstadt, Germany 
Sodium Hydroxide (NaOH) Roth GmbH & Co. KG, Karlsruhe, Germany 
Thymidine, (methyl-3H)-
NET027X005MC (3H-Thymidin) 
PerkinElmer, Inc., Waltham, MA, USA 
Transcription Factor Buffer Set BDBiosciences, Franklin Lakes, NJ, USA 
Triton X-100 Sigma-Aldrich, St. Louis, MO, USA 
Trypan Blue Solution (0,4%) Sigma-Aldrich, St. Louis, MO, USA 
Trypsin-Ethylenediaminetetraacetic 
Acid (Trypsin-ETDA) 
Sigma-Aldrich, St. Louis, MO, USA 
 
Table 2.3 Chemicals, reagents, and ready-to-use reagents. Exact description and company 
purchased from chemicals, reagents and ready-to-use reagents used.  
 
 
 
2.4 Antibodies 
 
Antibody Reactivity Isotyp Clone Conjugate Manufacturer 
CD3 Mouse Rat 
IgG2b, 
kappa 
17A2 PE-Cy7 BioLegend, San 
Diego, CA, USA 
CD4 Mouse Rat 
IgG2b, 
kappa 
GK1.5 eFluor 450 eBioscience, 
ThermoFisher 
Scientific Inc., 
Waltham, MA, 
USA 
CD4 Mouse Rat 
IgG2b, 
kappa 
GK1.5 PE-Cy7 BioLegend, San 
Diego, CA, USA 
CD8a Mouse Rat 
IgG2b, 
kappa 
53-6.7 APC eBioscience, 
ThermoFisher 
ScientificInc., 
Waltham, MA, 
USA 
CD8a Mouse Rat 
IgG2a, 
kappa 
53-6.7 PerCP BDBiosciences, 
Becton, Dickinson 
and Company, 
Franklin Lakes, 
USA 
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CD11b Mouse Rat 
IgG2b 
M1/70 APC ImmunoTools, 
Friesoythe, 
Germany 
CD11b Mouse Rat 
IgG2b 
M1/70 PE ImmunoTools, 
Friesoythe, 
Germany 
CD11c Mouse Armenian 
Hamster 
IgG 
N418 PE-Cy5 BioLegend, San 
Diego, CA, USA 
CD25 Mouse Rat 
(OFA) 
IgG1 
PC61 PE-Cy7 BDBiosciences, 
Becton, Dickinson 
and Company, 
Franklin Lakes, 
USA 
CD45 Mouse Rat 
IgG2b, 
kappa 
30-F11 APC-
eFluor 780 
eBioscience, 
ThermoFisher 
Scientific Inc., 
Waltham, MA, 
USA 
CD45R/B220 Mouse/Human Rat 
IgG2a, 
kappa 
RA3-
6B2 
PE-Cy7 BioLegend, San 
Diego, CA, USA 
CD115 Mouse Rat 
IgG2a, 
kappa 
AFS98 PE BioLegend, San 
Diego, CA, USA 
FC Block 
(CD16/CD32) 
Mouse Rat 
IgG2a, 
lambda 
93   eBioscience, 
ThermoFisher 
Scientific Inc., 
Waltham, MA, 
USA 
Fixable 
Viability Dye 
Mouse/Human     eFluor506 eBioscience, 
ThermoFisher 
Scientific Inc., 
Waltham, MA, 
USA 
FoxP3 Mouse/Human/Dog Rat 
IgG2a, 
kappa 
FJK-
16s 
PE eBioscience, 
ThermoFisher 
Scientific Inc., 
Waltham, MA, 
USA 
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KLRG-1 
(CSF-1R) 
Mouse Syrian 
hamster 
IgG 
2F1 FITC BioLegend, San 
Diego, CA, USA 
Ly-6C Mouse Rat 
IgG2c, 
kappa 
HK1.4 PerCP-
Cyanine5.5 
eBioscience, San 
Diego, USA 
Ly-6C Mouse Rat 
IgG2c, 
kappa 
HK1.4 PE-Cy7 BioLegend, San 
Diego, CA, USA 
Ly-6G Mouse Rat 
IgG2a, 
kappa 
1A8 PB BioLegend, San 
Diego, CA, USA 
NK1.1 Mouse Mouse 
IgG2a, 
kappa 
PK136 PE eBioscience, 
ThermoFisher 
Scientific Inc., 
Waltham, MA, 
USA 
NK-1.1 Mouse Mouse 
IgG2a, 
kappa 
PK136 PE-Cy7 BioLegend, San 
Diego, CA, USA 
TCR beta 
(TCRβ) chain 
Mouse Armenian 
Hamster 
IgG2 
H57-
597 
PE-Cy5 BD Biosciences, 
Becton, Dickinson 
and Company, 
Franklin Lakes, 
USA 
 
Table 2.4 Antibodies. Antibody, reactivity, isotype, clones, fluorescence, and company 
purchased of antibodies used.  
 
 
 
2.5 Buffers 
 
Buffer Composition 
0.5 M EDTA                                  
pH 8.0                                
(autoclaved after preparation, stored for ≥6 
months at 4 °C) 
181.1 g C10H14N2O8Na2.2H2O                                   
Ad 1L Aqua dest. 
10x PBS                                         
pH 6.6                             
(autoclaved after preparation) 
80.4 g NaCl                                                            
15.6 g NaH2PO4∙2H2O                                                 
Ad 1L Aqua dest. 
1xPBS 0.1 L 10xPBS                                                         
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Ad 1L Aqua dest.  
ACK (Ammonium-Chloride-Potassium)-
Buffer 
pH 7.4 
8.29 NH4Cl                                                            
1.0 g KHCO3                                                            
200 µl l 0.5 M EDTA                                          
Ad 1L Aqua dest. 
FACS-Buffer 25 ml HSA                                                          
2 ml 0,5 M EDTA                                             
200 µl Privigen Infusion Solution                           
Ad 1L1xPBS 
Freezing Media 20 ML FCS                                                            
5 ml DMSO 
MACS-Buffer 25 ml HSA                                                              
6 ml 0.5 M EDTA                                                    
Ad 1 L 1xPBS 
Trypan-Blue 1 ml Trypan Blue Solution (0.4%)                           
9 ml 1xPBS 
 
Table. 2.5 Buffers. Recipes of buffers used.  
 
 
 
2.6 Cell Culture Media 
 
Material Manufacturer 
Dulbecco’s Modified Medium 
(DMEM) 
Gibco®, ThermoFisher Scientific Inc., Waltham, 
MA, USA 
Iscove`s modified Dulbecco`s 
Medium (IMDM) with 4 mM L-
Glutamine and 25 mM (4-(2-
hydroxyethyl)-1-
piperazineethanesulfonic acid) 
HEPES  
Lonza Group AG, Basel, Switzerland 
Roswell Park Memorial Institute 
(RPMI)1640  
Gibco®, ThermoFisher Scientific Inc., Waltham, 
MA, USA 
RPMI 1640 with 2 mM L-
Glutamine 
Gibco®, ThermoFisher Scientific Inc., Waltham, 
MA, USA 
X-Vivo 20  Lonza Group AG, Basel, Switzerland 
 
Table 2.6 Cell culture media. Media and company purchased of media commonly used for 
cell culture. 
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2.7 Cell Lines 
 
Cell Line Description Source 
B16F10-OVA Murine 
Melanoma Cell 
Lines 
M. Dieken, TrOn, Mainz, Germany 
MC-38 Murine 
Adenocarcinoma 
Cell Line 
H.C. Probst, Institute of Immunology, University 
Medical Center Mainz, Mainz, Germany  
 
2.7 Cell lines. Cell Lines and source of cell lines used.  
 
 
 
2.8 Experimental Animals 
 
Strain Source Official Strain Name Stock Number 
C57BL/6J Jackson 
Laboratory, Bar 
Harbor, ME, USA 
C57BL/6J JAX Stock Number: 
000664 
Great Jackson 
Laboratory, Bar 
Harbor, ME, USA 
B6 129 S4-IFNg JAX Stock Number: 
017581 
Nur77 Jackson 
Laboratory, Bar 
Harbor, ME, USA 
Nur77-EGFP-
Cre(tg(Nr4a1-
EGFP/cre)820Khog) 
JAX Stock Number: 
016617 
DEREG Jackson 
Laboratory, Bar 
Harbor, ME, USA 
C57BL/6-Tg(Foxp3-
TR/EGFP)23.2Spae/Mmjax 
MMRRC Stock Number: 
32050-JAX 
OT-I Jackson 
Laboratory, Bar 
Harbor, ME, USA 
C57BL76-
Tg(TcraTcrb)1100Mjb/J 
JAX Stock Number: 
003831 
OT-II Jackson 
Laboratory, Bar 
Harbor, ME, USA 
B6.Cg-
g(TcraTcrb)425Cbn/J 
JAX Stock Number: 
004194 
 
Table 2.8 Experimental animals. Official strain name, company purchased, and stock 
number of mice used.  
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2.9 Software 
 
Software Manufacturer 
FlowJo version 7 Tree Star, Inc., Ashland, OR, USA 
GraphPad Prism 6 GraphPad Software, Inc., La Jolla, CA, USA 
KC Junior BioTek, Winooski, VT, USA 
 
Table 2.9 Software. Software and manufacturer of software used.  
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3. Methods 
 
 
3.1 Cell Biological Methods   
 
3.1.1 Cell Culture 
 
Cell culture was handled under a sterile workbench while using sterile materials. Materials or 
solutions introduced into the workbench were previously autoclaved or sterilised using 70% 
ethanol. Cells were cultivated in buffered media and incubated in an incubator at 37 °C and 5% 
CO2.  
 
 
3.1.2 Cell Lines 
 
The ovalbumin (OVA) expressing murine melanoma cell line B16F10-OVA (Fidler, I.J., 1970; 
Fidler, I.J., 1973a, Fidler, I.J., 1973b; Kedl, R.M. et al., 2001) was provided by M. Dieken, 
TrOn, Mainz, Germany while the murine colon adenocarcinoma cell line MC-38 (Corbett, T.H. 
et al., 1975) was provided by H.C. Probst, Institute of Immunology, University Medical Centre, 
Mainz, Mainz, Germany.  
 
 
3.1.2.1 B16F10-OVA 
 
The B16 melanoma is a melanin producing murine melanoma cell line characterized by a 
mixture of spindle-shaped and epithelial-like cells which is most commonly used to model 
human melanoma and metastasis. In 1954, B16 spontaneously developed in the skin at the base 
of the ear of a C57BL/6J mouse at the Jackson Laboratory, Bar Harbor, Main (Green, E, 1968; 
Alvarez, E., 2002, B16-F10 (ATCC® CRL-6475™). It was propagated in mice by subcutaneous 
transplantation, would kill the host within 3-5 weeks and metastasize into the lung, liver; and 
spleen (Bertalanffy, F.D. & McAskill, C., 1964).  
 
Isiah J. Fidler experimented with these cells in the 1970s and established the cell lines B16F1 
and B16F10. After intravenous injection, pulmonary metastases were continuously passaged in 
mice (Fidler, I.J., 1970; Fidler, I.J., 1973a; Fidler, I.J., 1973b; Alvarez, E., 2002). Both B16F1 
and B16F10 do form metastases in the lung upon intravenous injection, whereby B16F10, the 
most passaged of these two, is characterized by a significantly higher metastatic potential likely 
due to subtle cell surface modifications (Raz, A., et al., 1980). While B16F10 exclusively forms 
metastases in the lung, other sites can also be affected when B16F1 is used. These include the 
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liver, spleen, adrenal glands, and mesentery lymph nodes (Fidler, I.J. & Nicolson, G.L., 1976). 
The subcutaneous B16 model is commonly used for the evaluation of potential therapeutic 
regiments (Overwijk, W.W. & Restifo, N.P., 2001).  
 
B16F10 has been modified by its transfection with ovalbumin (OVA) to generate the B16F10-
OVA cell line. The full-length OVA gene with the neomycin-resistance selection gene was 
therefore placed under the control of the cytomegalovirus long terminal repeat promoter (Kedl, 
R.M. et al., 2001). OVA is a non-toxic, slightly immunogenic T cell dependent protein which 
was first isolated in 1889 from the egg white of a chicken’s egg. In immunology it is frequently 
used to study antigen-specific immune responses in mice. B16F10-OVA allows to do so in the 
context of tumour responses (Hofmeister, F., 1889; Bellone, M. et al., 2000). 
 
 
3.1.2.2 MC-38 
 
MC-38 is a chemically induced murine colon adenocarcinoma which was established in 1975 
in the laboratory of F.M. Schabel Jr., Kettering-Meyer Laboratories, Southern Research 
Institute, Birmingham, Alabama. It has been provoked by the subcutaneous injection of 
dimethylhydrazine (DMH) and is syngeneic to C57BL/6 mice. Upon subcutaneous 
implantation metastases have primarily been noted in the lung while intraperitoneal 
administration of the tumour cells results in the detection of metastases in the liver (Corbett, 
T.H. et al., 1975). 
 
 
3.1.3 Cryo-conservation of Cell Lines 
 
For cryo-conservation, 10x106 B16-OVA cells per cryotube, were stored for at least 24 hours 
in 1 ml freezing medium at -80 °C. For lasting preservation, the cells were transferred into 
liquid nitrogen tanks at -180 °C. 
 
 
3.1.4 Defrosting of cryo-conserved Cell Lines  
 
Cryo-conserved B16F10-OVA were thawed for 1 minute in a water bath at 37 °C. Together 
with 5 ml FCS and 10 ml Iscove's Modified Dulbecco's Medium (IMDM) with 4 mM L-
Glutamine and 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) the cells 
were transferred into a 15 ml falcon and centrifuged for 6 minutes at 360 g and 4 °C. The 
supernatant was discarded, the cells were suspended in 5 ml medium and centrifuged again at 
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the same settings. Once more the supernatant was discarded, the cells were suspended in 1 ml 
medium and then transferred into a 75 cm2 cell culture flask supplemented with 15 ml of 
medium. Dead cells were removed the next day by replacing the medium with fresh medium. 
To start the selection for OVA producing cells the medium of B16F10-OVA was supplemented 
with 300 µg/ml G418-BC Sulfate. 
 
 
3.1.5 Maintenance of B16-OVA  
 
B16F10-OVA were cultured in IMDM with 4 mM L-Glutamine and 25 mM HEPES 
supplemented with 10% fetal calf serum (FCS), 1% penicillum/streptomycin and 300 µg/ml 
G418-BC Sulfate. The cells were kept in a 75 cm2 cell culture flasks in an incubator at 37°C in 
5% CO2 and passaged when approximately 70% confluent. 
 
 
3.1.6 Maintenance of MC-38 
 
MC-38 were cultured in IMDM with 4 mM L-Glutamine and 25 mM HEPES supplemented 
with 10% FCS and 1% penicillum/streptomycin. The cells were kept in a 75 cm2 cell culture 
flasks in an incubator at 37 °C in 5% CO2 and passaged when approximately 70% confluent.   
 
 
3.1.7 Passaging of Cell Lines 
 
The medium was removed from the flask and the cells were twice washed with 1x phosphate 
buffered saline (PBS). 2 ml of trypsin-ethylenediaminetetraacetic acid (Trypsin-EDTA) were 
then added to the flask which was then incubated for 5 minutes at 37 °C in 5% CO2. As soon 
as the cells had detached from the plastic dish, the Trypsin-EDTA was neutralized with 2 ml of 
media. The suspension was then centrifuged for 6 minutes at 360 g and 4 °C. Following 
centrifugation, the supernatant was discarded, and the pellet was resuspended in an appropriate 
amount of medium. The cells were then placed into a new flask at the desired concentration and 
kept in an incubator at 37 °C in 5% CO2  
 
 
3.1.8 Determination of Live Cells 
 
The hemocytometer is a modified and calibrated microscope slide frequently used to estimate 
the number of cells in a known volume. Louis-Charles Malassez first used it to count blood 
cells (Malassez, L.C., 1873). Nowadays it is most commonly used in combination with trypan 
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blue which allows to distinguish viable from non-viable cells. To determine cell numbers cells 
within a large square of 16 individual squares are counted under a microscope. 
 
The number of viable cells, trypan blue negative, is calculated using the following formula: 
 
Total Cell Number = Cell Number per Big Square x Dilution Factor x Volume x 104 (Chamber 
Constant) 
 
 
3.1.9 Plating out of Cell Lines  
 
B16F10-OVA or MC-38 were plated out at a concentration of 2x106 cells/per well in a flat-
bottom 6-well plate or at 2x105 in a flat-bottom 96-well plate. After shortly centrifuging the 
cells at 360 g without breaks and 4 °C, the cells were placed in the incubator at 37 °C and 5% 
CO2 until they started to attach to the plastic dish.  
 
 
3.2 In Vitro Experiments  
 
3.2.1 Inhibition of cAMP by Adenylyl Cyclase Inhibition 
 
Adenylyl cyclases (AC) are enzymes which catalyse the conversion of ATP into the second 
messenger cAMP and pyrophosphate. In mammals, there exist in total 10 different adenylyl 
cyclases, nine transmembrane adenylyl cyclases (tAC1-9) and one soluble adenylyl cyclase 
(sAC10). They are differently expressed throughout the body, whereby most tissues express 
multiple adenylyl cyclases (Sadana, R. & Dessauer, C.W., 2009).  
 
Both transmembrane and soluble adenylyl cyclases are homodimers with one polypeptide chain 
which have two structurally similar catalytic sites, C1 and C2, forming a pseudo-heterodimer. 
Transmembrane adenylyl cyclases also feature two hydrophobic domains each representing six 
membrane spanning helices which localize these to membranes. G protein-coupled receptors 
and heterotrimeric G proteins regulate transmembrane adenylyl cyclases, while soluble 
adenylyl cyclases are directly regulated by Ca2+, the metabolite bicarbonate and variations of 
ATP levels (Sadana, R. & Dessauer, C.W., et al., 2009; Seifert, R., et al., 2012). 
 
Modulation of cAMP, which includes the inhibition of adenylyl cyclases, is of interest in a great 
number of research fields. There exists a vast variety of adenylyl cyclase inhibitors which at 
the catalytic site compete with the ATP substrate, mimic the cAMP∙PPi transition state or target 
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regulatory or yet undefined binding sites. One of the numerous inhibitors is MDL-12, 330A 
hydrochloride (Seifert, R., et al., 2012). 
 
 
3.2.1.1 MDL-12, 330A hydrochloride 
 
MDL-12, 330A hydrochloride also known as RMI 12330A or cis-N-(2phenylcyclopentyl) 
azacyclotridec-1-en-2-amine monohydrochloride is a lactam-imine which was devised at the 
Merrell Research Centre, Cincinnati, Ohio; USA and first reported on in the late 1970th (Siegel, 
B.W. & Wiech, N.L., 1976, Guellaen; G. et al., 1977). It is a hydrophobic cell-permeable non-
nucleotide-based inhibitor of soluble and transmembrane adenylyl cyclases which is well 
soluble in organic solutions. Its non-nucleotide-based structure is advantageous since cytotoxic 
long-term effects due to interference with deoxyribonucleic acid (DNA) synthesis or the purine 
metabolism can be avoided (Seifert, R. et al., 2012; Emery, A.C. et al., 2013). 
 
Inhibition of both basal as well as stimulated adenylyl cyclases by MDL-12, 330A 
hydrochloride is immediate and irreversible due to its association with the plasma membrane. 
It has furthermore been reported to interfere with the glycine transport, calcium related 
mechanisms and to affect Mg2+-ATPases but not Na+, and K+-ATPases and to inhibit 
phosphodiesterases (Hunt, N.H. & Evans, T. 1980; Grupp, G. et al., 1980; Gadea et al., 1999; 
Van Rossum et al., 2000). The non-competitive simultaneous inhibition of both adenylyl 
cyclases and phosphodiesterases is most likely due to a shared site of inhibition. Nevertheless, 
MDL-12, 330A hydrochloride is still more effective when inhibiting adenylyl cyclases (Lippe, 
C. & Ardizzone, C., 1991; Seifert, R. et al., 2012).  
 
MDL-12, 330A hydrochloride was purchased from Calbiochem, Merck KGaA, Darmstadt, 
Germany. A 10 mM stock solution was prepared upon its dissolution in DMSO, aliquoted and 
stored for up to three months at -20 °C. The proper working of every new charge was checked 
by incubating B16F10-OVA with lethal and sublethal concentrations of MDL-12, 330A 
hydrochloride. For short term in vitro experiments MDL-12, 330A hydrochloride was used at 
a final concentration of 10 µM, whereas in vivo inoculated tumours were treated with 20 µM or 
200 µM MDL-12, 330A hydrochloride/50 µl. 
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3.2.1.2 MDL-12, 330A hydrochloride loaded Micelles 
 
The amphiphilic peptide-based polypeptoid-block-polypeptide copolymer polysacrcosine-
block-polyglutamatic acid bezylester (PSar-b-PGlu(OBn)) was used for the preparation of 
empty and MDL-12, 330A hydrochloride loaded micelles. Synthesis and characterization of the 
polymer as well as the preparation of the micelles was carried out by Alexander Birke, AK 
Barz, Institute of Organic Chemistry, Johannes Gutenberg-University Mainz, Mainz, Germany.  
 
MDL-12, 330A hydrochloride loaded micelles were prepared by dual centrifugation upon 
vigorous mixing of the polymer and the drug. Free MDL-12, 330A hydrochloride was separated 
from the resulting solution by spin filtration. To quantify the amount of MDL-12, 330A 
hydrochloride encapsulated in the micelles, samples of the filtrate were subjected to High-
Performance Liquid Chromatography (HPLC). Portions of the purified micellar solution were 
lyophilized for the subsequent determination of the total mass concentration. For in vivo 
tracking studies the polymer was coupled with the fluorophore Oregon Green. Upon coupling 
free fluorophore was removed by dialysis and MDL-12, 330A hydrochloride loaded and empty 
micelles were prepared. Based on the HPLC quantification of MDL-12, 330A hydrochloride 
the amount of particle to be used for each individual experiment was determined. The amount 
of empty particle used was adjusted to MDL-12, 330A hydrochloride loaded particles based on 
the mass concentration determined for both. 
 
 
3.2.1.3 Treatment of Cell Lines with free MDL-12, 330A hydrochloride and MDL-12, 
330A hydrochloride-loaded Micelles to assess the Effect of the Treatment on 
Proliferation  
 
When the melanoma cells had started to attach to the plastic dish the appropriate reagents were 
added to the flat-bottom 96-well plate. They were forced to instantly associate with the cells by 
a short round of centrifugation at 360 g without breaks at 4 °C. The cells were subsequently 
incubated at 37 °C and 5% CO2. At the end of the incubation period, 0.5 µCi/well 
3H-Thymidin 
were added for another 18 hours. By default, DNA synthesis in proliferating cells is 
demonstrated by the incorporation of 3H-Thymedin during cell division. Autoradiographic 
methods such as the ß-Counter are then used to measure proliferation. 
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3.2.1.4 Treatment of Cell Lines with MDL-12, 330A hydrochloride and MDL-12,330A 
hydrochloride loaded Micelles for the Determination of the intracellular cAMP 
Content by Enzyme-linked Immunosorbent Assay (ELISA) 
 
As soon as the cells had started to attach to the plastic dish the relevant reagents were added to 
the flat-bottom 6-well plate. They were forced to immediately associate with the cells by a short 
round of centrifugation at 360 g without breaks and 4 °C. The cells were then left to incubate 
at 37 °C and 5% CO2. At the end of the incubation period the supernatant was removed and 
discarded. The cells were detached from the cell culture plate using 500 µl of Trypsin-EDTA. 
It was neutralized with 750 µl of IMDM with 4 mM L-Glutamine and 25mM HEPES and the 
cell suspension was transferred into a 1.5 ml Eppendorf tube which was then centrifuged for 10 
minutes at 360 g and 4 °C. The supernatant was discarded and twice centrifuged to remove the 
remaining media. The dry pellet was then frozen at -80 °C and stored at these conditions until 
measured by ELISA (Enzyme-linked Immunosorbent Assay). 
 
 
3.2.2 Determination of the cAMP content of In Vitro and In Vivo generated Probes 
 
3.2.2.1 cAMP ELISA 
 
The Direct cAMP ELISA kit from Enzo Life Sciences was used to determine the intracellular 
cAMP concentration of murine cell lines and tissue. It was carried out according to the 
manufacturer’s instructions. 
 
 
3.2.2.2 Lysis of In Vitro generated Probes for the Determination of the cAMP Content 
 
Cell samples stored at -80 °C were thawed at room temperature. To ensure complete cell lysis, 
they were resuspended in 150 µl of 0.1 M HCL spiked with 1% Triton X-100, thoroughly 
vortexed and snap-frozen at -80 °C. Mild thawing at room temperature and rigorous vortexing 
was followed by numerous freeze-thaw cycles. To remove cellular debris from the probe, it was 
centrifuged for 10 minutes at 4 °C and 600 g. In total 100 µl of the supernatant were used to 
determine the cAMP concentration by ELISA. The dilution factor (DF=1.5) was taken into 
consideration when calculating the probes cAMP content.    
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3.2.2.3 Lysis of Ex Vivo generated Probes for the Determination of the cAMP Content 
 
Tissue samples stored at -80 °C were thawed, shock-frozen in liquid nitrogen and a single cell 
suspension was prepared upon the disruption of the tissue on a 70 µm cell strainer. The cell 
strainer was washed with 300 µl of 0.1 M hydrochloric acid (HCL) spiked with 1% Triton X-
100 and the cell suspension was transferred into a 1.5 ml Eppendorf tube and frozen at -80 °C. 
Thawing of the probes at room temperature, rigorous vortexing and several freeze-thaw cycles 
were followed by the removal of cellular components by centrifugation for 10 minutes at 4 °C 
and 600 g. 100 µl of the supernatant were used to assay the cAMP content by ELISA. The 
dilution factor (DF=3) was taken into consideration when calculating the probes cAMP content.    
 
 
3.3 Handling of Mice used for Animal Experiments  
 
3.3.1 Mouse Strains used for Animal Experiments 
 
All mice were bread and housed in the facilities of the Translational Animal Research Centre 
(TARC) of the University Medical Centre in Mainz, Mainz, Germany. Animal experiments 
were carried out with the approval (Tierversuchsnummer: G12-1-087) of the 
Landesuntersuchungsamt Koblez, Koblenz, Rhineland-Palatinate, Germany and in accordance 
with the Helsinki Convention for the use and care of animals (WMA, 2016).  
 
 
3.3.1.1 C57BL/6 (JAX Stock Number: 000664) 
 
C57BL is an inbred laboratory mouse strain established by C.C. Little in 1921. C57BL/6J did 
separate from the original strain in 1937 while kept at the Jackson Laboratories. It has since 
been used extensively for the generation of novel mouse strains (Song, H.K. & Hwang, D.Y., 
2017).  
 
3.3.1.2 B16 129 S4-IFNg (JAX Stock Number: 017581) 
 
B6 129 S4-IFNg, also referred to as GREAT (interferon-gamma reporter with endogenous 
polyA transcript) is a homozygous interferon gamma reporter mouse on a C57BL/6 
background. When generating the mouse homologous recombination was utilized to introduce 
an internal ribosome entry site (IRES)-enhanced yellow fluorescent protein (eYFP) amongst 
the stop codon and the 3’ untranslated (UTR)/polyA tail of the ifng gene. The Interferon-gamma 
(IFN-γ) promoter/enhancer region and the endogenous 3’ UTR and polyA tail regulate the 
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IFNy-IRES-eYFP messenger ribonucleic acid (mRNA) transcription as in the endogenous 
gene. IFN-γ positive cells can be detected ex vivo and in vivo by means of Flow Cytometry or 
Fluorescent Microscopy without the need for prior re-stimulation (Reinhardt, R.L., et al., 2009; 
Reinhardt, R.L. et al., 2015). 
 
 
3.3.1.3 Nur77-EGFP-Cre(tg(Nr4a1-EGFP/cre)820Khog) (JAX Stock Number: 016617) 
 
Nur77-EGFP-Cre(tg(Nr4a1-EGFP/cre)820Khog), also called Nur77 is a hemizygous BAC 
(bacterial artificial chromosome) transgenic reporter mouse on a B6-820 background. An 
enhanced green fluorescent protein/codon-optimized “humanized” Cre recombinase fusion 
protein (eGFP-hCre) has been integrated within the BAC transgene and placed under the control 
of the orphan nuclear receptor Nr4a1 (Nur77) promoter/enhancer region. The observed levels 
of green fluorescent protein (GFP) follows the endogenous Nur77 expression but is delayed 
because of the longer half-life of the GFP. Cre recombinase activity is present throughout the 
hematopoietic cell compartment (Moran, A.E. et al., 2011). 
 
The Nur77 mouse is suitable for studying both the myeloid as well as the lymphoid cell 
compartment. T and B lymphocytes express low levels of Nur77 which are not affected by 
inflammatory stimuli but get elevated upon antigen receptor stimulation. Peak expression levels 
are reached between 12 and 24 hours and mirror the strength of the T cell receptor stimulation. 
Nur77 expression in mature naïve T cells results from a continuous contact with the Major 
Histocompatibility Complex (MHC) (Moran, A.E. et al., 2011). Significant levels of Nur77 are 
detected in Ly6Cneg monocytes, also referred to as vascular patrolling monocytes (Hanna, R.N. 
et al., 2012).  
 
 
3.3.1.4 C57BL/6-Tg(Foxp3-DTR/EGFP)23.2Spar/Mmjax (MMRRC Stock Number: 
32050-JAX) 
 
C57BL/6-Tg(Foxp3-DTR/EGFP)23.2Spar/Mmjax, commonly referred to as DEREG 
(depletion of regulatory T cells), is a hemizygous BAC transgenic mouse on a C57BL/6 
background which expresses a diphtheria toxin receptor (DTR) enhanced green fluorescence 
protein (eGFP) under the control of the forkhead box P3 (FoxP3) promoter. Mouse Tregs, which 
are defined by the transcription factor FoxP3, can be temporarily ablated by diphtheria toxin 
(DT) injection and tracked by the expression of GFP. Upon removal Treg frequencies recover 
within 6 days (Lahl, K. et al., 2007; Lahl, K. & Sparwasser, T., 2011).   
  Methods 
  
35 
Due to incomplete transgene expression and DT resistant Tregs the depletion efficiency of 
DREG mice only reaches up to 98%. These remaining Tregs prevent the onset of uncontrolled 
autoimmunity which makes the model particularly suitable when studying Treg function in 
adult mice. To avoid DT side effects such as weight loss or proteinuria, DT concentrations need 
to be carefully adjusted. The advent of anti-DT antibodies should be taken into consideration 
in long-term depletion regiments (Mayer, C.T. et al., 2014; Wang, J. et al., 2016).  
 
 
3.3.1.5 C57BL/6-Tg(TcraTcrb)1100Mjb/J (JAX Stock Number: 003831) 
 
C57BL/6-Tg(TcraTcrb)1100Mjb/J, also known as OT-I, is a hemizygous transgenic mouse on 
a C57BL/6 background. A rearranged T cell receptor, Tcra-v2/Tcrb-V5, specific for the 
H2Kb/chicken ovalbumin peptide 257-264 (SINFEKEL), was introduced into the genome. OT-
I mice are commonly used to examine the response of CD8+ T cells to ovalbumin (Hogquist, 
K.A., et al., 1994). 
 
 
3.3.1.6 B6.Cg-Tg(TcraTcrb)425Cbn/J (JAX Stock Number: 004194) 
 
B6.Cg-Tg(TcraTcrb)425Cbn/J, also referred to as OT-II.2, is a homozygous transgenic mouse 
on a C57BL/6 background. A T cell receptor, Tcr-v2/Tcrb-V5, specific for the H2-Ab1/chicken 
ovalbumin peptide 323-339, was inserted into the genome. The mice are characterized by a 
four-fold increase in the CD4+ to CD8+ ratio of peripheral T cells and are used when studying 
the response of CD4+ T cells to ovalbumin (Barnden, M.J. et al., 1998).  
 
3.3.2 Screening of Nur77 and DEREG Mice 
 
Mice were forcibly sized in a forced grip. Blood samples were obtained from the vena facialis 
at a point where the orbital vein, the submandibular vein and other veins meet to form the 
jugular vein. To obtain blood, it was punctured using a blood lancet. Several drops of blood 
were collected in a 1.5 ml Eppendorf tube supplemented with 50 µl Heparin-Natrium. The 
probes were stained with antibodies against CD45, CD4 and CD25 for 30 minutes in the dark 
at room temperature. To lyse the erythrocytes that otherwise would interfere with the flow 
cytometric measurement, 1 ml of BD Lysing Solution (1ml BD Lysing Solution added to 9 ml 
ddH20) was added, resuspended with each probe, and left to incubate for 20 minutes in the dark 
at room temperature. Up until clear samples were obtained, the probes were washed with 2 ml 
of FACS-Buffer and centrifuged for 6 minutes at 4 °C and 360 g. The samples were evaluated 
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using Flow Cytometry whereby Nur77 mice with elevated levels of eGFP expression in the 
myeloid compartment and DEREG mice with elevated levels of eGFP in the 
CD45+CD4+CD25+ compartment were designated to be Nur77 or DEREG positive. 
 
 
3.4 Immunological Methods 
 
3.4.1 Isolation of Organs and Preparation of Single Cell Suspensions 
 
CO2 fumigation was used when killing mice. The mice were opened, different organs were 
removed, and single cell suspensions were prepared for analysis by Flow Cytometry. When 
preparing single cell suspensions of organs well supplied with blood, erythrocytes were lysed 
by ACK (Ammonium-Chloride-Potassium) lysis. While lysing cells, ammonium chloride 
accumulates inside the cell, which leads to an increase in osmotic pressure and the rupture of 
the erythrocytes (Bossuyt, X. et al., 1997).   
 
 
3.4.1.1 Peritoneal Exudate Cells (PECs) 
 
Peritoneal exudate cells (PECs) can be found in the mammalian peritoneal cavity which 
harbours macrophages, T and B cells. For the extraction of these cells a euthanized mouse was 
mounted on a dissection pad, sprayed with 70% ethanol and the outer skin of the peritoneum 
was cut open with the help of forceps and scissors. The skin was gently separated from the inner 
skin of the peritoneal cavity and a syringe with a 26G needle was carefully inserted into the 
peritoneum while paying attention to not puncture any organs. 5 ml of ice cold 1x Hank’s 
Balanced Salt Solution (HBSS) were injected into the peritoneal cavity, the peritoneum was 
massaged to increase the yield of the cells harvested and a syringe with a 23G needle was 
introduced into the peritoneum to collect as much fluid as possible. The cell suspension was 
collected in a 15 ml falcon and the cells were pelletized by centrifuging them for 10 minutes at 
4 °C and 360 g. If necessary erythrocytes were removed by treating the cells with ACK-Buffer. 
Therefore, the supernatant was discarded, the cells were mixed and incubated for 2 minutes 
with 2 ml of ACK-Buffer. FACS-Buffer was then added, the cells were centrifuged for 10 
minutes at 4°C and 360 g and it was evaluated weather another round of ACK lysis was 
necessary.  
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3.4.1.2 Blood 
 
Blood was extracted from the heart of euthanized mice. The mouse was therefore mounted on 
a dissection pad. An incision was made a few millimetres above the urinary orifice and was 
guided down the mid ventral side to the chin. Subsequently the abdominal cavity was opened 
up to the base of the thorax. Upon lifting the thorax, the sternum and later the diaphragm were 
cut open and the rib folding’s were removed leading to the exposer of the thymus, lungs, and 
heart. A syringe with 100 µl of the anticoagulating agent Natrium-Heparin was used to puncture 
the right ventricle of the heart and to carefully remove as much blood as possible. The blood 
was collected in a 15 ml falcon which was filled with media and centrifuged for 10 minutes at 
4 °C and 360 g. After the supernatant had been discarded the blood was mixed with 2 ml of 
ACK-Buffer and left to incubate for 3 minutes. The addition of FACS-Buffer was followed by 
one round of centrifugation for 10 minutes at 4 °C and 360 g. This procedure was repeated until 
only a small pellet of cells was left.  
 
 
3.4.1.3 Skin 
 
To isolate skin cells, the fur of a euthanized mouse was removed with a razor prior to mounting 
the mouse on a dissection pad. Millimetres above the urinary orifices an incision was made and 
guided down the mid ventral side to the chin. Two lateral incisions were then extended towards 
the extremities of forelimbs and hindlimbs and the skin was separated from the underlying 
muscular layer. The skin was removed from the mouse, placed on the mounting pad and a skin 
biopsy stance was used to take about 6 biopsies. These biopsies were then transferred into one 
well of a flat-bottom 6-well plate with 2 ml of 1xPBS supplemented with 1 mg/ml Dispase II 
and 50 U/ml desoxyribonuklease I (DNase I). Prior to the start of 45 minutes of incubation at 
37 °C forceps and a scalpel were used to place numerous small incisions into each biopsy. To 
stop the digestion, 1 ml of FCS was added to each well and the biopsies were then carefully 
dried and subsequently transferred into 2 ml Eppendorf tubes each complemented with 300 µl 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FCS, 800 U/ml 
Collagenase IV and 50 U/ml DNase I. Fine scissors were utilized to cut the samples into small 
pieces prior to adding another 1.5 ml of DMEM supplemented with 10% FCS, 800 U/ml 
Collagenase IV and 50 U/ml DNase I. An hour of incubation in a thermoshaker at 37 °C and 
900 rpm was followed by the addition of 40 µl of 0.5 M EDTA and 10 more minutes of 
incubation at identical settings. The samples were then passed through a pre-wetted 70 µm cell 
strainer into a 50 ml falcon, filled up to 20 ml with 1xHBSS supplemented with 2 mM EDTA 
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and 0.5% Albumin Fraction V (BSA) and centrifuged for 7 minutes at 4 °C and 350 g. After 
the removal of the supernatant the samples were discarded and transferred into a pointed-bottom 
96-well plate. 
 
 
3.4.1.4 Bone Marrow 
 
The bone marrow can be found in the hollow cavity of the bones where components of the 
blood are formed. For bone marrow isolation, the hindlimbs were separated with scissors from 
a euthanized mouse. Skin, muscles, and connective tissue were removed to expose both the 
tibia and femur and the end of both bones was cut off. A syringe with a 26G needle and media 
was used when flushing out the bone marrow from the bones. The bone marrow was collected 
in a 15 ml falcon, centrifuged for 10 minutes at 4 °C and 360 g and the supernatant was removed. 
Cells were then resuspended with 2 ml of ACK-Buffer. After 2 minutes of incubation FACS-
Buffer was added and the sample was pelletized when centrifuging for 10 minutes at 4 °C and 
360 g. The sample was inspected to determine whether further ACK lysis was necessary.  
 
 
3.4.1.5 Tumour 
 
B16F10-OVA or MC-38 represent experimental murine tumour models which were implanted 
at the right flank on the back of a mouse and were left to grow until the by the animal protection 
agency maximally permitted size of 1 cm diameter had been reached. At the end of the 
experiment the mouse was euthanized, the tumour was carefully removed from the skin using 
forceps and scissors and cut into small pieces on a petri dish. After transferring the tissue to a 
50 ml falcon with 5 ml of dissociation buffer consisting of Roswell Park Memorial Institute 
(RPMI) 1640 + 2 mM L-Glutamine supplemented with 100 U/ml Collagenase Type II, 100 
µg/ml DNase I and 10% FCS it was incubated for 30 minutes at 37 °C and 5% CO2 while 
vigorously vortexing it every 5 to 10 minutes. The solution was then passed through a pre-
wetted 70 µm cell strainer, the cell strainer was washed with MACS-Buffer and the 50 ml falcon 
was filled up with MACS-Buffer. Thereafter, the cells were centrifuged for 10 minutes at 4 °C 
and 360 g, the supernatant was discarded, and the wash step was repeated twice with MACS-
Buffer before the cells were once washed with FACS-Buffer. The single cell suspension was 
transferred into a round-bottom 96-well plate for further analysis.  
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3.4.1.6 Lymph Nodes 
 
Lymph nodes can be found throughout the body and are part of the lymphatic system. For the 
extraction of lymph nodes, a euthanized mouse was mounted on a dissecting pad and an incision 
was made millimetres above the urinary orifices and guided down the mid ventral side to the 
chin. Two lateral incisions were then extended towards the extremities of forelimbs and 
hindlimbs, the skin was separated from the underlying muscular layer and pinned on the sides. 
The inguinal lymph node which is located above the hind paw, slightly above the stomach was 
removed using bent forceps. Individual lymph nodes were analysed, whereby it was 
differentiated between the draining lymph node (dLN) and the non-draining lymph node 
(ndLN). The draining lymph node refers to the lymph node which was removed from the site 
where a tumour had been grown or an immunisation or vaccination had been performed. Lymph 
nodes referred to as non-draining lymph nodes were taken from the opposite site where no 
manipulation had taken place. It was passed through a pre-wetted 70 µm cell strainer with the 
help of a plunger, transferred to 15 ml falcons, washed with media, and centrifuged for 10 
minutes at 4 °C and 360 g. Removal of the supernatant was then followed by the transfer of the 
cell suspension to a round-bottom 96-well plate.  
 
 
3.4.1.7 Spleen, Liver, Kidney, Heart, and Lung  
 
The heart and the lung are organs which have essential transport functions. Spleen, liver, and 
kidney however are mainly involved in the handling and breakdown of substances. To extract 
these organs, a euthanized mouse was mounted on a dissection pad and an incision that started 
millimetres above the urinary orifices was guided down the mid ventral side to the chin. Spleen, 
liver, and kidney were collected upon the opening of the abdominal cavity. To expose and 
extract the lung and heart, the thorax was lifted, the sternum and the diaphragm were removed 
as were the rib folding’s. A plunger was used to pass the organs through pre-wetted 70 µm cell 
strainers. The cell strainer was washed with media, the cells were transferred into a 15 ml falcon 
and pelletized when centrifuging these for 10 minutes at 4 °C and 360 g. Resuspension of the 
cell pellet in 2 ml of ACK-Buffer was followed by 2 minutes of incubation and the addition of 
FACS-Buffer. Cells were once again centrifuged for 10 minutes at 4° C and 360 g. This 
procedure was repeated until most erythrocytes had been removed and the remaining cells were 
ready to be transferred into a round-bottom 96-well plate. 
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3.4.2 Flow Cytometry 
 
Flow Cytometry is a laser- or impedance-based technology used for a multiparametric 
characterisation and/or separation of heterogeneous cell populations which allows for the 
measurement of cell fluorescence and light scattering (Cheung, K.C., et al., 2010; Jahan-Tigh, 
R.R. et al., 2012).  
 
Fundamentals in Flow Cytometry started to emerge in 1953 when Wallace H. Coulter had 
developed the Coulter Counter, an apparatus used for sizing and counting particles suspended 
in electrolytes (Coulter, W.H., 1957; Valet, G. et al., 2011). The device was later modified by 
Mack Fulwyler so that by 1965 the first electrostatic cell sorter had been built (Fulwyler, M.J., 
1965; Müller, S., 2011). Fluorescence based Flow Cytometry was reported in 1968 by M. Van 
Dilla (Van Dilla, M.A., 1968; Valet, G. et al., 2011) and Wolfgang Göhde (Dittrich, W. & 
Göhde, W., 1969; Valet, G. et al., 2011). Fluorescence based cell sorting had been established 
by 1972 by Leonard Herzenberg (Hulett, H.R. et al., 1969; Valet, G. et al., 2011). 
 
In Flow Cytometry single cell suspensions are introduced into a sheath fluid where a laminar 
flow is created. The cells individually pass the point of interrogation where monochromatic 
light from one or more lasers intersects the cells. Optics, filters, and dichroic mirrors direct the 
emitted light towards photomultiplier tubes (PMT). These detectors then translate the emitted 
light signals into electronic signals which are stored as measured data (Jahan-Tigh, R.R. et al., 
2012). 
 
Optical characteristics deduced from light scattering provide information regarding the size and 
complexity of a cell. Forward angle light scatters (Forward Scatter) are a measure for the 
diffraction of light at a flat angle and correlate with cell size. Right angle scatters (Side Scatter) 
ascertain the refraction at a right angle and provide information regarding the structure and 
granularity of a cell (Jahan-Tigh, R.R. et al., 2012).  
 
At the same time, fluorescent dyes and fluorescently labelled antibodies are routinely used to 
deduce further information from a single cell suspension. When passing a laser, fluorescent 
compounds absorb light energy into a characteristic wavelength range, elevating electrons to a 
higher energy level. Upon returning to their resting state the fluorescence arises when 
fluorochromes emit light energy at a higher wavelength (Jahan-Tigh, R.R. et al., 2012).   
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Since its first description the possibilities of cell analysis by Flow Cytometry have greatly 
expanded while its principles have not been significantly altered. Due to major advances in 
hardware technology, software tools and fluorochrome chemistry the number of concurrently 
measurable parameters has increased from 2 to more than 30 (Chattopadhyay, P.K. & Roeder, 
M., 2012; Chattopadhyay, P.K. et al., 2014). 
 
 
3.4.2.1 Surface Staining 
 
For the flow cytometric analysis of various tissue samples, 1x106 cells were used. In case of in 
vivo generated tumours the entire cell suspension was utilized. Cell suspensions to be stained 
and analyzed were transferred into an either round- or pointed-bottom 96-well plate, pelletized 
by centrifuging them for 10 minutes at 4 °C and 360 g and washed with 100 µl of FACS-Buffer. 
To prevent unspecific FC (Fragment, crystallizable) receptor binding during staining, the cells 
were mixed with 20 µl of CD16/CD32 Monoclonal Antibody and incubated for 15 minutes at 
4 °C. Subsequently 20 µl of a mixture of the desired antibodies was added, resuspended with 
each sample and incubated in the dark for 30 minutes at 4 °C. The optimal concentration of the 
antibodies used had previously been determined. At the end of the incubation excess unbound 
antibodies were removed when the cells were washed with 100 µl of cold FACS Buffer while 
centrifuged for 10 minutes at 4 °C and 360 g. The supernatant was then discarded, the probes 
were resuspended in 200 µl of cold FACS-Buffer and transferred into FACS tubes. Probes were 
now ready for the evaluation of surface staining on the BD™ LSR II, Becton Dickinson, 
Mountain View, CA, USA. To properly adjust the Flow Cytometer in terms of the voltage and 
compensation both unstained and single stained probes had also been prepared. In case of 
markers highly expressed on the cell populations the antibodies utilized for the initial staining 
were used. Otherwise antibodies with an identical fluorescent dye and higher expression levels 
had to be used.  
 
 
3.4.2.2 Intranuclear Staining 
 
Prior to intranuclear staining cells were treated with the commercially available 
Foxp3/Transcription Factor Staining Buffer Set purchased from ThermoFisher Scientific Inc.. 
Cells which had been washed after surface staining were resuspended in 100 µl of 
Fixation/Permeabilization solution previously prepared from 1 part of the 
Fixation/Permeabilization Concentrate and 3 parts of the Fixation/Permeabilization Diluent. 
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Fixation was performed at 4 °C, lasted for at least 30 minutes and resulted in the opening of the 
cells nuclear pores. The cells were then twice washed with 100 µl of 1xPermeabilization Buffer 
(1ml 10xPermeabilization Buffer added to 9 ml ddH2O) while centrifuged for 10 minutes at 4 
°C and 550 g. To stain for intranuclear molecules such as cytokines or transcription factors, the 
supernatant was removed, and the cells were incubated in the dark for 30 minutes at 4 °C with 
20 µl of a mixture of the appropriate antibodies previously prepared in 1xPermeabilization 
Buffer. Once again excess antibodies were removed when washing the cells with 
1xPermeabilization Buffer while centrifuging them for 10 minutes at 4 °C and 550 g. After the 
supernatant had been removed the cells were resuspended in 200 µl of cold FACS-Buffer and 
transferred into FACS tubes. Probes were now ready for the simultaneous evaluation of the 
surface and intranuclear staining of the probes on the BD™ LSR II, Becton Dickinson, 
Mountain View, CA, USA. 
 
 
3.4.2.3 Evaluation of Flow Cytometry Data 
 
All Flow Cytometric Data were acquired on a BD™ LSR II, Becton Dickinson, Mountain View, 
CA, USA. Data was analysed with FlowJo® Version 7, Tree Star, Inc., Ashland, OR, USA. 
 
 
3.4.2.4 Lymphocyte Migration and Proliferation Studies 
 
Carboxyfluorescein succinimidyl ester (CFSE), is a fluorescein based covalent cytoplasmic dye 
which in Flow Cytometry is excited by the blue laser (excitation/emission: 490/520 nm). At the 
beginning of the 1990th, Christopher R. Parish and colleagues reported on the dyes usefulness 
in migration, positioning and cell division studies both in vitro and in vivo. Since then it has 
been extensively used in research, mainly to study lymphocyte but also fibroblast and bacterial 
proliferation (Weston, S.A. & Parish, C.P., 1990; Lyons, A.B. & Parish, C.R.; 1994, Parish, 
C.R., 1999). 
 
Upon labelling the initially non-fluorescent dye accumulates in a cells cytoplasm where in 
viable cells cleavage by intracellular esterase’s render the dye highly fluorescent. The dye 
associates with the cell via an amide bond which is formed when its succinimidyle ester moiety 
covalently binds to intracellular protein amine groups. As labelled cells divide, CFSE is 
uniformly passed on to the next generation of cells, whereby the fluorescent intensity of every 
subsequent generation is halved. Considerable levels of cell toxicity when labelling cells at high 
concentrations represent one major constraint which however can be overcome by using 
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considerable amounts of buffering proteins during the labelling procedure. The dye has 
otherwise been very popular since cells can be tracked for several months and up to 11 division 
steps can be detected (Parish, C.R., 1999, Parish, C.R. et al., 2009; Quah, B.J.C. & Parish, C.R., 
2012). 
 
One of the major drawbacks of CFSE is that it is measured on one of the most frequently used 
channels in Flow Cytometry. Equally powerful dyes with different spectral properties, which 
also allow the simultaneous tracking of different population, have been welcomed. Such dyes 
include the red fluorescent Cell Proliferation Dye (CPD) eFluor 670 (excitation/emission: 
647/670 nm) and Cell Trace Violet (CTV) (excitation/emission: 405/450 nm). Since their 
introduction to the market these dyes have become available in a great range of fluorescence’s 
(Parish, C.R., 1999, Quah, B.J.C. & Parish, C.R., 2012).  
 
 
3.4.2.5 Carboxyfluorescein Succinimidyl Ester (CSFE) Labelling 
 
Spleens were harvested, a single cell suspension was prepared, and the cell number was 
determined. Cells were washed with warm 1xPBS while centrifuged for 10 minutes at 25 °C 
and 360 g. 1x108 cells were resuspended in 3 ml of a 1 µM solution of CFSE and left to incubate 
for 20 minutes at 37°C and 5% CO2. X-VIVO 20 supplemented with 10% FCS was 
subsequently added to the cells suspension, it was centrifuged for 10 minutes at 25 °C and 360 
g and the supernatant was later discarded. Resuspension of the cell pellet in X-VIVO 20 was 
followed by 30 minutes of incubation at 37 °C at 5% CO2. The cell suspension was then 
centrifuged for 10 minutes at 25 °C and 360 g, the cell pellet was resuspended in an appropriate 
amount of medium and the cell number was determined and set appropriately. While staining 
the cells all light sensitive reagents were protected from light. Successful CSFE staining was 
confirmed by Flow Cytometry. 
 
 
3.4.2.6 Cell Trace Violet (CTV) Labelling 
 
Spleens were harvested, a single cell suspension was prepared, and the cell number was 
determined. Cells were washed with warm 1xPBS while centrifuged for 10 minutes at 25 °C 
and 360 g and resuspended in 1 ml of a 0.5 µM solution of CTV per 1x106 cells. The cells were 
left to incubate for 20 minutes at 37 °C and 5% CO2. 4 ml of X-VIVO 20 per 1 ml of CTV were 
subsequently added to the cell suspension which was then incubated for another 5 minutes at 
room temperature. The cell suspension was then centrifuged for 10 minutes at 25 °C and 360 
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g, the supernatant was discarded, and the cell pellet was twice washed with X-VIVO 20 
supplemented with 10% FCS and warm 1xPBS. After washing the cell number was determined 
and set appropriately. To allow for the acetate-hydrolysis the cells were incubated for another 
10 minutes at 37 °C. While staining the cells all light sensitive reagents were protected from 
light. Successful CTV staining was confirmed by Flow Cytometry. 
 
 
3.5 In Vivo Manipulation of Mice 
 
Tumour experiments were carried out using female C57BL/6 or transgenic mice from the 
Jackson Laboratories, Bar Harbour, Main, USA aged between 4 and 8 weeks. Mice of different 
groups were age-matched. The animals were anesthetized for a variety of procedures. For 
anaesthesia they were shortly placed into a sealable container with a small amount of the 
anaesthetic Isoflurane (Forene) present. 
 
 
3.5.1 Inoculation of B16F10-OVA 
 
For tumour inoculation B16F10-OVA, under the selective pressure of G418-BC Sulfate, or 
MC-38 cells were detached from the 75 cm2 cell culture flask with Trypsin-EDTA, the reaction 
was neutralized with medium and the cells were transferred into a 15 ml falcon. The cells were 
washed at least three times with 1xHBSS while centrifuged for 10 minutes at 4°C and 360 g. 
Determination of the cell number was followed by the adjustment of the cell density to 2x105/50 
µl B16F10-OVA or 1x106/50 µl MC-38. The back of the mice was shaved with a razor, the 
mice were anesthetized, and tumour cells were subcutaneously placed at the right flank of the 
mouse.  
 
 
3.5.2 Tumour Growth Curve 
 
Tumour growth progression was assessed three times a week. After subcutaneous injection, 
tumours became visible at about seven days after inoculation. Measurements of the length and 
width were taken using a calliper, after any regrown fur had been removed from the back of the 
mouse. While taking measurements mice were shortly anesthetized. Tumour were only allowed 
to reach a maximum size of 1 cm. Mice whose tumours had passed that size had to be 
euthanized. The formula width2 x length x 0.5 was used to calculate the tumour volume.  
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3.5.3 Tumour Treatment  
 
3.5.3.1 In Vivo Tracking of Nanoparticles and MDL-12, 330A loaded Nanoparticles 
 
To judge the body distribution of MDL-12, 330A loaded and empty micelles, the polymer PSar-
b-PGlu(OBn) was coupled with the fluorochrome Oregon Green, and micelles were prepared. 
Mice were inoculated with tumours which were left to grow for 11 days. Empty or MDL-12, 
330A hydrochloride loaded particles were then injected subcutaneously next to the tumour, 
intravenously via the tail vein or retro-orbitally. One hour or 16 hours after injection the mice 
were euthanized, and the organs of interest were harvested. 
 
 
3.5.3.2 In Vivo Depletion of FoxP3+Tregs using the DEREG Mouse 
 
DEREG mice were used for the depletion of Treg. Mice were therefore intraperitoneally 
injected with 0.5 µg of diphtheria toxin (DT) at days 7, 12 and 18 after tumour inoculation. 
 
 
3.5.3.3 In Vivo Depletion of Granulocytes  
 
Granulocytes are continuously produced short lived bone marrow derived cells which are part 
of the adaptive immune system. To insure effective depletion, depletion antibodies have 
therefore to be administered on a tight schedule. One day prior to tumour inoculation mice were 
therefore intraperitoneally injected with 50 µg per mouse of anti-Gr-1 antibody (Clone: RB6-
8C5) provided by M. Radsak, Institute of Immunology, University Medical Center Mainz, 
Mainz, Germany. On the day of tumour inoculation, the injection was repeated. To maintain 
the depletion, the antibody was from then on injected every second day.  
 
 
3.5.4 Ovalbumin (OVA) as Model Antigen  
 
Ovalbumin (OVA) is an easily accessible, abundant, and slightly immunogenic T cell 
dependent protein which was first isolated in 1889 from the egg white of a chicken’s egg 
(Hofmeister, F., 1889). As a model antigen it was essential when the mechanism of antigen 
recognition, presentation and processing were elucidated (Moore, M.W. et al., 1988; Carbone, 
F.R. & Bevan, M.J., 1989). Therefore, it has been extensively studied, and a great number of 
well characterized transgenic OVA mouse model and cell lines do exist (Hogquist, K.A., et al., 
1994; Barnden, M.J. et al., 1998; Kedl, R.M. et al., 2001). Nowadays OVA is often transduced 
in non-immunogenic tumour cell lines to study cancer immunology (Kedl, R.M. et al., 2001), 
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used as allergen in models of acute allergic pulmonary inflammation (Kumar, R.K., et al., 2008) 
or to evaluate the potential of novel vaccination strategies (Bellone, M. et al., 2000). 
 
 
3.5.4.1 Polymer Brushes 
 
Azide functionalized polysarcosine brushes with polylysine backbone (polymerization: 250) 
and polysarcosine side chains (polymerization: 65) labelled with the fluorescent dye Alexa 
Fluor 647 were prepared. These brushes were then coupled with either or both the model antigen 
OVA and the nucleic-acid-based immune modulator cytosine-phosphate-guanine (CpG). 
Synthesis, characterization, and preparation was carried out by Meike Schinnerer, AK Barz/AK 
Schmidt, Institute of Organic Chemistry and Institute of Physical Chemistry, Johannes-
Gutenberg-University Mainz, Mainz, Germany.  
 
Following the preparation of the polymer brushes, they were labelled with the fluorescent dye 
Alexa Fluor 647 and later coupled with OVA, CpG or both OVA and CpG. Upon preparation 
and functionalization of the polymer brushes the free dye or CpG was removed by spin-filtration 
while unattached OVA was removed by Gel Permeation Chromatography (GPC). Successful 
elimination and quantification of the dye was determined by Fluorescent Correlation 
Spectroscopy (FCS) while Polyacrylamide Gel Electrophoresis (PAGE) was employed to 
confirm that all free OVA or CpG had been removed. A combination of Ultraviolet-Visible 
Spectroscopy (UV-Vis) and FCS measurement was employed to determine the amount of each 
component present per brush. Based on the quantification of the different component on the 
polymer brushes the amount of polymer brushes was calculated based on and normalized to the 
injection of 10 µg of OVA. For each experiment the amount of soluble OVA used was 10 µg.  
 
 
3.5.4.2 In Vivo Determination of T Cell Responses to OVA-coupled Polymer Brushes  
 
The ability of OVA-coupled polymer brushes to raise OVA-specific T cell responses upon 
subcutaneous injection was evaluated employing OT-I and OT-II OVA-specific transgenic 
mice. Therefore, single cell suspensions of spleens of OT-I and OT-II mice were prepared and 
labelled with 1 µM of CFSE and 0.5 µM of CTV respectively. C57BL/6J mice were then 
intraperitoneally injected with each 2x106 labelled OT-I and OT-II cells. Thereafter mice were 
subcutaneously immunized on their right flank with 1xHBSS, OVA, polymer brushes alone or 
coupled with OVA, CpG or OVA-CpG. Five days later mice were euthanized and the spleens, 
blood, draining and non-draining lymph nodes were harvested. Single cell suspensions were 
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prepared, stained with fluorescently labelled antibodies and the level of T cell proliferation was 
determined by Flow Cytometry. 
 
 
3.5.4.3 In Vivo Tracking of Polymer Brushes 
 
To investigate the handling of the different polymer brushes by mice, the body distribution of 
Alexa Fluor 647 labelled polymer brushes alone or coupled with OVA, CpG or OVA-CpG as 
well as commercially available Alexa Fluor 647 labelled OVA was studied. Therefore, OVA, 
polymer brushes alone and polymer brushes coupled with OVA or OVA-CpG were 
subcutaneously injected into the right flank of a mouse. Mice were euthanized 1 or 16 hours 
after injection. The skin, non-draining lymph nodes, draining lymph nodes, blood and spleen 
were harvested, single cell suspensions were prepared, and fluorescently labelled probes were 
analysed by Flow Cytometry. 
 
 
3.5.4.4 Immunization using Polymer Brushes 
 
For the evaluation of polymer brushes as a potential preventative measure against tumours, 
mice were immunized with polymer brushes alone or coupled with OVA, OVA-CpG and OVA 
alone. Therefore, mice were subcutaneously injected with the respective agent, on three 
consecutive weeks. One week later a tumour was inoculated at the site contralateral to the site 
of immunization, and the growth of the tumours was monitored for two weeks. 
 
 
3.5.4.5 Therapeutic Treatment using Polymer Brushes   
 
The value of polymer brushes for a potential therapeutic approach was determined. Mice were 
therefore inoculated with a tumour. At days 3 and 6 after tumour inoculation, OVA alone and 
polymer brushes with and without OVA or OVA-CpG were injected contralaterally to the 
tumour. Tumour growth was subsequently monitored.   
 
 
3.6 Statistical Evaluation 
 
GraphPad Prism® 6, GraPhpad Software, Inc., La Jolla, CA, USA was used for the statistical 
analysis of all data. Results are shown as mean ±SEM. The unpaired Student t test was applied 
to evaluate differences between 2 study groups. One-way ANOVA with post hoc Tukey 
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multiple comparisons test was performed when comparing >2 groups. P values of ≤0.05 denote 
significant changes. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
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4. Results 
 
 
4.1 The Effect of MDL-12, 330A hydrochloride Treatment on Tumour Growth 
 
Studying the effect of cAMP inhibition using the adenylyl cyclase inhibitor MDL-12, 330A, 
both the transplantable murine melanoma model B16F10-OVA as well as the colon 
adenocarcinoma model MC-38 were employed. Initially, tumour growth dynamics of the 
B16F10-OVA and the MC-38 model were compared. Therefore, tumours were subcutaneously 
injected in C57BL/6J and left to grow (Figure 4.1 A). The tumour growth curve and volume of 
both B16F10-OVA and MC-38 developed evenly and could be in both cases followed for up to 
15 days after implantation. Furthermore, mice inoculated with either tumour displayed identical 
Kaplan-Meier plots (Figure 4.1 B). The cAMP content of the skin as well as B16F10-OVA and 
MC-38 in vivo grown tumours was determined by ELISA. In contrast to both the skin and MC-
38, B16F10-OVA did display significantly increased levels of cAMP (Figure 4.1 C). 
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Figure 4.1 Subcutaneous growth and intracellular cAMP levels of B16F10-OVA and 
MC-38. 
A) Schematic representation of the experimental setup. 2x105 B16F10-OVA or 1x106 MC-38 were 
subcutaneously (s.c.) injected at the right flank of C57BL/6J. Tumour growth progression was assessed 
three times a week using a digital calliper. Mice were sacrificed due to poor health or at 1 cm2 tumour 
dimensions. B) Representative growth curves and Kaplan-Meier plots. C) Intracellular cAMP levels at 
day 14 after tumour implantation. For cAMP measurements, tumours at day 14 after inoculation and 
skin were excised, weighted, and stored at -80 °C. Upon tissue lysis, a cAMP specific Enzyme-linked 
Immunosorbant Assay (ELISA) was employed to determine the cAMP content. Results are shown as 
mean±SEM *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. ns: not significant. 
 
 
 
With the intent of decreasing the extraordinarily high levels of cAMP measured in both in vivo 
and in vitro grown B16F10-OVA, B16F10-OVA was treated in vitro with subtoxic levels of 
MDL-12, 330A hydrochloride. Subsequently its effect on the cAMP content and cell 
proliferation were determined (Figure 4.2 A). MDL-12, 330A hydrochloride, a hydrophobic 
cell-permeable inhibitor capable of irreversibly blocking all adenylyl cyclases (Figure 4.2 B), 
was able to drastically lower cAMP levels in vitro (Figure 4.2 C) while not impacting on their 
capacity to proliferate (Figure 4.2. D). 
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Figure 4.2 MDL-12, 330A hydrochloride reduces the intracellular cAMP content in 
B16F10-OVA without affecting proliferation. 
A) Schematic representation of the experimental setup. B16F10-OVA were plated out at a 
concentration of 2x106 cells/per well in a 6-well plate or at 2x105 cells per well in a flat-bottom 96-well 
plate. They were kept at 37 °C and 5% CO2 until they started to attach to the plastic dish. The cells were 
then incubated for 8 hours with 10 µM MDL-12, 330A hydrochloride or an equivalent amount of 
dimethyl sulfoxide (DMSO). To later determine the cells cyclic adenosine monophosphate (cAMP) 
content by Enzyme-linked Immunosorband Assay (ELISA), the cells were harvested, counted, 
pelletized, and stored at -80 °C. Proliferation was determined by autoradiographic methods following 
18 hours of incubation after the addition of 0.5 µCi/well 3H-Thymidin. B) Representation of the 
structural formula of the adenylyl cyclase inhibitor MDL-12, 330A hydrochloride. C) Intracellular 
cAMP content of B16F10-OVA in presence of MDL-12, 330A hydrochloride or its solvent. D) 
Proliferation of B16F10-OVA in presence of MDL-12, 330A or its solvent DMSO. Results are shown 
as mean±SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. ns: not significant; MDL: MDL-12, 
330A hydrochloride.  
 
 
 
Having established that in vitro subtoxic levels of MDL-12, 330A hydrochloride efficiently 
interferes with the cAMP pathway while not affecting cellular functions, it was applied towards 
B16F10-OVA and MC-38 subcutaneously implanted in C57BL/6J (Figure 4.3 A). As 
melanomas are easily accessible and due to concerns that systemic application of MDL-12, 
330A hydrochloride would result in adverse effects elsewhere, peritumoral injection of the 
inhibitor was chosen as the route of administration. Repeated local injection of MDL-12, 330A 
hydrochloride at the tumour site resulted in a significantly reduced tumour burden. In contrast, 
MDL-12, 330A hydrochloride had no effect on MC-38, a tumour virtually devoid of cAMP. As 
previously established in vitro, DMSO, the solvent of the hydrophobic MDL-12, 330A 
hydrochloride, did not display any unfavourable effects towards cellular functions (Figure 4.3 
B). 
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Figure 4.3 Peritumoral MDL-12, 330A hydrochloride injection reduces B16F10-OVA 
but not MC-38 tumour growth. 
A) Schematic representation of the experimental setup. 2x105 B16F10-OVA or 1x106 MC-38 were 
subcutaneously (s.c.) injected at the right flank of C57BL/6J. Three times a week, tumours were treated 
with subcutaneous injections of 20 µM MDL-12, 330A hydrochloride/50µl or an equivalent amount of 
dimethyl sulfoxide (DMSO) at the site of tumour inoculation. Tumour growth progression was assessed 
at the same time using a digital calliper. Mice were sacrificed due to poor health or upon the tumour 
reaching 1 cm2 tumour dimensions. B) Tumour growth curves for B16F10-OVA and MC-38 upon 
treatment with DMSO or MDL-12, 330A hydrochloride. Results are shown as mean±SEM *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001. d: day, days; MDL: MDL-12, 330A hydrochloride.   
 
 
 
4.2 In Vitro and In Vivo testing of novel MDL-12, 330A hydrochloride loaded Micelles 
 
To achieve a controlled and locally restricted release but also to circumvent unfavourable 
properties of MDL-12, 330A hydrochloride, water soluble drug loaded or empty micelles with 
a hydrophilic shell and a hydrophobic core were prepared from the polypeptoid-block-polypeptide 
copolymer polysacrcosine-block-polyglutamatic acid bezylester (PSar-b-PGlu(OBn)) and the 
hydrophobic drug (Figure 4.4 A). The inhibitor was passively incorporated when PSar-b-
PGlu(OBn) was subjected to dual asymmetric centrifugation in the presence or absence of 
MDL-12, 330A hydrochloride (Figure 4.4 B). Absence of any non-encapsulated adenylyl 
cyclase inhibitor was assured by spin filtration while Reverse-Phase High Performance Liquid 
Chromatography (RP-HPLC) was carried out to determine actual drug loading (Figure 4.4 C). 
MDL-12, 330A hydrochloride loaded micelles were found to have a 60% loading efficiency, a 
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reproducible 9% drug load and a hydrodynamic radius of an average diameter of around 76 nm. 
The hydrodynamic radius of empty micelles was determined to be on average 182 nm. Besides 
it was shown that loaded and non-loaded micelles could be lyophilized and later be reconstituted 
with an average shelf life of above 3 months. 
 
 
 
 
 
Figure 4.4 Manufacturing and loading of polymer micelles with MDL-12, 330A 
hydrochloride. 
A) Schematic representation of the components of MDL-12, 330A hydrochloride loaded micelles. The 
amphiphilic peptide based polypeptoid-block-polypeptide copolymer polysacrcosine-block-
polyglutamatic acid bezylester (PSar-b-PGlu(OBn)) and the hydrophilic adenylyl cyclase inhibitor 
MDL-12, 330A hydrochloride were used for the preparation of empty and MDL-12, 330A hydrochloride 
loaded micelles. B) Schematic representation of the manufacturing of MDL-12, 330A hydrochloride 
loaded micelles. MDL-12, 330A hydrochloride loaded micelles were prepared by dual centrifugation 
upon vigorous mixing of the polymer and the drug. C) Schematic representation of the purification of 
micelles and the quantification of its MDL-12, 330A hydrochloride content. Free MDL-12, 330A 
hydrochloride was separated from the resulting solution by spin filtration. To quantify the amount of 
MDL-12, 330A hydrochloride encapsulated in the micelles, samples of the filtrate were subjected to 
Reverse Phase-High-Performance Liquid Chromatography (RP-HPLC). Portions of the purified 
micellar solution were lyophilized for the determination of the total mass concentration. AC: adenylyl 
cyclase; C: concentration; DMSO: dimethyl sulfoxide; MDL: MDL-12, 330A hydrochloride; PBS: 
phosphate buffered saline. Graphic provided by Alexander Birke, AK Barz, Institute of Organic 
Chemistry, Johannes Gutenberg-University Mainz, Mainz, Germany.  
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Empty and MDL-12, 330A hydrochloride loaded micelles were tested in vitro regarding their 
ability to properly release the inhibitor and subsequently repress intracellular cAMP levels. 
Therefore, B16F10-OVA were incubated with toxic and subtoxic levels of MDL-12, 330A 
hydrochloride loaded micelles and its effect on the intracellular cAMP content and cell viability 
was determined (Figure 4.5 A). In contrast to empty micelles, cAMP measurements by ELISA 
revealed a continuous, nearly linear dose dependent decrease of cAMP levels as a result of the 
cells short incubation with inhibitor loaded micelles (Figure 4.5 B). Upon a prolonged period 
of incubation cell viability and morphology were inspected. While toxic levels of MDL-12, 
330A hydrochloride released from the micelles proved lethal, no adverse effects could be 
observed upon the cells incubation with empty particles (Figure 4.5 B). In vitro testing of the 
newly prepared micelles revealed that they were able to efficiently released the inhibitor. 
Components used for particle preparation proved non-toxic and did not interfere with cellular 
functions. Furthermore, it could be deduced that processes employed during particle preparation 
did not alter the function of MDL-12, 330A hydrochloride.  
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Figure 4.5 MDL-12, 330A hydrochloride loaded micelles repress cAMP production in 
vitro. 
A) Schematic representation of the experimental setup. B16F10-OVA were plated out at a concentration 
of 2x106 cells/per well in a flat-bottom 6-well plate and kept at 37 °C and 5% CO2 until they started to 
attach to the plastic dish. The cells were incubated for 4 hours with 5, 10 or 25 µg/ml of MDL-12, 330A 
hydrochloride loaded micelles and the equivalent of empty micelles determined based on their total mass 
concentration. To later determine the cells cyclic adenosine monophosphate (cAMP) content by 
Enzyme-linked Immunosorband Assay (ELISA), the cells were harvested, counted, pelletized, and 
stored at -80 °C. B16F10-OVA were furthermore incubated overnight without any agent, 25 µg/ml of 
MDL-12, 330A hydrochloride loaded micelles, the equivalent of empty micelles or 10 µM of MDL-12, 
330A hydrochloride. Cell viability was determined and documented using the EVOSfl Fluorescence 
Microscope from AMG. B) Graphic representation and statistical evaluation (t-test) of the cAMP ELISA 
data from B16F10-OVA treated with different concentrations of empty and MDL-12, 330A 
hydrochloride loaded micelles. C) Microscopy images of B16F10-OVA incubated over night with 
DMSO, MDL-12, 330A hydrochloride, empty micelles and MDL-12, 330A hydrochloride loaded 
micelles. Results are shown as mean±SEM *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. DMSO: 
dimethyl sulfoxide; MDL: MDL-12, 330A hydrochloride; NP: nanoparticle; NP-MDL: nanoparticle 
loaded with MDL-12, 330A hydrochloride. 
 
 
 
Since the particles likely redistribution into other tissues it is critical, with regard to its potential 
application, to be aware of its fate. Its distribution was tracked by flow cytometric analysis of 
fluorescently labelled empty or MDL-12, 330A hydrochloride loaded micelles at 1 or 16 hours 
upon peritumoral and at 1 hour after retro-orbital or intravenous application into tumour bearing 
C57BL/6J (Figure 4. 6A). It became apparent that regardless of the route chosen for systemic 
venous administration, MDL-12, 330A hydrochloride loaded or empty micelles in case of the 
heart, liver, kidney, lung, PECs, draining or non-draining lymph node associated with much 
less than 0.1% of viable CD45+ cells. This was different for the blood, spleen, bone marrow and 
tumour where more than 0.1% of viable CD45+ cells associated with the micellar formulation. 
In case of all organs investigated, empty and loaded micelles did however not significantly 
associate with viable CD45- cell. Upon peritumoral injection of the fluorescently labelled empty 
or inhibitor loaded micelles, at 1 hour at the tumour site, non to negligible amounts of particles 
had associated with viable CD45- or CD45+ cells in the blood, heart, liver, kidney, spleen, bone 
marrow, PECs, lung as well as the draining and non-draining lymph node. In the tumour 
however less than 0.01% of viable CD45+ cells and about 1% of CD45- cells did associate with 
the micelles. At a later timepoint, 16 hours after peritumoral injection of micelles, the number 
of micelles associated to viable CD45+ and CD45- had significantly increased at the tumour 
site. In contrast to all other organs, increased association of viable CD45+ cells with micelles 
was also the case for the lung and the kidney, whereby the overall increase of micelles 
associated to the kidney was most prominent (Figure 4.6 B). As systemic venous application of 
MDL-12, 330A hydrochloride loaded or empty micelles did not result in its preferential 
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accumulation at the tumour site it was deemed unfavourable for the intended application. 
Instead peritumoral injection seems favourable due to it amassing at the tumour site over time 
and its redistribution towards the kidney, implying the particles route of excretion. 
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Figure 4.6 Body distribution of MDL-12, 330A hydrochloride loaded micelles and 
empty micelles following peritumoral, intravenous or retro-orbital 
injection. 
A) Schematic representation of the experimental setup. 2x105 B16F10-OVA were subcutaneously (s.c.) 
injected at the right flank of C57BL/6J and left to grow for 11 days. Empty and MDL-12, 330A loaded 
micelles coupled with the fluorophore Oregon Green had been prepared and were subcutaneously 
injected at the tumour site, intravenously or retro-orbitally. 20 µM of MDL-12, 330A hydrochloride 
loaded micelles/50 µl and the equivalent of an empty micelle based on the particles mass concentration 
were used for the experiments. Upon injection of the particle, 1 or 16 hours were allowed to pass until 
the mice were euthanized and the blood, heart, liver, kidney, spleen, bone marrow, peritoneal exudate 
cells (PECs), lung, tumour, draining lymph node (dLN) and non-draining lymph node (ndLN) were 
harvested. Single cell suspensions were prepared and labelled with fluorescently labelled antibodies 
against CD45 and acquired by Flow Cytometry. Dead cells were excluded using Fixable Viability Dye. 
B) Graphic representation and statistical evaluation (t-test) of the association of Oregon Green labelled 
empty and MDL-12, 330A loaded micelles after 1 or 16 hours upon peritumoral, intravenous or retro-
orbital injection. Results are shown as mean±SEM *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
LN: lymph node; ns: not significant. 
 
 
 
Now that peritumoral application of MDL-12, 330A hydrochloride loaded micelles made from 
PSar-b-PGlu(OBn) was deemed favourable and since in case of melanoma this route of 
application is feasible, peritumoral injection of empty or drug loaded micelles was applied 
towards an earlier defined in vivo experimental regiment of tumour reduction in the context of 
B16F10-OVA (Figure 4.7 A). As previously established, treatment of B16F10-OVA with 
MDL-12, 330A hydrochloride did result in significantly reduced tumour volumes when 
compared to tumours treated with its polar solvent DMSO. No significant difference in terms 
of reduced tumour volume or survival when comparing tumour volume upon treatment with 
free or encapsulated MDL-12, 330A hydrochloride could however be observed. While 
encapsulation of MDL-12, 330A hydrochloride did not improve tumour reduction, treatment of 
tumours with empty micelles did however also not seem to cause any adverse or toxic side 
effects (Figure 4.7 B; Figure 4.7 C).   
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Figure 4.7 B16F10-OVA growth curve upon treatment with MDL-12, 330A 
hydrochloride loaded or empty micelles. 
A) Schematic representation of the experimental setup. 2x105 B16F10-OVA were subcutaneously 
(s.c.) injected at the right flank of C57BL/6J. Three times a week, tumours were treated with 
subcutaneous injections at the site of tumour inoculation of 20 µM MDL-12,330A hydrochloride /50µl, 
an equivalent amount of dimethyl sulfoxide (DMSO), 20 µM of MDL-12, 330A hydrochloride loaded 
micelles/50 µl and the equivalent of an empty micelle based on the particles mass concentration. B) 
Tumour growth curve of B16F10-OVA upon treatment with DMSO, MDL-12, 330A hydrochloride, 
empty and MDL-12, 330A hydrochloride loaded micelles. Tumour growth progression was assessed at 
the same time using a digital calliper. Mice were sacrificed due to poor health or upon the tumour 
reaching or passing the maximum tumour dimensions of 1 cm2 C) Kaplan-Meier plots for mice with 
B16F10-OVA tumours treated with DMSO, MDL-12, 330A hydrochloride, empty and MDL-12, 330A 
hydrochloride loaded micelles. Results are shown as mean±SEM *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001. d: day, days; MDL: MDL-12, 330A hydrochloride; NP: nanoparticle; NP-MDL: 
nanoparticle loaded with MDL-12, 330A hydrochloride. 
 
 
 
4.3 Effect of MDL-12, 330A hydrochloride loaded Micelles on the Immune Cell 
Content of B16F10-OVA  
 
In vivo treatment of the murine melanoma B16F10-OVA with the adenylyl cyclase inhibitor 
MDL-12, 330A hydrochloride resulted in a significant decrease of the tumour growth rate and 
supposedly a reduction of the tumours cAMP content. To elucidate mechanisms which could 
explain or add towards an understanding of these observations the immune cell content of an 
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end stage B16F10-OVA melanoma was systematically investigated upon its treatment with 
empty or MDL-12, 330A hydrochloride loaded micelles (Figure 4.8 A, Figure 4.9 A, Figure 
4.10 A, Figure 4.11 A).  
 
Flow Cytometric analysis of the immune cell content of murine end stage B16F10-OVA treated 
with MDL-12, 330A hydrochloride loaded or empty micelles regarding the composition of the 
T cell compartment revealed that inhibition of the adenylyl cyclases resulted in a significant 
increase of T cells (viable CD45+NK1.1-TCRß+) (Figure 4.8 C) and Natural Killer T (NKT) 
(viable CD45+TCRß+NK1.1+) (Figure 4.8 D) cells into the tumour. No numerical changes in 
terms of Natural Killer (NK) (viable CD45+NK1.1+) cells could be observed in MDL-12, 330A 
hydrochloride treated when compared to untreated tumours (Figure 4.8 E). In contrast to the 
prominent increase in T and NKT cells, a significant decrease of Tregs (viable CD45+NK1.1-
TCRß+CD4+Foxp3+) was noted in the tumour tissue when treated with MDL-12, 330A 
hydrochloride loaded micelles (Figure 4.8 F).  
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Figure 4.8 Local micelle-based cAMP repression alters the tumour immune cell 
infiltrate (I). 
A) Schematic representation of the experimental setup. 2x105 B16F10-OVA were subcutaneously (s.c.) 
injected at the right flank of C57BL/6J. Three times a week, tumours were treated with subcutaneous 
injections at the site of tumour inoculation of 20 µM of MDL-12, 330A hydrochloride loaded 
micelles/50 µl or the equivalent of an empty micelle based on the particles mass concentration. Mice 
were sacrificed 14 days after tumour inoculation and tumours were harvested. Single cell suspensions 
were stained with fluorescently labelled antibodies against CD45, the beta chain of the alpha/beta T cell 
receptor (TCR β), NK1.1, CD4 and the transcription factor forkhead box P3 (Foxp3). The number of T 
(CD45+NK1.1-TCRβ+), Natural Killer T (NKT) (CD45+TCRβ+NK1.1+), Natural Killer (NK) 
(CD45+NK1.1+) and regulatory T (Treg) (CD45+NK1.1-TCRβ+CD4+Foxp3+) cells were determined by 
Flow Cytometry. Dead cells were excluded using Fixable Viability Dye. B) Gating strategy for different 
subsets of the T cell compartment. Graphic representation and statistical evaluation (t-test) of C) T cells, 
D) NKT cells, E) NK cells, F) Tregs in the tumour with and without treatment with MDL-12, 330A 
hydrochloride. Results are shown as mean±SEM *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. d: 
say, days; FSC-A: Forward Scatter Area; NP: nanoparticle; NP-MDL: nanoparticle loaded with MDL-
12, 330A hydrochloride; ns: not significant; SSC-A: Side Scatter Area; SSC-H: Side Scatter Hight.  
 
 
 
The functional state of CD4+ (viable CD45+NK1.1-TCRß+CD4+) and CD8+ (viable 
CD45+NK1.1-TCRß+CD8+) cells upon treatment of B16F10-OVA with MDL-12, 330A 
hydrochloride loaded and empty micelles was investigated by assessing the production of IFN-
γ and Killer cell lectin-like receptor subfamily G member 1 (KLRG-1) (Figure 4.9 A). While 
the treatment did not affect the IFN-γ production in CD4+ cells, it was significantly decreased 
in CD8+ cells (Figure 4.9 B). The expression of KLRG-1 was however greatly reduced in both 
the CD4+ and CD8+ compartment when treated with MDL-12, 330A hydrochloride (Figure 4.9 
C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Results 
  
61 
 
 
 
 
Figure 4.9 Local micelle-based cAMP repression alters the tumour immune cell 
infiltrate (II). 
A) Schematic representation and experimental setup. 2x105 B16F10-OVA were subcutaneously injected 
at the right flank of B6 129 S4-IFNg or C57BL/6J. Three times a week, tumours were treated with 
subcutaneous (s.c.) injections at the site of tumour inoculation of 20 µM of MDL-12, 330A 
hydrochloride loaded micelles/50 µl or the equivalent of an empty micelle based on the particles mass 
concentration. Mice were sacrificed 14 days after tumour inoculation and tumours were harvested. 
Single cell suspensions were stained with fluorescently labelled antibodies against CD45, the beta chain 
of the alpha/beta T cell receptor (TCRβ), NK1.1, CD4, the transcription factor forkhead box P3 (Foxp3) 
and Killer cell lectin-like receptor subfamily G member 1 (KLRG-1). The number of Interferon -gamma 
(IFN-γ) producing CD4 (CD45+NK1.1-TCRβ+CD4+Foxp3-IFN-γ+), IFN-γ producing CD8+ 
(CD45+NK1.1-TCRβ+CD4-Foxp3-IFN-γ+), KLRG-1+CD4+ (CD45+NK1.1-TCRβ+CD4+Foxp3-KLRG-
1+) and KLRG-1+CD8+ (CD45+NK1.1-TCRβ+CD4-KLRG-1+) cells were determined by Flow 
Cytometry. Dead cells were excluded using Fixable Viability Dye. B) Representative contour plots, 
graphic representation, and statistical evaluation (t-test) of data from the analysis of B16F10-OVA 
tumours treated with empty and MDL-12, 330A hydrochloride loaded micelles regarding IFN-γ 
producing and C) KLRG-1 expressing CD4+ and CD8+ T cells. Results are shown as mean±SEM. 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. d: day, days; neg: negative; NP: nanoparticle; NP-
MDL: nanoparticle loaded with MDL-12, 330A hydrochloride ns: not significant; YFP: yellow 
fluorescent protein.  
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Next to the T cell compartment, it was probed weather upon treatment of B16F10-OVA with 
MDL-12, 330A hydrochloride loaded or empty micelles, there were apparent changes in the 
myeloid compartment. Flow cytometric analysis of the CD45+Lin(CD3, CD45R/B220, NK1.1)-
CD11c-CD11b+Ly6G+ (Figure 4.10 B) revealed that upon tumour treatment the number of 
neutrophils/granulocytes significantly decreased (Figure 4.10 C).  
 
 
 
 
 
Figure 4.10 Local micelle-based cAMP repression alters the tumour immune cell 
infiltrate (III). 
A) Schematic representation of the experimental setup. 2x105 B16F10-OVA were subcutaneously (s.c.) 
injected at the right flank of C57BL/6J. Three times a week, tumours were treated with subcutaneous 
injections at the site of tumour inoculation of 20 µM of MDL-12, 330A hydrochloride loaded 
micelles/50 µl or the equivalent of an empty micelle based on the particles mass concentration. Mice 
were sacrificed 14 days after tumour inoculation and tumours were harvested. Single cell suspensions 
were stained with fluorescently labelled antibodies against CD45, CD11b, CD11c, Ly6G and the lineage 
markers CD3, CD45R/B220 and NK1.1. The number of granulocytes/neutrophils (CD45+Lin (CD3, 
CD45R/B220, NK1.1)-CD11c-CD11b+Ly6G+) was determined by Flow Cytometry. Dead cells were 
excluded using Fixable Viability Dye. B) Gating strategy for the evaluation of granulocytes/neutrophils. 
C) Representative contour plots, graphic representation, and statistical evaluation (t-test) of data from 
the analysis of B16F10-OVA treated with empty and MDL-12, 330A hydrochloride loaded micelles 
regarding granulocytes/neutrophils. Results are shown as mean±SEM. *P<0.05, **P<0.01, ***P<0.001, 
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****P<0.0001. d; day, days; FSC-A: Forward Scatter Area; FSC-H: Forward Scatter Hight; Lin: 
lineage; neg: negative; NP: nanoparticle; NP-MDL: nanoparticle loaded with MDL-12, 330A 
hydrochloride, SSC-A: Side Scatter Area; SSC-H: Side Scatter Hight; MDL: MDL-12.   
 
 
 
Furthermore, the functional state of these myeloid tumour infiltrating lymphocytes (TILs) was 
determined by studying the endogenous expression of the GFP-tagged orphan nuclear receptor 
Nr4a1 (Nur77) using the Nur77 mouse. With the help of the differential expression of both 
Nur77 and Ly6C, it is thus possible to distinguish between patrolling (Ly6ClowNur77+) and 
inflammatory (Ly6ChighNur77) monocytes (Moran, A.E. et al., 2011; Hanna, R.N. et al., 2012). 
Treatment of B16F10-OVA with MDL-12, 330A hydrochloride resulted in a shift from the 
number of patrolling monocytes (CD45+Lin(CD3, CD45R/B220, NK1.1, Ly6G)-
CD11b+CD115+Ly6ClowNur77l+) in untreated tumours to an increase in the number of 
inflammatory monocytes (CD45+Lin (CD3, CD45R/B220, NK1.1, Ly6G)-
CD11b+CD115+Ly6ChighNur77l-) (Figure 4.11 B, Figure 4. 11 C).  
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Figure 4.11 Local micelle-based cAMP repression alters the tumour immune cell 
infiltrate (IV). 
A) Schematic representation of the experimental setup. 2x105 B16F10-OVA were subcutaneously (s.c.) 
injected at the right flank of Nur77. Three times a week, tumours were treated with subcutaneous 
injections at the site of tumour inoculation of 20 µM of MDL-12,330A hydrochloride loaded micelles/50 
µl or the equivalent of an empty micelle based on the particles mass concentration. Mice were sacrificed 
14 days after tumour inoculation and tumours were harvested. Single cell suspensions were prepared 
and stained with fluorescently labelled antibodies against CD45, CD11b, CD115 and the lineage 
markers CD3, CD45R/B220, NK1.1 and Ly6G. The number of inflammatory (CD45+Lin (CD3, 
CD45R/B220, NK1.1, Ly6G)-CD11b+CD115+Nur77high) and patrolling CD45+Lin (CD3, CD45R/B220, 
NK1.1, Ly6G)-CD11b+CD115+Nur77low) monocytes was determined by Flow Cytometry and their ratio 
was calculated. Dead cells were excluded using Fixable Viability Dye. B) Gating strategy for the 
evaluation of inflammatory and patrolling monocytes. C) Representative contour plots, graphic 
representation, and statistical evaluation (t-test) of data from the analysis of B16F10-OVA tumours 
treated with empty and MDL-12, hydrochloride loaded micelles regarding inflammatory and patrolling 
monocytes. Results are shown as mean±SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. d: day, 
days; FSC-A: Forward Scatter Area; FSC-H: Forward Scatter Hight; GFP: green fluorescent protein; 
Lin: lineage; neg: negative; NP: nanoparticle; NP-MDL: nanoparticle loaded with MDL-12, 330A 
hydrochloride; SSC-A: Side Scatter Area; SSC-H: Side Scatter Hight. 
 
 
 
4.4 Combining MDL-12, 330A hydrochloride and Cell Depletion Strategies for 
Melanoma Therapy 
 
The current trend in tumour therapy towards the combination of successfully tested treatment 
approaches has been strongly advocated and already proven beneficial (Koller, K.M. et al., 
2016). Drastic changes in the immune cell compartment upon in vivo cAMP interference in the 
context of the B16F10-OVA tumour model regarding granulocytes/neutrophils (Figure 4.10 C) 
as well as reports indicating a reduction of the tumour burden upon the depletion of the myeloid 
compartment (Jablonska, J. et al., 2010) initiated efforts to test the combination of both cAMP 
reduction and granulocyte depletion (Figure 4. 12 A). Granulocyte depletion alone and its 
combination with cAMP interference did result in a reduction of the tumour size compared to 
the sole treatment of the tumour with DMSO, the decrease in tumour size did however equal its 
reduction upon administration of MDL-12, 330A hydrochloride only (Figure 4.12 B). 
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Figure 4.12 The effect of continuous granulocyte depletion on the treatment of B16F10-
OVA with MDL-12, 330A hydrochloride. 
A) Schematic representation of the experimental setup. 2x105 B16F10-OVA were subcutaneously (s.c.) 
injected at the right flank of C57BL/6J. One day prior to the implantation of B16F10-OVA, the day of 
the implantation and from then on, every second day until the experiment ended the animals were 
intraperitoneally (i.p.) injected with 50 µg of anti-Gr-1 antibody (Clone: RB6-8C5 (Ly-6G/Ly6-C). At 
the same time, tumours were treated with subcutaneous injections of 20 µM of MDL-12, 330A 
hydrochloride/50 µl or the equivalent of dimethyl sulfoxide (DMSO)/50µl at the site of tumour 
inoculation. Tumour growth progression was concurrently assessed using a digital calliper. Mice were 
sacrificed due to poor health or upon the tumour reaching or passing the maximum tumour dimensions 
of 1 cm2. The treatment was controlled with the individual treatment of groups of mice with MDL-12A, 
hydrochloride, its equivalent of DMSO or the depletion of granulocytes. B) Tumour growth curve of 
B16F10-OVA upon anti-Gr-1 antibody depletion and treatment with either DMSO or MDL-12, 330A 
hydrochloride. d: day, days; MDL: MDL-12,330A hydrochloride. ns: not significant.  
 
 
 
The drastic reduction of the number of Treg in the tumour microenvironment upon cAMP 
interference (Figure 4.8 H), the presumably resulting resolution of immunosuppression as well 
as studies pointing towards the initiation of a beneficial anti-tumour response due to transient 
Treg depletion (Klages, K. et al., 2010) prompted the efforts to combine cAMP interference 
and Treg depletion with the intent to fully abolish tumour growth. DEREG, a transgenic mouse 
model which under the control of the FoxP3 locus, a transcription factor defining mouse Treg, 
expresses both a diphtheria toxin receptor and an eGFP protein, were used for this study. 
Intraperitoneal injection of diphtheria toxin (DT) thus allows for the temporary removal of 
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Tregs while the eGFP is frequently used for tracking their presence (Figure 4.13 A) (Lahl, K. 
et al., 2007; Lahl, K. & Sparwasser, T., 2011). As previously established by intranuclear 
antibody staining of the transcription factor FoxP3 (Figure 4.8 H), the observation that as a 
result of MDL-12, 330A hydrochloride treatment of B16F10-OVA, the number of Tregs 
(viableCD45+NK1.1-TCRß+CD4+Foxp3+/Dereg+) was drastically reduced, could be 
corroborated when using DEREG mice (Figure 4.13 B).  
 
Effectiveness of the combination of cAMP interference and punctual Treg depletion to reach 
lasting tumour removal was tested. The timepoints for Treg removal, days 7, 12 and 18 after 
tumour implantation, were carefully chosen based on previously reported effects of Treg 
ablation on tumour growth. While Treg depletion shortly after tumour implantation results in 
the cessation of tumour growth, Treg ablation at later timepoints does not alter tumour 
development (Klages, K. et al., 2010). To avoid that favourable effects of cAMP interference 
and Treg depletion could be ascribed to an untimely depletion of Tregs, intermediate timepoints 
for DT injections were chosen (Figure 4. 13 C). Combing cAMP interference using MDL-12, 
330A hydrochloride with punctual Treg removal as well as Treg depletion alone resulted in a 
significant decrease of tumour growth compared to tumour treatment with just MDL-12, 330A 
hydrochloride. While for both treatment strategies the tumour growth was initially halted it 
would vanish completely when cAMP interference and Treg depletion were combined. In case 
of Treg depletion only it would later start to re-emerge (Figure 4.13 D). When looking at the 
Kaplan-Meier plot, it becomes apparent that the combination of Treg ablation and cAMP 
interference was much more effective than Treg depletion alone. While at day 36 after initial 
tumour inoculation all mice had died upon Treg removal, none of the mice treated with both 
MDL-12, 330A hydrochloride and DT had succumbed to the tumour (Figure 4.13 E) 
consequently also highlighting the superiority of this treatment approach. The surviving mice 
were subjected to a challenge with B16F10-OVA. While in a control group the tumours did 
grow out as expected, no tumour growth could be detected in the mice previously subjected to 
the novel combination of therapeutic approaches implying a state of systemic immunity (Figure 
4.13 F). 
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Figure 4.13 Combination of tumour treatment with MDL-12, 330A hydrochloride 
loaded micelles with ablation of regulatory T cells.  
A) Representative contour plot of regulatory T cells (Tregs) in the blood from a DEREG (depletion of 
regulatory T cells) mouse prior to and after several diphtheria toxin (DT) injections. B) Representative 
contour plots, graphic representation, and statistical evaluation (t-test) of data from the analysis of 
B16F10-OVA tumours in DEREG treated with empty or MDL-12, hydrochloride loadedmicelles 
regarding regulatory T cells. C) Schematic representation of the experimental setup. 2x105 B16F10-
OVA were subcutaneously (s.c.) injected at the right flank of C57BL/6J or DEREG. Three times a week, 
tumours were treated with subcutaneous injections at the site of tumour inoculation of 20 µM of MDL-
12, 330A hydrochloride loaded micelles/50 µl and the equivalent of an empty micelle based on the 
particles mass concentration. To ablate Tregs, mice were intraperitoneally (i.p.) injected with 0.5 µg of 
DT at days 7, 12 and 18 after tumour inoculation. Tumour growth progression was assessed using a 
digital calliper. Mice were sacrificed due to poor health or upon the tumour reaching or passing the 
maximum tumour dimensions of 1 cm2. The treatment was controlled with the individual treatment of 
groups of mice with MDL-12, 330A hydrochloride, its equivalent of dimethyl sulfoxide (DMSO) or the 
depletion of Tregs. Animals which had survived the treatment regimen past day 35 were subcutaneously 
injected with 2x105 B16F10-OVA at their left flank. Tumour growth was assessed until 60 days after 
the initial tumour inoculation. D) Tumour growth curve in C57BL/6J and DEREG mice upon treatment 
of B16F10-OVA with empty and MDL-12, 330A loaded micelles and depletion of Tregs. E) Kaplan-
Meier plot for C57BL/6J and DEREG mice upon treatment of B16F10-OVA with empty and MDL-12, 
330A loaded micelles and depletion of Tregs. Results are shown as mean±SEM. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001. Ctrl: control; d: day, days; GFP: green fluorescent protein; NP: 
nanoparticle; NP-MDL: nanoparticle loaded with MDL-12, 330A hydrochloride; WT: C57BL/6J also 
referred to as wild type. 
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4.5 In Vivo testing and Protective and Therapeutic Intervention of B16F10-OVA with 
Polymer Brushes 
 
Another therapeutic strategy successfully ventured in the fight against cancer are protective and 
therapeutic vaccination strategies. In contrast to traditional vaccine where the use of soluble 
antigens frequently leads to the favouring of the CD4+ T cell response, it is essential to promote 
the CD8+ T cell response in the context of cancer vaccines (Fan, Y. & Moon, J.J., 2015). 
Nanoparticle-based systems have recently been developed to improve the efficacy of protective 
and therapeutic tumour vaccination strategies (Zhao, L. et al., 2014). 
 
In the present study azide functionalized polysarcosine brushes with polylysine backbone and 
polysarcosine side chains labelled with the fluorescent dye Alexa Fluor 647 and coupled with 
either or both the antigen OVA or the nucleic-acid-based immune modulator CpG were tested 
as a potential tumor vaccine in the context of the B16F10-OVA melanoma model. The brushes 
were therefore labelled with the fluorescent dye Alexa Fluor 647 and functionalized with the 
model antigen OVA and the nucleic-acid-based immune modulator CpG (Figure 4.14 A). 
Following the preparation of the brushes, free dye or CpG was gotten rid of by spin-filtration, 
while unattached OVA was removed by means of Gel Permeation Chromatography (GPC) 
(Figure 4.14 B). To confirm that all free dye had been successfully eliminated and to determine 
the amount of dye per brush present, Fluorescent Correlation Spectroscopy (FCS) was 
performed (Figure 4.14 C), while Polyacrylamide Gel Electrophoresis (PAGE) was used to 
confirm that all free OVA or CpG had been removed (Figure 4.14 D, Figure 4.14. E). A 
combination of Ultraviolet-Visible Spectroscopy (UV-Vis) (Figure 4.14 F) and FCS 
measurements was employed to determine the number of each component per brush (Figure 4. 
14 G). 
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Figure 4.14 The making of polymer brushes. 
Example of the synthesis of Polymer Brushes. Purification and characterization of an 
ovalbumine (OVA) - anti-DEC205 (aDEC205) - cytosin-phosphate-guanine (CpG) polymer 
brush conjugate starting from polymer brush 1. A) Stepwise synthesis of the conjugates. B) 
Purification: separation of free fluorescence and CpG by means of spin filtration. Separation of 
OVA and antibody by means of Gel Permeation Chromatography (GPC). C) Fluorescence 
Correlation Spectroscopy (FCS) of the dye labelled brushes determining the amount of dye per 
brush as well as the absence of free dye. D) Polyacrylamide gel electrophoresis (PAGE) bands: 
1= aDEC205- dibenzocyclooctyne (DBCO) (0.3 µg), 2= OVA-DBCO (0.5 µg), 3= Brush-OVA 
(5 µg OVA), 4= Brush-OVA-aDEC205 (5 µg OVA, 8 µg aDEC205). E) PAGE bands: 1= CpG-
DBCO (50 ng), 2= Brush-OVA-aDEC205-CpG (1000 ng). F) Ultraviolet-Visible Spectroscopy 
(UV-VIS) spectrum of the brush and conjugates normalized to the absorption of the dye. G) 
Quantification of OVA, aDEC205 and CpG per brush. Data is calculated from the amount of 
dye per brush determined over FCS and the UV-Vis spectra. Graphic provided by Meike 
Schinnerer, AK Barz/AK Schmidt, Institute of Organic Chemistry and Institute of Physical 
Chemistry, Johannes-Gutenberg-University Mainz, Mainz, Germany. 
 
 
 
To elucidate the differences between the in vivo handling of soluble Alexa Fluor 647 labelled 
OVA in comparison to Alexa Fluor 647 labelled brushes alone or coupled with OVA, CpG or 
OVA-CpG, their body distribution upon subcutaneous injection was examined at 1 or 16 hours 
after their initial administration into C57BL/6J. Body distribution was assessed by flow 
cytometric analysis of the skin, blood, spleen, draining lymph node and non-draining lymph 
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node (Figure 4.15 A). Alexa Fluor 647 labelled OVA or polymer brushes associated with 
CD45+ cells were identified in the different organs by gating for ViabelCD45+AF647+ cells 
(Figure 4.15 B). The body distribution of each of the Alexa Fluor 647 labelled polymer brush 
alone or coupled with OVA, CpG or OVA-CpG has been summarized in one graph since no 
significant differences in terms of distribution were observed 1 or 16 hours after subcutaneous 
administration. While 1 hour after injection the polymer brushes did mainly associate with 
CD45+ cells in the skin, soluble OVA was detected not only in the skin but also in the draining 
and non-draining lymph node. After 16 hours the brushes were still present in the skin but had 
distributed to the draining lymph node and the spleen. At that stage the soluble OVA had 
completely vanished from the organism (Figure 4. 16 C). These results indicate that the 
intermediate sized polymer brushes with a hydrodynamic radius of 21 nm prevent a fast 
redistribution of the antigen and adjuvant but instead anchor these in the skin allowing them to 
efficiently drain to close by lymph nodes and for a prolonged exposition to antigen presenting 
cells (APCs) (Fan, Y. & Moon, J.J., 2015).  Although it is not expected that significant 
alterations in the outcome would occur, it should be kept in mind that in case of the polymer 
brushes the fluorescent labelling was at the backbone of the brushes, whereas the soluble OVA 
was directly labelled with the fluorescent dye. 
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Figure 4.15 In vivo tracking of polymer brushes 
A) Schematic representation of the experimental setup. C57BL/6J were subcutaneously (s.c.) injected 
at their right flank with Alexa Fluor 647 (AF647) labelled polymer brushes alone or coupled with 
ovalbumin (OVA), cytosine-phosphate-guanine (CpG) or OVA-CpG as well as commercially available 
Alexa Fluor 647 labelled OVA. The amount of particle used was calculated based on and normalized to 
the injection of 10 µg of OVA. Mice were sacrificed 1 or 16 hours after injection and the skin, blood, 
spleen, draining lymph node (dLN) and non-draining lymph node were (ndLN) harvested. Single cell 
suspensions were prepared and stained with CD45 while dead cells were excluded using Fixable 
Viability Dye. B) Gating strategy for the evaluation of Alexa Fluor 647 labelled OVA or polymer 
brushes associated with CD45+ cells. C) Graphic representation of the results from different time points 
of the body distribution of Alexa Fluor 647 labelled OVA or polymer brushes associated with CD45+ 
cells. FSC-A: Forward Scatter Area; pos: positive; SSC-A: Side Scatter Area; SSC-H: Side Scatter 
Hight.  
 
 
 
Subsequently, in vivo T cell proliferation after immunization was evaluated to study the efficacy 
of OVA presentation using polymer brushes coupled with OVA in contrast to soluble OVA.  
Therefore, CTV or CFSE labelled spleens from OT-I and OT-II mice were adoptively 
transferred into C57BL/6J which shortly after were immunized with HBSS, soluble OVA, 
polymer brushes alone or coupled with OVA, CpG or OVA-CpG. Five days later the T cell 
response was investigated by Flow Cytometry (Figure 4.15 A). A response towards the 
vaccination in form of T cell proliferation in both the CD4+ (OT-I CD4+) and CD8+ (OT-II 
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CD8+) compartment was evident in the draining lymph node and the spleen of mice immunized 
with the polymer brush coupled with OVA or OVA-CpG, while it could only be observed in 
the spleen of mice immunized with OVA only (Figure 4.15 B). It appears that in contrast to 
soluble OVA, the polymer brushes coupled with OVA or OVA-CpG induce a lasting systemic 
response, whereby it stays unclear whether the adjuvant CpG adds towards the effectiveness of 
the vaccination. The results also correlate with the observations from the brushes body 
distribution where the polymer brushes prevented an immediate redistribution of the antigen 
and adjuvant, consequently promoting systemic distribution. 
 
 
 
 
 
Figure 4.16 In vivo T cell response to polymer brushes. 
A) Schematic representation of the experimental setup. Single cell suspensions of the spleens of OT-I 
and OT-II mice were prepared and labelled with 1 µM Carboxyfluorescein Succinimidyl Ester (CFSE) 
and 0.5 µM Cell Trace Violet (CTV) respectively. 2x106 labelled OT-I and OT-II cells were each 
intraperitoneally (i.p.) injected into C57BL/6J mice. Mice were then subcutaneously (s.c.) injected at 
their right flank with Hank’s Balanced Salt Medium (HBSS), ovalbumin (OVA), polymer brushes (#) 
alone or coupled with OVA, cytosine-phosphate-guanine (CpG) or OVA-CpG. The amount of particle 
used was calculated based on and normalized to the injection of 10 µg of OVA. Five days later mice 
were euthanized and the spleen, blood and draining lymph nodes (dLN) and non-draining lymph nodes 
(ndLN) were harvested. Single cell suspensions were prepared and stained with fluorescently labelled 
antibodies against CD45, CD4 and CD8. Flow Cytometry was employed to determine the proliferative 
capacity of OT-I (CD45+CD4+CTV+) and OT-II (CD45+CD8+CFSE+) cells. Dead cells were excluded 
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using Fixable Viability Dye. B) Representative contour plots of adoptively transferred OT-II CD4+CTV+ 
and OT-I CD8+CFSE+ cells from the blood, spleen, draining lymph node and non-draining lymph node 
upon treatment with HBSS, OVA alone, brushes only and coupled with CpG, OVA and CpG-OVA.       
 
 
 
The effectiveness of the polymer brushes as a protective vaccine were subsequently tested in 
the context of the B16F10-OVA model. Therefore, polymer brushes alone or coupled with 
OVA, OVA-CpG, were subcutaneously injected in C57BL/6J on three consecutive weeks. One 
week later, mice were challenged with B16F10-OVA and tumour growth progression was 
monitored (Figure 4.17 A). No significant difference in the tumour growth rate was observed 
between the control group and the mice vaccinated with the polymer brushes only. The use of 
polymer brushes coupled with OVA or CpG-OVA as a protective vaccine did however result 
in a complete prevention of tumour growth (Figure 4.17 B). Once again as already demonstrated 
while investigating the T cell response towards the polymer brushes it could be concluded that 
the polymer brushes themselves do not cause any notable adverse reactions when compared to 
these coupled with a suitable antigen or adjuvant. 
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Figure 4.17 The effect of immunization using polymer brushes on the growth of B16F10-
OVA. 
A) Schematic representation of the experimental setup. C57BL/6J were subcutaneously (s.c.) injected 
on three consecutive weeks at their right flank with 1x Hank’s Balanced Salt Solution (HBSS) (Ctrl.); 
polymer brushes (#) alone or coupled with ovalbumin (OVA), OVA-cytosine-phosphate-guanine (CpG) 
or OVA alone. The amount of particle used was calculated based on and normalized to the injection of 
10 µg of OVA. One week after the last injection mice were subcutaneously inoculated at the left flank 
with 2x105 B16OVA-F10. Tumour growth was monitored for two weeks. Mice were sacrificed due to 
poor health or upon the tumour reaching or passing the maximum tumour dimensions of 1cm2. B) 
Graphic representation and statistical evaluation (t-test) of tumour volume following protective 
treatment with 1xHBSS, polymer brushes alone and coupled with OVA and OVA-CpG. Results are 
shown as mean±SEM *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. ns: not significant. 
 
 
 
Since the polymer brushes coupled with OVA only or in combination with CpG did prove to 
be effective in preventing tumour outgrowth in a protective vaccination strategy, they were once 
again tested in the contest of the B16F10-OVA model in a therapeutic vaccination regiment. 
Upon the inoculation of B16F10-OVA into C57BL/6J mice, soluble OVA, polymer brushes 
alone or with and without OVA or OVA-CpG were subcutaneously injected at days 3 and 6 
after tumour inoculation (Figure 4. 18A). Observation of the tumours treated with soluble OVA 
or polymer brushes only revealed their inability to supress tumour growth. Polymer brushes 
coupled with OVA or OVA-CpG were however able to significantly halt tumour outgrowth. 
When considering the outcome of the therapeutic vaccination using polymer brushes coupled 
with OVA or OVA-CpG, no obvious benefit could be attributed to the use of the adjuvant in 
combination with the antigen over the use of just the antigen in the context of the B16F10-OVA 
model (Figure 4. 18 B). While these results were generated using a highly artificial model, they 
do still give the incentive to further investigate the azide functionalized polysarcosine brushes 
with polylysine backbone and polysarcosine side chains and to combine this strategy possibly 
even with the reduction of cAMP by intervening at the cAMP pathway. 
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Figure 4.18 The effect of therapeutic treatment using polymer brushes on the growth of 
B16F10-OVA. 
A) Schematic representation of the experimental setup. 2x105 B16F10-OVA were subcutaneously 
injected at the right flank of C57BL/6J. At days 3 and 6 after tumour inoculation, ovalbumin (OVA) 
alone and polymer brushes (#) alone with and without OVA or OVA-cytosine-phosphate-guanine (CpG) 
were subcutaneously (s.c.) injected at the left flank of a mouse. The amount of particle used was 
calculated based on and normalized to the injection of 10 µg of OVA. Tumour progression was 
monitored. Mice were sacrificed due to poor health or upon the tumour reaching or passing the 
maximum tumour dimensions of 1cm2. B) Graphic representation and statistical evaluation (t-test) of 
tumour volume after therapeutic treatment with polymer brushes alone and coupled with OVA and 
OVA-CpG. Results are shown as mean±SEM *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
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5. Discussion 
 
 
5.1 The Relationship between cAMP and Melanoma 
 
Alteration in metabolic pathways have only recently been recognized as a hallmark of cancer 
(Hanahan, D. & Weinberg, R.A., 2011; Pavlova, N.N. & Thompson, C.B., 2016) and have been 
characterized by features which include the deregulated uptake of glucose and amino acids, the 
use of opportunistic modes of nutrient acquisition, the use of glycolysis/tricarboxylic acid 
(TCA) cycle intermediates for biosynthesis and nicotinamide adenine dinucleotide phosphate 
(NADPH) production, increased demand for nitrogen, alterations in metabolite-driven gene 
regulation and metabolic interactions with the microenvironment. While the minority of 
tumours rely on the whole set of these characteristics, most feature only a selected few (Pavlova, 
N.N. & Thompson, C.B., 2016). Malignant melanoma has for example been shown to be highly 
dependent on glycolysis and to be closely associated with the MAPK pathway (Fischer, G.M. 
et al., 2018). 
 
Metabolites in general, but also those specifically pertaining to glycolysis have been 
investigated and related to certain types of cancer. This includes serum lactate dehydrogenase 
(LDH), a ubiquitously expressed enzyme investigated in a great variety of cancers which 
catalyses the conversion of lactate to pyruvic acid as well as nicotinamide adenine dinucleotide, 
oxidized form (NAD+) to nicotinamide adenine dinucleotide, reduced form (NADH) and back 
(Miao, P. et al., 2013). In general, elevated LDH levels have been associated with an 
unfavourable survival (Zhang, J. et al., 2015). In relation to melanoma, LDH has been 
recognized as a valid prognostic marker regarding Stage IV melanoma patients (Balch, C.M. et 
al., 2009). Its inhibition in the context of the B16F10 melanoma model, ultimately provoking a 
shift from glycolysis to glucose oxidation, seems favourable since in vitro it initiates decreased 
cellular viability, invasion as well as by angiogenesis affected metabolic pathways such as the 
PKA/cAMP pathway while in vivo it resulted in smaller tumours and the lack of metastasis 
(Franco-Molina, M.A. et al., 2012). cAMP, another ubiquitously expressed glycolysis 
dependent metabolite, which is closely linked to processes involved in skin pigmentation, 
protection from UV radiation and ultimately also skin cancer (Costin, G.E. & Hearing, V.J. , 
2007; Rodriguez, C.I. & Setaluri, C., 2014) has been noted to be elevated in melanoma and to 
correlated with a heightened metastatic potential in both a human and murine setting (Shepard, 
J.R. et al., 1984; Ito, A., et al., 2000; Raskovalova, T., et al., 2007; Villares, G.J., et al., 2009). 
Its repression with the help of the adenylyl cyclase inhibitor MDL-12, 330A hydrochloride has 
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previously been confirmed in the human melanoma cell line MaMel91 (Birke, A. et al., 2014) 
and was reported to revoke Treg induced immunosuppression (Klein, M. et al., 2012). 
Furthermore, IFN-α, an agent commonly used in melanoma therapy, has been reported to alter 
cAMP production (Bacher, N.et al., 2013).   
 
Intervention at different metabolic levels, lactate and cAMP, in the context of melanoma have 
in the past shown favourable results and have been advocated as adequate points of intervention 
(Farnco-Molina, M.A. et al., 2012; Miao, P. et al., 2013; Muller-Haegele, S. et al., 2014). As 
LDH is regulated by cAMP (Miles, M.F. et al., 1981; Valvona, C.J. et al., 2016), intervention 
at the cAMP level, namely at the phosphodiesterases, adenylyl cyclases or any of its five target 
proteins, seems reasonable (Amunjela, J.N. & Tucker, S.J., 2016). As it has been suggested that 
immunosuppression in the tumour microenvironment is promoted by a subtle interplay between 
the metabolites adenosine, prostaglandin E2 (PGE2) and signalling of adenosine and E 
prostaglandin receptor (EPR) which all ultimately converge on the adenylyl cyclase/3’5’-cAMP 
axis, intervention at the adenylyl cyclase presents as an adequate option (Muller-Haegele, S., et 
al., 2014). MDL-12, 330A hydrochloride, a cell-permeable non-nucleotide-based adenylyl 
cyclase inhibitor previously used when studying the effects of cAMP on the suppressive 
capacity of Treg, which irreversibly blocks all ten known adenylyl cyclases, represents a valid 
choice (Seifert, R. et al., 2012; Klein, M. et al., 2012). In contrast to traditionally used 
nucleotide-based structures such as SQ22, 536, long-term effects due to interference with DNA 
synthesis or the purine metabolism can be avoided. Furthermore, ATP mimetics could be 
considered as options, since they are however too hydrophilic to be absorbed by intact cells, 
they are unsuitable for the intended use (Seifert, R. et al., 2012). Besides its ability to block all 
adenylyl cyclases it represents an essential feature as their individual contribution and 
spatiotemporal distribution across signalling compartments represented by lipid rafts has so far 
not been resolved (Cooper, D.M.F. et al., 2005; Seifert, R. et al., 2012). 
 
While MDL-12, 330A hydrochloride is well able to in vitro reduce the cAMP content of the 
human melanoma cell line (Birke, A. et al., 2014), it is also capable to in vitro and presumably 
also in vivo decrease cAMP levels in its murine counterpart, the extensively studied B16F10-
OVA cell line (Figure 4.2 A, Figure 4.2 C), without affecting its proliferative capacity (Figure 
4.2 A, Figure 4.2 D). Its repeated local in vivo application towards a subcutaneously growing 
B16F10-OVA tumour leads to a significant reduction of the tumour burden (Figure 4.3 A, 
Figure 4.3 B) most likely as a result of the resolution of immunosuppression due to significant 
changes in the tumour microenvironment but also its immune cell content. In stark contrast 
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MDL-12, 330A hydrochloride has no effect on the tumour burden of the subcutaneously 
growing adenocarcinoma MC-38 (Figure 4.3 A, Figure 4.3 B), a tumour virtually devoid of 
cAMP (Figure 4.1 A, Figure 4.1 C). These results show that MDL-12, 330A hydrochloride 
exclusively affects cAMP, but also demonstrate that the outcome of mechanisms shared by two 
types of cancer are highly influenced by subtle mechanistic differences. While for example in 
melanoma glycolysis is mainly associated with the MAPK pathway (Fischer, G.M. et al., 2018), 
in colon carcinoma it has been linked to micro ribonucleic acids (miRNAs) (Fang, S. & Fang, 
X. et al., 2016) but also to the presence of glutaminase which not only via the regulation of 
glycolysis but also glutaminolysis sustains cell survival (Song, Z. et al., 2017). 
 
 
5.2 Successful Application of novel MDL-12, 330A hydrochloride loaded Micelles  
 
Nanoparticle-based drug delivery has successfully been introduced into the clinic and 
represents a strategy with which one anticipates to achieve a prolonged and selective delivery 
of increased drug doses. Furthermore, it presents a platform to circumvent unfavourable 
physiochemical and biopharmaceutical properties of potential therapeutics (Berciano-Guerrero, 
M.A., et al., 2014). To secure continuous inhibition of all adenylyl cyclases, to achieve a 
tolerable delivery of higher drug doses but also to bypass the use of hydrophilic polar solvents 
such as DMSO to avail of MDL-12, 330A hydrochloride, a micellar nanoparticle-based delivery 
was considered.   
 
Amphiphilic block copolymers such as PEG (poly(ethylene glycol))-block-polypeptides, which 
allow for the decoupling of the hydrophobic inner core by a hydrophilic outer corona, have 
previously been employed to solubilize hydrophobic agents in micellar drug formulations 
(Huesmann, D. et al., 2015; Klinker, K. & Barz, M., 2015). For the nanoparticle-based delivery 
of the hydrophobic adenylyl cyclase inhibitor MDL-12, 330A hydrochloride, it was made 
available by its encapsulation with the novel amphiphilic polypeptoid-block-polypeptide 
copolymer polysacrcosine-block-polyglutamatic acid bezylester (PSar-b-PGlu(OBn)). While 
the functional inner block, made from the water stable polypeptide polyglutamatic acid 
benzylester (PGlu(OBn)), entrapped the drug, the hydrophilic polypeptoid polysacrcosine 
(PSar) shields the micelles core from their surrounding and prevents interactions with proteins 
and immune cells (Figure 4.4 A). In addition, the protein resistant polypeptoid is mainly 
responsible for a prolonged in vivo circulation time of particles made from polypeptoid-block-
polypeptides (Birke, A. et al., 2014; Klinker, K. & Barz, M., 2015). The replacement of PEG 
by PSar, entities with very similar chemical and physicochemical properties, allows to avoid 
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recently uncovered drawbacks of the protein resistant but hardly degradable PEG (Huesmann, 
D. et al., 2015; Klinker, K. & Barz, M., 2015). While the efficacy of PEG-based nanoparticles 
has been reported to be reduced due to accelerated blood clearance because of the presence of 
IgM antibodies against PEG (Ishida, T. et al., 2006; Wang, X. et al., 2007; Garay, R.P. et al., 
2012; Klinker, K. & Barz, M., 2015) or complement activation (Hamad, I. et al., 2008a; Hamad, 
I. et al., 2008b; Moghimi, S.M. et al., 2010; Klinker, K. & Barz, M., 2015), PEG has also been 
reported to contribute to storage disease which eventually affects kidney, spleen, and liver 
function as well as high dose therapy (Young, M.A. et al., 2007; Webster, R. et al. 2009; 
Klinker, K. & Barz, M., 2015). 
 
MDL-12, 330A hydrochloride loaded micelles made from PSar-b-PGlu(OBn) were able to 
successfully release the adenylyl cyclase inhibitor as could be evaluated by a dose dependent 
decrease of the intracellular cAMP content (Figure 4.5 A, Figure 4.5 B). Processes associated 
with particle formulation (Figure 4.4 B, Figure 4.4 C) did not alter the function of MDL-12, 
330A hydrochloride. Also, the amphiphilic block copolymer, PSar-b-PGlu(OBn), did as 
expected not interfere with cellular functions or display any toxic side effects (Figure 4.5 A, 
Figure 4.5 B, Figure 4.5 C). Hydrophilic synthetic polypeptides such as PGlu(OBn) represent 
biocompatible, nontoxic as well as degradable entities which risk activating the immune system 
due to the presence of charged or hydrophobic residues. The polypeptoid PSar, which naturally 
is a part of muscle metabolism and has previously been found to have negligible 
immunogenicity, does however prevent such interactions as it shields the polypeptide. Next to 
this it also influences the circulation time of nanoparticle-based formulations (Klinker, K. & 
Barz, M., 2015). 
 
As cancer therapeutics are generally administered systemically in high doses by intravenous 
injections and packaging of therapeutics into nanoparticular formulations extends a drugs 
availability but also alters their distribution (Berciano-Guerrero, M.A., et al., 2014), the 
distribution of empty and MDL-12, 330A hydrochloride loaded micelles was investigated upon 
systemic venous application on tumour bearing mice. Therefore, MDL-12, 330A hydrochloride 
loaded micelles coupled with the fluorophore Oregon Green were introduced by the iliac or 
jugular vein by intravenous or retro-orbital injection and followed by Flow Cytometry (Figure 
4.6 A). Intravenous injection of MDL-12, 330A hydrochloride loaded or empty micelles did 
not result in preferential accumulation of the particles at the tumour site (Figure 4.6 B), therefore 
modifications to the particle or alternative forms of administration would have to be taken into 
consideration. Such modifications could for example include surface modifications of the 
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particle to promote accumulation at the tumour site based on an increased expression of an 
entity by a tumour such as for example in case of melanoma SPARC or the 
CD13/aminopeptidase N (APN) receptor isoform (Hersh, E.M. et al., 2015; Mundra, V. et al., 
2015; Enyedi, K.N. et al., 2017).  
 
Since in contrast to other cancers, melanomas are easily accessible, the body distribution of 
MDL-12, 330A hydrochloride loaded and empty particles was investigated at 1 or 16 hours 
upon peritumoral injection of the particles on tumour bearing mice. Upon injection at the 
tumour site, micelles preferentially associated with viable CD45- and CD45+ cells and would 
accumulate at the tumour site. While initially insignificant numbers of cells had not associated 
with any other tissue, over time a significant number of micelles did associate with the kidney 
(Figure 4.6 B). Since there was no indication for particle excretion 1 hour after intravenous 
injection, it can be assumed that the micelles favourable size, shape and the hydrophilic PSar 
was responsible for advantageous conditions for prolonged blood circulation and the prevention 
of the drugs immediate clearance (Choi, H.S., et al., 2007; Liu, J. et al., 2013). Furthermore, it 
can be suspected that upon peritumoral injection micelles could avoid being captured by the 
reticuloendothelial system (RES), as over time micelles primarily associated with the tumour 
or the kidney. It can also be assumed that prior to the micelles degradation and the materials 
clearance via the kidney, micelles must have been intact for at least 6 hours for accumulation 
at the tumour site for the EPR effect to properly function (Iyer, A.K. et al., 2006; Liu, J. et al., 
2013). It however must be taken into consideration that site specific accumulation of particles 
believed to have taken place solely based on the EPR effect may not well translate into the 
clinical setting as the animal models used when studying the EPR effect differ quite drastically 
in several key aspects from clinically relevant tumours. Amongst others such key differences 
have been described to be represented by the tumours rate of development, its size relative to 
the host, differing metabolic rates as well as a deviant architecture of the tumour 
microenvironment. With the intention to reflect clinically relevant tumours more accurately, 
the use of patient-derived tumour explant in vivo tumour models has been suggested 
(Matsumura, J. & Maeda, H., 1986; Nichols, W. & Bae, Y.H., 2014; Danhier, F., 2016; Din, F. 
et al., 2017). 
 
The MDL-12, 330A hydrochloride loaded or empty micellar formulation, made from PSar-b-
PGlu(OBn), did previously not show any adverse effects in vitro (Figure 4.5 A, Figure 4.5 B, 
Figure 4.5C) and were found to preferentially accumulate at the tumour site upon peritumoral 
administration (Figure 4.6 A, Figure 4.6B). Therefore, its effect on an established experimental 
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regiment of in vivo tumour reduction upon peritumoral melanoma treatment with the adenylyl 
cyclase inhibitor MDL-12, 330A hydrochloride was tested (Figure 4.7 A). As previously 
established, treatment of B16F10-OVA with MDL-12, 330A hydrochloride did result in 
significantly reduced tumour volumes, however when compared to tumour volumes upon 
treatment with free or encapsulated MDL-12, 330A hydrochloride no significant differences 
could be observed. While encapsulation of MDL-12, 330A hydrochloride did not improve 
tumour reduction, treatment of tumours with empty micelles did however also not seem to cause 
any adverse or toxic side effects (Figure 4.7 B, Figure 4.7 C). The failure to further reduce 
tumour burden upon nanoparticle-based adenylyl cyclase inhibitor delivery might indicate that 
this strategy alone, the continuous delivery of increased doses of the inhibitor, is in general not 
suitable to effectively eliminate tumour burden. Instead it might need to be considered to 
combine cAMP repression with other strategies previously shown to convey at least partial 
effectiveness. 
 
 
5.3 Effect of cAMP Repression on the Immune Cell Content of B16F10-OVA 
 
Spontaneous melanoma regression, a sporadically observed phenomena, is associated with 
dermal lymphocyte infiltration, also referred to as tumour infiltrating lymphocytes (TILs) 
which were first described in 1863 by Rudolf Virchow. The heterogenous group of TILs, which 
amongst others includes effector, tolerogenic, regulatory or functionally exhaust T cells, natural 
killer (NK) cells, macrophages, dendritic cells, or myeloid-derived suppressor cells (MDSCs), 
represents an essential part of the host’s response against melanoma (Lee, N. et al., 2016). TILs, 
which in in vitro studies were found to display cytolytic activity against autologous melanoma 
(Hersey, P. et al., 1981; Lee, N. et al., 2016), have not only been identified in the primary 
tumour of numerous cancers but also in affected lymph nodes and visceral metastases (Azimi, 
F. et al., 2012; Lee, N. et al., 2016). Recruitment occurs during the tumours radical growth 
phase (Clark Jr., W.H., et al., 1969; Lee, N. et al., 2016) and their presence during the vertical 
growth phase has been associated with a higher likelihood of survival and fewer metastases 
(Clark Jr., W.H., et al., 1989; Lee, N. et al., 2016).  
 
From the late 1970th on, except for few, numerous studies corroborated indications of an 
increased survival and better prognosis for patients with moderate to marked melanoma 
infiltrating lymphocytes (Schatton, T. et al., 2014; Lee, N. et al., 2016). Patterns of TILs in 
melanoma were first classified by Clark and colleagues in 1989 where the three categories, 
absent, non-brisk (focal TIL infiltrate) or brisk (infiltrate at the base or diffuse of the entire 
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vertical growth phase), were described (Clark Jr, W.H. et al., 1989; Lee, N. et al., 2016). The 
Melanoma Institute of Australia (MIA) recently proposed a novel TIL grading system (grades 
0-3) which is based on their density and location in the dermis (Azimi, F. et al., 2012). Efforts 
are currently underway for the introduction of a cancer classification system, the Immunoscore, 
a TIL grading system based on the immune context and the enumeration of lymphocyte 
populations (CD3/CD45RO, CD3/CD8 or CD8/CD45RO) currently developed for colorectal 
cancer but ultimately also applicable to melanoma (Galon, J. et al., 2014). Based on the 
emerging prominence of T cell infiltrates in the diagnosis of melanoma but also due to reports 
that cAMP repression with the help of the adenylyl cyclase inhibitor MDL-12, 330A 
hydrochloride revokes Treg induced immunosuppression (Klein, M. et al., 2012), the effect of 
cAMP inhibition on the immune cell content of the B16F10-OVA murine melanoma model 
was studied. 
 
cAMP reduction as a result of the application of MDL-12, 330A hydrochloride loaded, or empty 
micelles revealed that inhibition of the adenylyl cyclases resulted in a significant increase of T 
and NKT cells infiltrating the tumour (Figure 4.8 A, Figure 4.8 B, Figure 4.8 C, Figure 4.8 D). 
The positive correlation of increased survival upon TIL infiltration (Galon, J. et al., 2014), 
could be corroborated for the intervention with the cAMP reducing strategy of adenyl cyclase 
inhibition. While no numerical changes were observed in terms of NK cells (Figure 4.8 A, 
Figure 4.8 B, Figure 4.8 E), it remains to be investigated weather subpopulations of NK cells 
had not been affected by the treatment. In contrast to the prominent increase in T cells (Figure 
4.8 A, Figure 4.8 B, Figure 4.8 C), a significant decrease of Tregs was noted in the tumour 
tissue upon its treatment with MDL-12 330A, hydrochloride loaded micelles (Figure 4.8 A, 
Figure 4.8 B, Figure 4.8 F). The reduction of Tregs in treated tumours too correlates with a 
better survival (Galon, J. et al., 2014). It also comes with the resolution of immunosuppression, 
a state provoked by signalling of adenosine through the adenosine receptors A2aR and A2bR 
which leads to engagement of the adenylyl cyclases and consequently production of cAMP. 
The dampening of immunosuppression is however also helped by the reduction in the number 
of Tregs which upon the expression of CD39 and CD73 can generate adenosine (Muller-
Haegele, S. et al., 2014). Furthermore, it is known that cAMP repression by MDL-12, 330A 
hydrochloride leads to the re-expression of nuclear factor of activated T cells, cytoplasmic 1 
(NFATc1) expression which subsequently induces expression of an isoform of NFATc1, 
namely NFATc1/αA (Klein, M. et al., 2012). In a glucose deficient environment such as in 
tumours, the diminished anti-tumour response has been linked to a lack of the glycolytic 
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metabolite phosphoenolpyruvate (PEP) which in a well glycosylated environment blocks 
sarco/ER Ca2+-NFAT signalling (SERCA) to sustain T cell receptor-mediated Ca2+-NFAT 
signalling (Ho, P.C. et al., 2015). NFATc1 has also been linked to cytotoxic T lymphocyte 
exhaustion in the context of chronic infection (Agnellini, P., et al., 2007). 
  
The functional state of CD4+ and CD8+ cells upon cAMP repression was investigated by 
assessing the production of IFN-γ and KLRG-1 (Figure 4.9 A). While IFN-γ production in 
CD4+ cells was not affected, it was significantly decreased in CD8+ cells (Figure 4.9 B). The 
expression of KLRG-1 was however greatly reduced in both the CD4+ and CD8+ compartment 
upon treatment with MDL-12, 330A hydrochloride (Figure 4.9 C). Decreased expression of 
KLRG-1 on both CD4+ and CD8+ cells revoked T cell exhaustion, a state marked by an 
increased expression of KLRG-1 and a decrease in the number of CD4+ cells (Wherry, E.J. et 
al., 2003; Gholami, M.D. et al., 2017). It is furthermore associated with an expression of surface 
markers CD57, CD95, PD-1, CTLA-4, T cell immunoglobulin and mucin-domain containing-
3 (TIM-3), LAG-3 or B and T lymphocyte attenuator (BTLA), the transcription factors NFAT, 
PR domain  zinc finger protein 1 (Blimp-1), basic leucine zipper transcription factor, ATF-like 
(BATF) and FoxP3 (Gholami, M.D., et al., 2017) as well as CD8+ cells origining from the 
CD127+ subset of memory precursors (Angelosanto, J.M., et al., 2012; Wherry, E.J. & Kurachi, 
M., 2016). Exhausted CD8+ have been further defined by the differential expression of the T 
cell associated transcription factor T-box transcription factor TBX21 (T-bet) and 
Eomesodormin (Eomes), a marker for immunosuppression. TbethighEomeslowPD-1int CD8+ 
which proliferate and produce cytokines convert upon antigen exposure to TbetlowEomeshighPD-
1hiCD8+, a population expressing multiple inhibitory receptors with decreased proliferative and 
cytokine producing capacity which displays lytic functions and accumulates in the periphery 
(Paley, M.A. et al., 2012; Zarour, H.M., 2016). The ability to produce IFN-γ by PD-1-CD8+ in 
contrast to PD-1+CD8+ has previously been reported in a study based on human melanoma 
tissue (Inozume, T., et al., 2010). 
 
Next to the T cell compartment, the effect of MDL-12, 330 A hydrochloride on the myeloid 
compartment was probed. As the number of neutrophils/granulocytes significantly decreased 
upon cAMP repression (Figure 4.10 A, Figure 4.10 B, Figure 4.10 C), the functional state of 
these myeloid TILs was determined. cAMP interference resulted in a shift from patrolling 
monocytes (CD45+Lin(CD3, CD45R/B220, NK1.1, Ly6G)-CD11b+CD115+Ly6ClowNur77+) in 
untreated tumours to an increase in the number of inflammatory monocytes (CD45+Lin (CD3, 
CD45R/B220, NK1.1, Ly6G)-CD11b+CD115+Ly6ChighNur77-) (Figure 4.11 A, Figure 4.11 B, 
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Figure 4.11C). It has previously been acknowledged that myeloid-derived suppressor cells 
(MDSCs), which are subdivided into monocytic (CD11b+Ly6GlowLy6Chigh) and 
granulocytic/neutrophil-like (CD11b+Ly6GhighLy6Clow) cells, promote carcinogenesis, induce 
T cell exhaustion, and supress T cell activation (Jiang, Y. et al., 2015). Their suppressive 
activities, provoked by the accumulation of cAMP, is due to the adenosine receptor A2bR 
expressed on MDSC. These are further promoted by an increase of both CD39 and CD73, 
needed for the generation of adenosine on granulocytic MDSCs (Ryzhov, S. et al., 2011; 
Muller-Haegele, S. et al., 2014). 
 
cAMP interference using the adenylyl cyclase inhibitor MDL-12, 330A hydrochloride revealed 
previously described favourable changes in the tumour microenvironment which includes a 
number of different immune cell subpopulations. These alterations can be explained and 
correlated to findings in the context of the glucose metabolism in general and the cAMP 
pathway in particular. In addition, these observations demonstrate the close interlink between 
the different cell populations. While cAMP interference can interfere with T cell exhaustion, 
the expression of NFATc1 by Tregs upon cAMP repression has been linked to cytotoxic T cell 
exhaustion (Agnellini, P. et al., 2007), in addition MDSCs have been described to induce T cell 
exhaustion and supress T cell activation (Jiang, Y. et al., 2015). As these observations represent 
an explanation for the repression of the tumour growth upon decrease of the cAMP content, 
functional studies as well as the use of more markers would be needed to extend our 
understanding of the mechanisms contributing towards the reduction of the tumour burden. 
Furthermore, it would be interesting to study the impact of cAMP interference not only with 
regard to immune cells but also the greater tumour microenvironment. 
 
 
5.4 Combination of cAMP Repression and Cell Depletion Strategies for Melanoma 
Therapy 
 
Reduction of the tumour size of the murine B16F10-OVA model upon intervention with the 
adenylyl cyclase inhibitor MDL-12, 330A hydrochloride (Figure 4.3 A, Figure 4.3 B) the 
detailed insight gained regarding the provoked changes of the immune cell infiltrate (Figure 
4.8, Figure 4.9, Figure 4.10, Figure 4.11) as well as propositions to move towards a combination 
of different approaches to ultimately reach an effective therapeutic regiment (Koller, K.M. et 
al., 2016), led to the idea of combining cAMP interference with the depletion of immune cell 
subsets. The drastic changes in the myeloid compartment (Figure 4.10, Figure 4.11) and 
previous reports indicating a reduction of the tumour size upon depletion of the myeloid 
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compartment (Jablonska, J. et al., 2010) initiated the combination of both cAMP reduction and 
granulocyte depletion. Further reduction of the number of granulocytes, in particular 
neutrophils, by their depletion while interfering with the accumulation of cAMP by treatment 
with the adenylyl cyclase inhibitor MDL-12, 330A hydrochloride did not result in a further 
reduction of the tumour burden (Figure 4.12 A, Figure 4.12, B) indicating that granulocytes are 
either indispensable for the working of MDL-12, 330A hydrochloride or that their depletion 
alters other mechanisms of tumour defence. 
 
The drastic reduction of Treg in the tumour microenvironment upon cAMP interference (Figure 
4.13 B), the presumably resulting resolution of immunosuppression as well as studies pointing 
towards the initiation of a beneficial anti-tumour response upon transient Treg depletion 
(Klages, K.et al., 2010) promoted the efforts to try to combine cAMP interference and Treg 
depletion to fully abolish tumour growth. MDL-12, 330A hydrochloride treatment and non-
therapeutic punctual Treg depletion (Figure 4.13 C) resulted in a complete tumour abolishment 
(Figure 4.13 D), survival (Figure 4.13 E) and a later persisting protection (Figure 4.13 F) 
demonstrating that the MDL-12, 330A hydrochloride driven tumour tissue reprogramming 
efficiently combines with the removal of Tregs. Regrettably, so far it has not been possible to 
convincingly translate Treg depletion regiments successfully established in mice into the 
clinical setting (Jacobs, F.M. et al., 2012). This is mainly due to the lack of a sole and specific 
Treg marker in humans. While in mice the transcription factor FoxP3 has been recognized as a 
reliable marker, it cannot be used as such for human Tregs since it can also be expressed by 
activated CD4+ T effector or tissue cells and might not be expressed in selected activated Tregs. 
Instead the expression level of CD25 has commonly been used to identify activated Tregs 
(CD4+CD25+).  The expression of molecules such as CTLA-4, glucocorticoid-induced TNFR-
related protein (GITR), PD-1, inducible T cell costimulator (ICOS), Chemokine Receptor 
(CCR) 4, CCR6 or CCR7 is commonly used to ascribe further functional characteristics to 
Tregs (Whiteside, T.L. & Jackson, E.K., 2013). Cyclophosphamide, Denileukin diftitox, anti-
CD25 (Clone: PC61), daclizumab, immunotoxin as well as FoxP3 vaccination have been 
studied both in the murine and human setting. Variable responses in terms of Treg ablation, 
tumour reduction and immunological responses have been observed. It has however been 
suggested that further studies into the timing, dosage and possibly also trials in patients prior to 
stage IV might reveal a route to successfully establish Treg ablation as a therapeutic option 
(Jacobs, F.M et al., 2012) 
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5.5 Protective and Therapeutic Intervention of B16F10-OVA with Polymer Brushes 
 
Another therapeutic strategy ventured in the fight against cancer are protective and therapeutic 
vaccination strategies (Fan, Y. & Moon, J.J., 2015). Since the first effort by Dr. William Coley 
in 1891 to cure cancer by the intratumoral administration of Coley’s Toxin (inactivated 
Streptococcus pyogenes and Serratia marsescenses), the FDA has approved two prophylactic 
and one therapeutic cancer vaccine. While since 1981 potential liver cancer caused by hepatitis 
B can be prevented, protective measures against cervical cancer were introduced in 2006 with 
a vaccination regiment against human papillomavirus (HPV) (Guo, C. et al., 2013). In 2010, 
Sipuleucel-T also referred to as Provengen, a vaccine made from endogenous DCs incubated 
with a genetically engineered fusion protein made from granulocyte-macrophage colony 
stimulating factor (GM-CSF) and prostate-specific phosphatase (PAP), was approved by the 
FDA for the therapeutic treatment of prostate cancer (Cheever, M.A. & Higano, C.S., 2011; 
Guo, C. et al., 2013). Since then extensive efforts have been made to expand on the already 
existing cancer vaccines, with the help of numerous strategies which include: autologous and 
allogenic tumour whole cell vaccines, DC vaccines as well as subunit antigen specific protein, 
peptide, DNA, ribonucleic acid (RNA) and viral based vaccines and the use of adjuvants and 
other immune modulating agents (Guo, C. et al., 2013).  
 
Next to the lack of suitable antigens, traditional vaccine delivery systems are unable to 
efficiently present tumour antigens or adjuvants to APCs and intracellular compartments (Fan, 
Y. & Moon, J.J., 2015). Nanoparticle-based systems in the form of for example emulsions, self-
assembled proteins, virus-like particles, liposomes, immune-stimulating complexes and 
inorganic or polymeric nanoparticles have been developed to improve the efficacy of protective 
and therapeutic tumour vaccination strategies (Zhao, L. et al., 2014). Novel azide functionalized 
polysarcosine brushes with polylysine backbone and polysarcosine side chains labelled with 
the fluorescent dye Alexa Fluor 647 and functionalized with the model antigen OVA and the 
nucleic-acid-based immune modulator CpG (Figure 4.14 A, Figure 4.14 B, Figure 4.14 C) were 
characterized and compared to soluble OVA. In contrast to soluble OVA, the nanoparticle-
based system was able to delay and significantly alter the body distribution of the nanoparticle 
bound antigen and adjuvant (Figure 4.15 A, Figure 4.15 B, Figure 4.15 C). These results 
indicate that the intermediate sized polymer brushes with a hydrodynamic radius of 21 nm 
prevent a fast redistribution of the antigen and adjuvant but instead anchor these in the skin 
allowing them to efficiently drain to close by lymph nodes and for a prolonged exposition to 
APCs (Fan, Y. & Moon, J.J., 2015). The results also correlate with the observations when the 
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T cell response upon vaccination with brushes coupled with OVA or OVA-CpG was probed, 
which in contrast to soluble OVA resulted in a lasting systemic response (Figure 4.16 A, Figure 
4.16 B). 
 
Investigations into the potential of the polymer brushes as a protective cancer vaccine revealed 
favourable results as tumour onset could be prevented (Figure 4.17 A, Figure 4.17 B). When 
used in a therapeutic regiment, it was possible to significantly reduce tumour outgrowth (Figure 
4.18 A, Figure 4.18 B). Unlike soluble OVA, the use of polymer brushes anchors the vaccine 
in the skin and allows for a steady redistribution and an extended contact of the antigen and 
adjuvant with professional APCs, such as B cells, macrophages, or DCs. Prolonged contact 
with APCs allows for cross presentation of exogenous materials resulting in activated cytotoxic 
CD8+ T lymphocytes entering systemic circulation to, upon the encounter of a target cell, 
eradicate them by secreting granzymes and perforins. In stark contrast to traditional vaccines 
where the use of soluble antigens frequently leads to the favouring of the CD4+ T cell response, 
which, determined by polarizing cytokines, leads to their conversion to distinctive helper T cell 
subtypes, it is essential to promote the CD8+ T cell response in the context of cancer vaccines 
(Fan, Y. & Moon, J.J., 2015). While these results were generated using a highly artificial model, 
they do still give the incentive to further investigate the azide functionalized polysarcosine 
brushes with polylysine backbone and polysarcosine side chains and to possibly even combine 
this strategy with the reduction of cAMP by intervening the cAMP pathway. A similar 
approach, the administration of a cancer vaccine in combination with IFN-α, which leads to an 
optimized antitumor response by a concerted induction of immune stimulation of DCs and T 
cells as well as antagonized Treg mediated immune suppression, has previously been proposed 
(Pace, L., et al., 2010; Guo, C. et al., 2013). As IFN-α has extensively been used to, amongst 
others, treat cancer, considerable off target effects have however also been unravelled which 
include a contribution towards the breaking of peripheral tolerance through activation and 
differentiation of naïve autoreactive T cells as well as the onset of type I diabetes mellitus or 
systemic lupus erythematosus (Gogas, H. et al., 2006; Guo, C. et al., 2013).  
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6. Conclusion 
 
In vivo evaluation of cAMP inhibition using the adenylyl cyclase inhibitor MDL-12, 330A 
hydrochloride in the context of the murine melanoma B16F10-OVA and the MC-38 murine 
adenocarcinoma model showcased its potential as a therapeutic in the context of the B16F10-
OVA melanoma model as it was able to significantly reduce tumour burden. Its failure to 
effectively fight adenocarcinoma is not only justified by its lack of cAMP but also by metabolic 
mechanism divergent of malignant melanoma.  
 
Encapsulation of the adenylyl cyclase inhibitor MDL-12, 330A hydrochloride into micellar 
structures made from the novel amphiphilic polypeptoid-block-polypeptide copolymer 
polysacrcosine-block-polyglutamatic acid bezylester (PSar-b-PGlu(OBn)) and its in vitro and 
in vivo application towards B16F10-OVA revealed that cAMP repression effectively reduces 
tumour growth. It is able to emulate its therapeutic effect without provoking any detectable 
adverse or toxic side effects. In vivo, peritumoral application was selected as in contrast to 
venous administration it permits the therapeutic to primarily accumulate at the tumour site, 
presumably due to the EPR effect, and is readily excreted via the kidney. Modification of the 
particle in form of for example surface modifications is warranted to improve peritumoral and 
allow for venous administration. It however must be kept in mind that possible improvements 
of therapy solely based on the EPR effect might not translate into the clinical settings as the 
animal model used for its study differs quite drastically from clinically relevant tumours. 
 
A detailed investigation into the tumour immune cell content upon cAMP repression revealed 
significant quantitative and functional changes in terms of T cells and neutrophils/granulocytes 
congruent with observations by others. Based on these results but also due to a trend towards 
the combination of current and novel strategies a therapeutic regiment involving cAMP 
repression and punctual Treg ablation to abolish tumour growth was successfully probed. 
Translation of the proposed regiment into the clinic does however seem unlikely as regrettably, 
so far, mainly due to a lack of a sole and specific human Treg marker, it has not been possible 
to convincingly implement regiments involving Treg depletion in humans. 
 
Azide functionalized polysarcosine brushes with polylysine backbone and polysarcosine side 
chains coupled with antigen and adjuvant revealed its potential as a protective and therapeutic 
cancer vaccine. In contrast to soluble OVA, polymer brushes allow for a prolonged contact of 
APCs with both antigen and adjuvant presumably resulting in cross presentation and activation 
  Conclusion 
  
89 
of cytotoxic CD8+ T lymphocytes. To ultimately fully eradicate tumour growth in a therapeutic 
regiment, it would be interesting to try to combine this approach with cAMP repression. 
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8. Appendix 
 
 
8.1 List of Abbreviations 
 
5´AMP    5´adenosine monophosphate-activated protein kinase 
°C   degree Celcius 
%   percent 
#   polymer brushes 
α-MSH   alpha-Melanocype-stimulating hormone 
α/β TCR    alpha/beta T cell receptor 
µCi     micro Curie, unit of radioactivity 
µg     microgram    
µg/ml     microgram per milliliter 
µl     mirocliter 
µM     micromolar 
τ/ms     measurement of time in Fluorescent Correlation 
     Spectroscopy (FCS) 
A2aR     adenosine A2a receptor 
A2bR     adenosine A2b receptor 
ABC transporter   ATP-binding cassette transporter 
AC     adenylyl cyclases 
ACK Lysis    Ammonium-Chloride-Potassium Lysis 
ACTH     adrenocorticotropic hormone 
AF647     Alexa Fluor 647 
AFM     Atomic Force Microscope 
AG     Aktiengesellschaft 
AJCC     American Joint Commission on Cancer 
AMG     American Microscopy Groupe 
ANOVA    analysis of variance 
APC     Allophycocyanin 
APC     antigen presenting cell 
APN     aminopeptidase N 
ATCC     American Type Culture Collection 
ATP     adenosine triphosphate 
Aqua dest.    aqua destillata, distilled water 
B16F10-OVA    murine melanoma cell line expressing OVA 
BAC     bacterial artificial chromosome  
BATF     basic leucine zipper transcription factor, ATF-like 
BC     before Christ 
Blimp-1    PR domain zinc finger protein 1 
BTAL     B and T lymphocyte attenuator 
BRAF serine/threonine-protein kinase B-Raf, proto-oncogene, 
also referred to as B-Raf or v-Raf murine sarcoma viral 
oncogene homolog B 
BRAF V600E    serine/threonine-protein kinase B-Raf with a mutation at  
the location V600E, substitution of valine (V) for 
glutamate E (E) at codon 600, which hints towards a 
sensitivity towards proteasome inhibitors 
BRAF V600K    serine/threonine-protein kinase B-Raf with a mutation at  
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the location V600K, substitution of valine (V) for lysine 
(K) at codon 600, it occurs within the activation segment 
of the kinase domain  
C     concentration  
C10H14N2O8Na2.2H2O  ethylenediaminetetraacetic acid disodium salt dihydrate 
CA     California 
Ca2+     calcium ions 
cAMP     cyclic adenosine monophosphate 
CBP     CREB-binding protein, protein activating transcription 
CCR     chemokine receptor 
CD     cluster of differentiation 
CFSE     carboxyfluorescin succinimidyl ester 
cGMP     cyclic guanosine monophosphate 
CKIT, c-KIT    mast/stem cell growth factor receptor (SCFR), also 
known as proto-oncogene c-Kit or tyrosine-protein 
kinase Kit or CD117, is a receptor tyrosine kinase protein 
that in humans is encoded by the KIT gene 
cm2     square centimeter 
CNG     cyclic nucleotide-gated ion channel 
Co.     company 
CO2     carbon dioxide 
CPD     Cell Proliferation Dye 
CpG     cytosine-phosphate-guanine 
CRAF RAF proto-oncogene serine/threonine-protein kinase, an 
enzyme also known as proto-oncogene c-RAF, c-Raf or 
Raf-1 
CRE     cyclic adenosine monophosphate response element 
CREB cyclic adenosine monophosphate response element 
binding unit 
CRIS     cyclic nucleotide receptor involved in sperm function 
CSC     cancer stem cell 
CTL     cytotoxic T lymphocyte 
CTLA-4    cytotoxic lymphocyte associated antigen 4 
Ctrl.     control  
CTV     Cell Trace Violet 
Cy     cyanine 
d     day, days 
DBCO     dibenzocyclooctyne 
DC     dendritic cell 
dd H2O    double distilled water 
DEC205 lymphocyte antigen 75 (LY 75), also known as CD205, 
an endocytic receptor highly expressed by cortical 
thymic epithelial cells and dendritic cells  
DEREG    depletion of regulatory T cells 
DF     dilution factor 
dLN     draining lymph node 
DMEM    Dulbecco’s Modified Eagle Medium 
DMH     dimethylhydrazine 
DMSO    dimethyl sulfoxide 
DNA     deoxyribonucleic acid 
DNase     deoxyribonuclease 
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DOPAquinone   L-Dopaquinone 
DT     diphtheria toxin 
DTR     diphtheria toxin receptor 
eGFP     enhanced green fluorescent protein 
eGFP-hCre enhanced green fluorescent protein /codon-optemized 
“humanized” Cre recombinase fusion protein  
EDTR     ethylenediaminetetraacetic acid 
ELISA     Enzyme-linked Immunosorbant Assay 
Eomes  Eomesodormin 
EPAC exchange protein directly activated by cyclic adenosine 
monophosphate 
EPR     E prostaglandin receptor  
EPR effect    enhanced permeation and retention effect 
ERK extracellular signal-regulated kinases or classical 
mitogen activated protein (MAP) kinases, a widely 
expressed protein kinase intracellular signaling molecule 
eYFP     enhanced yellow fluorescent protein 
FC receptor    Fragment, crystallizable receptor 
FCS     fetal calf serum 
FCS     Fluorescent Correlation Spectroscopy 
FDA     Food and Drug Administration 
FITC     Fluorescein Isothiocyanate 
FoxP3     transcription factor forkhead box P3 
FSC-A     Forward Scatter Area 
FSC-H     Forwards Scatter Hight 
G1(t)     autocorrelation function  
g     gravitational constant 
G Birmingham Gauge, system to specify thickness or 
diameter of hypodermic needles and tube products 
GB     Great Britain 
GDP     guanosine diphosphate 
GFP     green fluorescent protein 
GITR glucocorticoid-induced TNFR-related protein, also 
known as tumor necrosis factor receptor superfamily 
member 18 (TNFRSF18 or) activation-inducible TNFR 
family receptor (AITR)  
GmbH     Gesellschaft mit beschränkter Haftung 
GmbH & Co. KG Gesellschaft mit beschränkter Haftung & Compagnie 
Kommanditgesellschaft 
GM-CSF    granulocyte-macrophage colony stimulating factor 
GPC     Gel Permeation Chromatography 
GREAT interferon-gamma reporter with endogenous polyA 
transcript 
GsPCR    Gs protein coupled receptor 
GTP     Guanosine-5´-triphosphate 
HBSS     Hank`s Balanced Salt Solution  
HCL     hydrochloric acid 
HEDGEHOG pathway signaling pathway that transmits information to 
embryonic cells required for proper cell differentiation 
HEPES    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV     human immunodeficiency virus 
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HMB45    Human Melanoma Black 45, monoclonal antibody that  
     reacts against Pmel17, an antigen present in melanocytic 
     melanomas 
HPLC     High-performance liquid chromatography 
HPV     human papillomavirus 
HSA     human serum albumin, Human Albumin 20%, salzarm 
hUBC9    ubiquitin-conjugated enzyme UBC9 
i.p.     intraperitoneal 
IDO1     Indoleamine 2,3-dioxygenase-1 
ICOS     inducible T cell costimulator, also known as CD278 
IFN-α     Interferon-alpha 
IFN-γ     Interferon-gamma 
Ig     Immunoglobulin  
Il-10     Interleukin 10 
IMDM     Iscove’s Modified Dulbecco`s Medium  
Inc.     Incorporation 
IRES     internal ribosome entry site 
ISO     International Organization for Standardization 
JAX     The Jackson Laboratory  
K+-ATPase    potassium-ATPase, ATP driven proton pump 
KGaA     Kommanditgesellschaft auf Aktien 
KHCO3    potassium hydrogen carbonate 
KLRG-1    Killer cell lectin-like receptor subfamily G member 1  
L-DOPA    levodopa 
LAG-3    Lymphocyte-activation gene-3 
LDH     lactate dehydrogenase 
Lin     lineage 
LLC     Limited Liability Company 
LN     lymph node 
Ltd.     Limited 
MA     Massachusetts 
MAPK pathway   mitogen-activated protein kinase, a type of protein kinase 
     which is phosphorylated by mitogen-activated protein  
     kinase kinase enzymes MEK1 and/or MEK2   
MAMel91    human melanoma cell line 
MC-38    murine colon adenocarcinoma cell line 
MCR1     melanocortin-1 receptor 
MDL     MDL-12, 330A hydrochloride, adenylyl cyclase inhibitor 
MDL-12,330 A hydrochloride  adenylyl cyclase inhibitor 
MDR     multidrug resistance 
MDSC     myeloid-derived suppressor cells 
ME     Maine 
MEK1/2    mitogen-activated protein kinase kinase enzyme   
MEK1 and/or MEK2, a kinase enzyme which 
phosphorylates mitogen-activated protein kinase 
(MAPK)  
Melan-A    protein melan-A or melanoma antigen recognized by T  
     cells 1 (MART-1), a protein antigen found on the surface 
     of melanocytes 
mg     milligram  
Mg2+-ATPase    magnesium ATPase, ATP driven proton pump 
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MHC     major histocompatibility complex 
MIA     Melanoma Institute of Australia 
miRNA    micro ribonucleic acid 
MITF     microphthalamia-associated transcription factor   
ml     milliliter 
mm     millimeter 
mM     millimolar 
mm3     cubic millimeter 
MMRRC    Mutant Mouse Resource & Research Centers 
MO     Missouri 
mRNA    messenger ribonucleic acid  
Na+-ATPase    sodium-ATPase, ATP driven proton pump 
NaCl     sodium chloride 
NAD+     nicotinamide adenine dinucleotide, oxidized form 
NADH    nicotinamide adenine dinucleotide, reduced form 
NADPH reduced form of nicotinamide adenine dinucleotide 
phosphate 
NaH2PO4·2H2O   sodium phosphate monobasic dihydrate 
NANOG    transcription factor critically involved with self-renewal 
  of undifferentiated embryonic stem cells 
NaOH     sodium hydroxide 
ndLN     non-draining lymph node 
neg     negative 
NFAT     nuclear factor of activated T cells  
NFATc1    nuclear factor of activated T cells, cytoplasmic 1 
NFATc1/αA    isoform of nuclear factor of activated T cells, 
cytoplasmic 1 
NH4Cl     ammonium chloride 
NICAS Australian National Industrial Chemical Notification and 
Assessment Scheme 
NJ     New Jersey 
NK      Natural Killer Cells 
NKT      Natural Killer T Cells 
nm     nanometer 
NOTCH pathway highly conserved cell signaling pathway that occurs in 
most multicellular organisms 
NP     nanoparticle 
NP-MDL    nanoparticle loaded with MDL-12, 330A hydrochloride 
NR     no remission 
NRAS neuroblastoma RAS viral oncogene homolog, one of 
three members of the Ras gene family 
ns     not significant 
Nur77     orphan nuclear receptor Nr4a1 
NY     New York 
OR     Oregon 
OVA     ovalbumin 
PA     Pennsylvania 
PAGE     Polyacrylamide Gel Electrophoresis  
PAP     prostate-specific phosphatase 
PB     Pacific Blue 
PE     Phycoerythrin 
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PEC     peritoneal exudate cell 
PEG     poly(ethylene glycol) 
PerCP     Peridinin-Chlorophyll-protein 
PBS     phosphate buffered saline 
PD     progressive disease 
PD-1     Programmed Death Receptor-1  
PD-1L     Programmed Death Receptor-1 Ligand 
PDE     phosphodiesterase 
PEP     phosphoenolpyruvate  
PGE2     prostaglandin E2 
PGlu(OBn)    polyglutamatic acid benzylester 
PKA     protein kinase A 
pmol     picomole 
PMT     photomultiplier tube 
POPDC    Popey domain-containing proteins  
Pos     positive 
PPi     proton-pump inhibitors 
PSar     polysarcosine 
PSar- b-PGlu(OBn)   polysacrosine-block-polyglutamatic acid benzylester 
PTX     paclitaxel 
RAS  family of related proteins which belong to a class of  
  proteins referred to as small GTPases 
Ras-Raf-MEK-ERK pathway also referred to as the MAPK/ERK pathway, is a chain of  
proteins in the cell that communicates a receptor on the 
surface of the cell to the DNA in the nucleus 
RES     reticuloendothelial system 
RI     Rhode Island 
RNA     ribonucleic acid 
ROS     reactive oxygen species 
rpm     rotations per minute 
RPMI     Roswell Park Memorial Institute medium 
RP-HPLC Reverse Phase-High-Performance Liquid 
Chromatography 
S-100 protein    family of at least 21 low-molecular-weight proteins  
     characterized by two calcium-binding sites that have  
     helix-loop-helix conformation which are also considered 
                                                           as damage-associated molecular pattern molecules  
     (DAMPs) 
s.c.     subcutaneous 
sAC     soluble adenylyl cylases 
SCENIHR Scientific Committee on Emerging and Newly Identified 
Health Risks 
SCF stem cell factor, also referred to as KITligand, KL or 
steel factor, a cytokine which binds to CD117, the c-KIT 
receptor 
SEM     standard error of the mean 
SERCA sacro/endoplasmic reticulum (ER) Ca2+-nuclear factor of 
activated T cells (NFAT) signalling 
SINFEKEL    H2Kb/chicken ovalbumin peptide 257-264 
SPARC    secreted protein acidic and rich in cysteine also referred  
     to as osteonectin or basement-membrane-protein 40 
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SSC-A     Side Scatter Are 
SSC-H     Side Scatter Hight 
STM     Scanning Tunnelling Microscope  
SQ22, 536    adenylyl cyclase inhibitor  
T-bet     T-box transcription factor TBX21 
tAC     transmembrane adenylyl cylases 
TARC     Translational Animal Research Center  
TCA cycle tricarboxylic acid cycle, also known as citric acid or 
Krebs cycle  
TCR β     the beta chain of the alpha/beta T cell receptor 
TEM     Transmission Electron Microscope 
Treg     regulatory T cell 
TGF-β     transforming growth factor beta 
TIL     tumour infiltrating lymphocytes 
TIM-3 T cell immunoglobulin and mucin-domain containing-3, 
also known as Hepatitis A virus cellular receptor 2 
(HAVCR2)  
TNF-α     tumour necrosis factor alpha 
Trypsin-EDTA   trypsin-ethylenediaminetetraacetic acid 
TUBB3    anti-apoptotic class III β-tubulin 
TYRP1    tyrosine-related-protein-1 
TYRP2    tyrosine-related-protein-2  
U-U-MITF    ubiquinated microphtalamina-associated transcription  
     factor (MITF)  
UK     United Kingdom 
USA     United States of America 
US-FDA    United States Food and Drug Administration  
UTR     untranslated region 
UV     ultraviolet 
UV-Vis    Ultraviolet-Visible Spectroscopy 
V/V     volume percent 
VT     Vermont 
WI     Wisconsin 
WMA     World Medical Association  
WNT pathway   a group of three signal transduction pathways which pass  
     signals into a cell through cell surface receptors 
WT     C57BL/6J also referred to as wild type 
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Figure 1.1  Guidelines for the primary therapy of malignant melanoma. 
 
Figure 1.2  Guidelines for the treatment of patients with Stage IV melanoma. 
 
Figure 1.3  The cAMP signalling pathway. 
 
Figure 1.4   Signalling pathways involved in the regulation of melanogenesis. 
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   and MC-38. 
 
Figure 4.2  MDL-12, 330A hydrochloride reduces the intracellular cAMP content in 
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Figure 4.3 Peritumoral MDL-12, 330A hydrochloride injection reduces B16F10-
OVA but not MC-38 tumour growth. 
 
Figure 4.4 In vitro and in vivo testing of novel MDL-12, 330A hydrochloride loaded 
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Figure 4.5  MDL-12, 330A hydrochloride loaded micelles repress cAMP production  
   in vitro. 
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   injection. 
 
Figure 4.7 B16F10-OVA growth curve upon treatment with MDL-12, 330A 
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Figure 4.12 The effect of continuous granulocyte depletion on the treatment of 
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Figure 4.13 Combination of tumour treatment with MDL-12, 330A hydrochloride 
loaded micelles with ablation of regulatory T cells. 
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